rct_number,antibody_name,antibody_category,trial_design,control_arm,phase,enrollment,dose_mg_m2,dose_frequency,duration_days,age_range,gender_distribution,ecog_performance,prior_treatments,comorbidities,baseline_organ_function,adverse_event,toxicity_type,organ_system,severity,ctcae_grade,fraction_affected_%,reversible,manageable,management_strategy,mitigation_strategy,time_to_onset_days,resolution_days,dose_modification_required,dose_modification_type,treatment_discontinuation,fatal_outcome,is_failed_candidate,failure_reason,contributed_to_failure,biomarker_correlation,predictive_factor,risk_stratification
RCT21195,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,214,13,Every 3 weeks,97,21-85,40% M/60% F,1-2,3,3,Moderate impairment,Infusion reaction,Cardiac,Skin,Severe,2,2.36,Yes,Yes,Dose reduction,Dose adjustment,27,48,Yes,Delay,Yes,Yes,Yes,Efficacy,Yes,Positive,Gender,High
RCT84259,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,211,11,Bi-weekly,55,18-65,40% M/60% F,1-2,4,0,Normal,Rash,Gastrointestinal,Blood,Mild,1,28.16,No,No,Discontinuation,Monitoring,8,47,Yes,None,Yes,Yes,No,Regulatory,,Unknown,None,Low
RCT24326,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,131,6,Bi-weekly,107,18-75,40% M/60% F,1-2,0,2,Moderate impairment,Rash,Cardiac,Gastrointestinal,Moderate,2,12.55,Yes,No,Treatment hold,Dose adjustment,11,36,Yes,Reduction,Yes,Yes,Yes,Safety,Yes,Negative,Age,Low
RCT48381,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 3,270,5,Every 3 weeks,31,≥18,60% M/40% F,0-2,3,1,Mild impairment,Rash,Gastrointestinal,Cardiac,Severe,2,4.37,No,No,Discontinuation,Monitoring,18,41,No,Reduction,Yes,Yes,No,,Yes,Negative,None,Unknown
RCT28184,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 3,117,10,Every 3 weeks,132,21-85,50% M/50% F,1-2,0,0,Normal,Nausea,Cardiac,Hepatic,Mild,4,14.83,No,No,Dose reduction,Monitoring,5,45,Yes,Discontinuation,No,Yes,No,Efficacy,No,Unknown,None,High
RCT80276,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 3,20,10,Bi-weekly,90,≥18,40% M/60% F,0-2,4,1,Normal,Rash,Dermatological,Cardiac,Moderate,1,9.52,Yes,No,Treatment hold,Patient education,11,38,Yes,Discontinuation,No,No,Yes,Efficacy,Yes,Positive,Age,Low
RCT29941,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 3,110,15,Every 3 weeks,78,≥18,40% M/60% F,0-2,4,2,Normal,Neutropenia,Cardiac,Cardiac,Moderate,4,9.24,Yes,No,Discontinuation,Patient education,26,45,Yes,Reduction,No,No,Yes,Safety,,Positive,Prior treatments,High
RCT61992,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 3,296,1,Every 3 weeks,35,18-65,40% M/60% F,0-1,3,0,Moderate impairment,Neutropenia,Cardiac,Hepatic,Moderate,3,27.83,Yes,Yes,Discontinuation,Monitoring,13,36,No,None,Yes,No,No,Safety,No,Positive,None,Unknown
RCT84286,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,126,9,Every 3 weeks,175,21-85,60% M/40% F,1-2,1,2,Normal,Rash,Dermatological,Cardiac,Moderate,4,5.7,No,Yes,Discontinuation,Patient education,9,24,No,Discontinuation,No,Yes,Yes,Efficacy,,None,ECOG,Medium
RCT93001,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,191,10,Every 3 weeks,146,21-85,40% M/60% F,1-2,2,0,Normal,Rash,Gastrointestinal,Gastrointestinal,Mild,5,16.79,Yes,Yes,Treatment hold,Patient education,6,35,Yes,Discontinuation,No,No,No,Safety,,Positive,ECOG,High
RCT52590,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,260,9,Weekly,83,≥18,50% M/50% F,1-2,3,2,Mild impairment,Neutropenia,Hematological,Skin,Moderate,1,20.17,No,Yes,Dose reduction,Dose adjustment,5,18,Yes,Discontinuation,No,No,No,Efficacy,,Unknown,Gender,Low
RCT57118,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 1,284,6,Weekly,84,18-75,50% M/50% F,0-1,3,3,Normal,Nausea,Dermatological,Cardiac,Severe,2,7.78,No,No,Dose reduction,Dose adjustment,4,51,No,None,No,No,Yes,Efficacy,Yes,Unknown,Age,Low
RCT82947,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,171,13,Monthly,110,18-65,40% M/60% F,1-2,1,1,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Severe,2,27.32,Yes,Yes,Discontinuation,Monitoring,3,38,Yes,Discontinuation,No,Yes,No,Competition,Yes,Negative,ECOG,Low
RCT92988,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,88,14,Monthly,170,≥18,40% M/60% F,1-2,0,0,Moderate impairment,Nausea,Dermatological,Hepatic,Moderate,5,7.21,No,Yes,Supportive care,Premedication,9,57,No,Delay,Yes,Yes,Yes,,No,Negative,Age,Unknown
RCT17194,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,81,2,Weekly,71,21-85,50% M/50% F,0-2,4,0,Moderate impairment,Fatigue,Hematological,Gastrointestinal,Mild,4,23.42,Yes,Yes,Treatment hold,Dose adjustment,27,15,Yes,Delay,Yes,Yes,No,Efficacy,Yes,Positive,Gender,Medium
RCT73562,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 3,151,11,Every 3 weeks,57,≥18,40% M/60% F,0-2,4,3,Mild impairment,Neutropenia,Hepatic,Skin,Mild,1,13.03,Yes,No,Treatment hold,Dose adjustment,15,52,Yes,Delay,Yes,Yes,No,Efficacy,No,Negative,ECOG,Medium
RCT97104,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,116,1,Weekly,60,18-75,40% M/60% F,0-2,3,1,Normal,Rash,Gastrointestinal,Hepatic,Moderate,4,11.67,No,Yes,Treatment hold,Premedication,3,20,No,Discontinuation,Yes,No,Yes,Regulatory,No,Unknown,None,Low
RCT49508,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 1,234,5,Every 3 weeks,98,21-85,50% M/50% F,1-2,4,1,Moderate impairment,Fatigue,Dermatological,Skin,Mild,5,15.91,Yes,Yes,Dose reduction,Patient education,18,41,Yes,Discontinuation,No,Yes,No,Competition,,Positive,Age,Low
RCT45202,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 1,62,5,Weekly,139,18-65,50% M/50% F,0-1,5,1,Mild impairment,Neutropenia,Gastrointestinal,Hepatic,Mild,5,25.52,Yes,Yes,Dose reduction,Patient education,4,16,Yes,None,No,No,Yes,Regulatory,Yes,Negative,None,High
RCT29827,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 3,27,12,Bi-weekly,49,21-85,60% M/40% F,0-2,0,1,Mild impairment,Nausea,Hematological,Gastrointestinal,Severe,3,27.39,No,Yes,Treatment hold,Monitoring,16,25,No,None,No,Yes,No,Regulatory,No,Unknown,Age,Low
RCT62598,Rituximab,Anti-CD20,Single-arm,None,Phase 3,159,6,Every 3 weeks,86,21-85,60% M/40% F,0-1,4,0,Mild impairment,Infusion reaction,Hepatic,Gastrointestinal,Severe,2,21.06,Yes,Yes,Supportive care,Patient education,27,8,No,Delay,Yes,Yes,Yes,Regulatory,Yes,Negative,ECOG,Low
RCT15283,Trastuzumab,Anti-HER2,Crossover,None,Phase 1,233,14,Weekly,163,18-75,40% M/60% F,0-1,2,3,Moderate impairment,Rash,Dermatological,Cardiac,Severe,3,13.37,Yes,No,Discontinuation,Monitoring,5,13,No,Reduction,No,Yes,Yes,Efficacy,Yes,Negative,Age,Medium
RCT94987,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 2,246,13,Monthly,43,18-75,60% M/40% F,1-2,0,0,Normal,Fatigue,Hematological,Cardiac,Mild,1,25.97,Yes,No,Supportive care,Dose adjustment,11,36,Yes,Reduction,No,Yes,No,Competition,No,Positive,Age,High
RCT47189,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,198,7,Weekly,173,≥18,50% M/50% F,1-2,5,3,Mild impairment,Fatigue,Cardiac,Skin,Mild,3,28.31,No,Yes,Treatment hold,Premedication,7,14,No,Reduction,Yes,No,No,Efficacy,Yes,None,None,Low
RCT59623,Cetuximab,Anti-EGFR,Crossover,None,Phase 3,251,15,Bi-weekly,97,18-75,60% M/40% F,1-2,4,3,Moderate impairment,Rash,Cardiac,Skin,Moderate,5,16.81,No,No,Treatment hold,Monitoring,1,10,No,Reduction,No,No,Yes,Efficacy,No,Negative,Gender,High
RCT33822,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,120,6,Weekly,93,18-75,40% M/60% F,1-2,0,0,Moderate impairment,Neutropenia,Dermatological,Blood,Mild,2,19.9,No,Yes,Treatment hold,Monitoring,13,4,Yes,Discontinuation,Yes,Yes,Yes,Efficacy,,None,Age,High
RCT70589,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,241,15,Bi-weekly,67,21-85,60% M/40% F,1-2,1,3,Moderate impairment,Rash,Gastrointestinal,Blood,Moderate,4,6.04,No,No,Dose reduction,Monitoring,6,26,Yes,Discontinuation,Yes,Yes,Yes,Safety,Yes,None,Age,Low
RCT13104,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,274,1,Monthly,55,18-75,40% M/60% F,0-2,2,0,Normal,Nausea,Gastrointestinal,Hepatic,Severe,2,28.37,No,No,Treatment hold,Patient education,2,12,No,Delay,No,No,No,Regulatory,No,Negative,Prior treatments,Low
RCT41688,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 1,175,3,Bi-weekly,76,18-75,60% M/40% F,1-2,4,2,Moderate impairment,Rash,Hematological,Gastrointestinal,Mild,1,16.16,Yes,Yes,Discontinuation,Monitoring,3,20,No,None,No,Yes,Yes,Competition,Yes,Negative,Age,Medium
RCT31992,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,199,11,Monthly,70,21-85,60% M/40% F,0-1,5,2,Mild impairment,Nausea,Dermatological,Cardiac,Severe,4,4.73,No,No,Discontinuation,Premedication,22,16,Yes,Reduction,Yes,Yes,No,Safety,No,Negative,Gender,Low
RCT65579,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,293,13,Every 3 weeks,158,18-65,50% M/50% F,0-1,2,1,Moderate impairment,Rash,Hematological,Cardiac,Mild,4,3.8,Yes,Yes,Discontinuation,Patient education,19,60,No,Discontinuation,Yes,No,Yes,Competition,No,Negative,Prior treatments,High
RCT39232,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,273,5,Monthly,63,21-85,40% M/60% F,0-1,4,0,Mild impairment,Neutropenia,Hematological,Skin,Mild,2,27.06,No,No,Discontinuation,Patient education,12,3,Yes,Reduction,No,Yes,No,,Yes,Unknown,None,Unknown
RCT17147,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,273,5,Every 3 weeks,72,≥18,40% M/60% F,1-2,0,0,Moderate impairment,Rash,Hepatic,Skin,Mild,1,11.17,Yes,No,Discontinuation,Monitoring,17,44,No,None,Yes,Yes,No,Safety,No,Unknown,Prior treatments,Low
RCT21869,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,196,5,Bi-weekly,65,21-85,60% M/40% F,0-1,4,0,Mild impairment,Infusion reaction,Dermatological,Skin,Moderate,2,23.42,Yes,No,Dose reduction,Patient education,7,57,Yes,Reduction,Yes,Yes,No,,No,None,Gender,Unknown
RCT30096,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 1,74,2,Monthly,148,18-65,40% M/60% F,0-2,4,2,Moderate impairment,Infusion reaction,Cardiac,Blood,Mild,2,23.66,No,No,Discontinuation,Monitoring,11,17,No,Discontinuation,Yes,No,Yes,Competition,No,None,Prior treatments,High
RCT49195,Rituximab,Anti-CD20,Randomized,Placebo,Phase 3,157,2,Weekly,38,18-65,60% M/40% F,0-2,0,3,Moderate impairment,Infusion reaction,Hepatic,Cardiac,Severe,5,16.06,Yes,Yes,Dose reduction,Dose adjustment,17,3,No,None,No,No,No,Efficacy,No,Positive,None,High
RCT94762,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 3,138,1,Weekly,117,18-65,60% M/40% F,1-2,1,1,Mild impairment,Rash,Cardiac,Blood,Severe,2,29.86,Yes,Yes,Supportive care,Premedication,16,4,Yes,Delay,Yes,No,Yes,Safety,No,Positive,Gender,Medium
RCT76938,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 3,272,8,Bi-weekly,45,18-75,60% M/40% F,0-2,0,2,Normal,Rash,Dermatological,Cardiac,Moderate,4,16.26,No,Yes,Supportive care,Patient education,26,60,Yes,Delay,Yes,No,Yes,Competition,,Negative,Gender,High
RCT56960,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,69,10,Bi-weekly,125,≥18,60% M/40% F,0-2,3,3,Moderate impairment,Nausea,Dermatological,Gastrointestinal,Moderate,3,16.07,No,Yes,Dose reduction,Premedication,2,47,Yes,Delay,No,Yes,No,Regulatory,,Positive,Age,Unknown
RCT98555,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 2,120,8,Monthly,36,18-75,50% M/50% F,0-1,2,0,Moderate impairment,Fatigue,Hepatic,Hepatic,Moderate,5,12.24,Yes,No,Treatment hold,Dose adjustment,1,59,No,Delay,Yes,No,Yes,Efficacy,Yes,Negative,Gender,Low
RCT25992,Rituximab,Anti-CD20,Crossover,None,Phase 1,226,11,Monthly,141,≥18,40% M/60% F,0-1,1,2,Normal,Rash,Cardiac,Blood,Severe,4,29.04,Yes,Yes,Discontinuation,Monitoring,24,9,No,Discontinuation,Yes,Yes,No,Regulatory,,Unknown,None,Medium
RCT19963,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,163,8,Monthly,159,21-85,50% M/50% F,0-2,0,0,Moderate impairment,Infusion reaction,Hepatic,Cardiac,Mild,5,13.71,Yes,Yes,Discontinuation,Monitoring,13,9,No,Reduction,No,Yes,Yes,Regulatory,No,Unknown,Age,High
RCT30430,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,245,1,Bi-weekly,121,21-85,50% M/50% F,0-1,0,0,Mild impairment,Nausea,Hematological,Blood,Severe,1,7.83,No,Yes,Discontinuation,Premedication,18,5,Yes,None,Yes,No,No,Safety,,None,Gender,High
RCT76335,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,277,4,Weekly,126,18-75,50% M/50% F,1-2,2,0,Moderate impairment,Nausea,Hepatic,Hepatic,Severe,2,16.44,No,No,Discontinuation,Patient education,9,13,No,None,No,Yes,Yes,,Yes,Unknown,Age,Medium
RCT24368,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 1,42,6,Bi-weekly,162,18-65,60% M/40% F,1-2,0,1,Mild impairment,Nausea,Hematological,Blood,Severe,2,5.76,No,Yes,Supportive care,Patient education,9,29,Yes,Reduction,Yes,No,Yes,Competition,No,None,ECOG,Medium
RCT49743,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,83,13,Bi-weekly,57,18-75,60% M/40% F,1-2,4,2,Mild impairment,Nausea,Cardiac,Cardiac,Moderate,3,16.78,Yes,No,Treatment hold,Patient education,11,40,Yes,Delay,Yes,No,Yes,Efficacy,,Unknown,Prior treatments,Unknown
RCT82587,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,211,10,Monthly,150,21-85,50% M/50% F,0-2,5,1,Moderate impairment,Infusion reaction,Hematological,Gastrointestinal,Mild,3,26.11,Yes,No,Treatment hold,Monitoring,13,42,No,Reduction,Yes,No,No,Safety,,Positive,Gender,Medium
RCT22850,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 1,219,2,Every 3 weeks,129,18-65,60% M/40% F,1-2,1,3,Moderate impairment,Fatigue,Cardiac,Blood,Severe,2,23.96,Yes,Yes,Dose reduction,Monitoring,15,5,No,None,Yes,Yes,No,Safety,,Positive,None,Medium
RCT12828,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 1,56,8,Monthly,106,18-65,40% M/60% F,0-1,2,2,Normal,Neutropenia,Dermatological,Blood,Moderate,1,5.52,No,No,Treatment hold,Patient education,25,46,Yes,Delay,No,Yes,No,Safety,Yes,Positive,ECOG,Low
RCT29535,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,67,4,Weekly,121,21-85,40% M/60% F,0-2,1,0,Mild impairment,Fatigue,Cardiac,Hepatic,Severe,5,8.68,Yes,No,Dose reduction,Premedication,4,55,Yes,Delay,Yes,No,Yes,,Yes,Positive,Prior treatments,Medium
RCT45858,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,145,8,Monthly,125,18-75,60% M/40% F,0-2,4,1,Moderate impairment,Neutropenia,Cardiac,Cardiac,Mild,2,13.01,No,Yes,Discontinuation,Premedication,1,24,Yes,None,No,No,No,,Yes,None,Age,Low
RCT59310,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 3,138,14,Bi-weekly,47,21-85,40% M/60% F,0-2,1,0,Mild impairment,Rash,Hematological,Hepatic,Moderate,3,29.89,Yes,No,Supportive care,Monitoring,10,9,Yes,Reduction,Yes,Yes,Yes,Efficacy,,Negative,ECOG,High
RCT53516,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 1,111,2,Every 3 weeks,131,21-85,60% M/40% F,0-2,5,3,Mild impairment,Neutropenia,Dermatological,Hepatic,Severe,4,10.52,Yes,Yes,Supportive care,Monitoring,12,9,No,Reduction,No,No,No,Competition,No,Negative,Age,Unknown
RCT72175,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 3,230,10,Bi-weekly,161,≥18,40% M/60% F,0-1,3,2,Normal,Fatigue,Dermatological,Hepatic,Moderate,2,17.5,No,Yes,Treatment hold,Premedication,5,20,Yes,Delay,No,Yes,No,Efficacy,No,Negative,Gender,High
RCT82469,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,179,4,Weekly,76,18-75,40% M/60% F,0-2,3,1,Normal,Fatigue,Cardiac,Cardiac,Moderate,3,19.86,Yes,Yes,Treatment hold,Premedication,1,14,No,Reduction,Yes,Yes,No,Regulatory,No,Negative,Prior treatments,High
RCT23102,Rituximab,Anti-CD20,Crossover,None,Phase 2,25,1,Monthly,116,21-85,60% M/40% F,1-2,1,3,Mild impairment,Rash,Dermatological,Blood,Severe,5,29.87,No,No,Treatment hold,Patient education,12,36,Yes,Delay,Yes,Yes,No,Safety,Yes,None,None,Unknown
RCT31558,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,266,3,Every 3 weeks,103,18-75,60% M/40% F,1-2,5,3,Mild impairment,Nausea,Gastrointestinal,Skin,Moderate,3,15.91,Yes,Yes,Dose reduction,Patient education,19,38,Yes,Discontinuation,Yes,No,Yes,Competition,No,Positive,Age,High
RCT72657,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,33,1,Weekly,122,≥18,50% M/50% F,0-1,5,1,Mild impairment,Rash,Hepatic,Cardiac,Mild,1,8.2,No,Yes,Discontinuation,Patient education,28,51,No,Delay,Yes,Yes,No,,,Positive,Age,Unknown
RCT41594,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,76,4,Every 3 weeks,65,18-75,50% M/50% F,1-2,5,1,Moderate impairment,Rash,Gastrointestinal,Hepatic,Moderate,4,14.92,No,Yes,Discontinuation,Patient education,24,57,Yes,Delay,No,Yes,No,Efficacy,Yes,Positive,Age,Unknown
RCT19058,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,183,2,Every 3 weeks,105,21-85,40% M/60% F,1-2,0,1,Normal,Infusion reaction,Hepatic,Cardiac,Moderate,3,26.3,No,No,Dose reduction,Dose adjustment,1,39,Yes,Discontinuation,Yes,Yes,Yes,Safety,No,Positive,Prior treatments,High
RCT69613,Rituximab,Anti-CD20,Randomized,None,Phase 3,224,4,Monthly,170,21-85,40% M/60% F,0-2,1,2,Moderate impairment,Nausea,Gastrointestinal,Cardiac,Moderate,1,16.46,Yes,Yes,Treatment hold,Patient education,2,27,No,Discontinuation,No,No,Yes,,Yes,Unknown,Age,Low
RCT18532,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,100,14,Bi-weekly,40,18-65,50% M/50% F,0-2,4,3,Normal,Rash,Cardiac,Cardiac,Mild,2,17.98,No,Yes,Discontinuation,Premedication,4,10,Yes,None,No,No,No,,,Positive,Gender,Unknown
RCT90870,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,29,8,Every 3 weeks,169,≥18,40% M/60% F,0-2,5,3,Mild impairment,Rash,Hematological,Blood,Mild,3,11.19,No,No,Supportive care,Monitoring,23,16,Yes,Delay,Yes,No,Yes,Efficacy,,Positive,ECOG,Unknown
RCT20365,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,279,5,Monthly,47,≥18,40% M/60% F,0-2,0,0,Moderate impairment,Nausea,Cardiac,Hepatic,Severe,5,4.88,No,Yes,Discontinuation,Monitoring,2,24,Yes,Reduction,No,No,No,Regulatory,,Unknown,Age,Low
RCT54884,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,133,12,Bi-weekly,129,18-75,50% M/50% F,0-1,4,0,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Moderate,3,29.33,No,Yes,Dose reduction,Patient education,2,33,Yes,Discontinuation,Yes,No,Yes,Competition,,Unknown,None,Unknown
RCT99931,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 2,172,4,Every 3 weeks,81,≥18,40% M/60% F,0-1,1,2,Mild impairment,Nausea,Dermatological,Skin,Severe,3,23.46,Yes,No,Dose reduction,Monitoring,8,54,No,None,Yes,No,No,,Yes,None,Gender,Unknown
RCT37028,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 3,30,2,Every 3 weeks,162,18-75,60% M/40% F,0-1,3,3,Moderate impairment,Neutropenia,Dermatological,Hepatic,Moderate,2,27.63,Yes,No,Discontinuation,Patient education,23,12,Yes,Discontinuation,No,No,No,Efficacy,,Positive,Age,Unknown
RCT59366,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 1,277,7,Weekly,30,≥18,50% M/50% F,1-2,3,0,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Mild,1,13.4,Yes,Yes,Supportive care,Patient education,23,2,Yes,Delay,No,No,Yes,,Yes,Positive,Age,High
RCT27301,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,102,2,Bi-weekly,168,≥18,40% M/60% F,1-2,3,0,Normal,Fatigue,Gastrointestinal,Hepatic,Severe,5,25.47,Yes,Yes,Dose reduction,Premedication,19,21,Yes,Reduction,No,Yes,Yes,,No,Negative,Age,Low
RCT39458,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,140,13,Monthly,76,≥18,40% M/60% F,1-2,0,3,Normal,Rash,Hepatic,Gastrointestinal,Moderate,4,29.98,Yes,Yes,Discontinuation,Premedication,23,19,No,Discontinuation,No,Yes,Yes,,Yes,Positive,Age,Low
RCT85356,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 2,287,14,Bi-weekly,76,21-85,60% M/40% F,0-2,4,0,Normal,Fatigue,Dermatological,Blood,Severe,4,19.96,No,No,Supportive care,Monitoring,16,49,No,None,No,Yes,Yes,Safety,No,Negative,Gender,Unknown
RCT86413,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 2,133,1,Every 3 weeks,174,≥18,60% M/40% F,0-1,2,0,Moderate impairment,Fatigue,Gastrointestinal,Gastrointestinal,Severe,5,23.01,No,Yes,Treatment hold,Patient education,25,39,Yes,Discontinuation,No,Yes,No,Efficacy,,Negative,Age,Low
RCT65971,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,160,5,Every 3 weeks,166,18-75,40% M/60% F,0-1,0,3,Normal,Neutropenia,Gastrointestinal,Hepatic,Mild,4,16.0,Yes,No,Supportive care,Premedication,17,15,No,Reduction,No,Yes,Yes,Competition,Yes,Positive,None,High
RCT66677,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,157,5,Weekly,49,≥18,60% M/40% F,1-2,1,0,Normal,Infusion reaction,Dermatological,Hepatic,Moderate,3,19.37,No,Yes,Supportive care,Monitoring,12,4,Yes,None,No,No,Yes,Competition,No,Negative,ECOG,Low
RCT20975,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,241,12,Weekly,151,≥18,40% M/60% F,0-1,5,1,Moderate impairment,Rash,Cardiac,Cardiac,Moderate,3,6.08,No,Yes,Supportive care,Patient education,12,3,Yes,None,No,Yes,Yes,Competition,,Unknown,Age,Medium
RCT48247,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 2,116,6,Weekly,160,≥18,50% M/50% F,0-1,5,2,Normal,Neutropenia,Hematological,Gastrointestinal,Mild,3,8.31,No,Yes,Treatment hold,Monitoring,7,43,No,Discontinuation,Yes,No,Yes,Competition,,None,None,Unknown
RCT61070,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 2,163,3,Bi-weekly,142,21-85,50% M/50% F,0-2,4,2,Normal,Rash,Hepatic,Hepatic,Mild,1,23.31,Yes,Yes,Dose reduction,Monitoring,28,35,No,Delay,Yes,Yes,No,Efficacy,No,None,Age,Low
RCT90610,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,242,15,Weekly,167,18-75,50% M/50% F,1-2,1,1,Moderate impairment,Nausea,Hepatic,Skin,Moderate,2,3.81,No,Yes,Discontinuation,Monitoring,6,30,Yes,None,Yes,No,Yes,Competition,,Positive,Prior treatments,Low
RCT90524,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 1,120,3,Monthly,72,≥18,40% M/60% F,1-2,3,3,Normal,Neutropenia,Cardiac,Blood,Severe,5,28.17,No,No,Treatment hold,Premedication,17,18,No,None,No,Yes,Yes,Regulatory,No,Unknown,Age,Medium
RCT25732,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,50,7,Bi-weekly,107,≥18,40% M/60% F,0-1,5,1,Mild impairment,Infusion reaction,Hematological,Gastrointestinal,Moderate,3,9.96,Yes,Yes,Supportive care,Premedication,27,4,Yes,None,No,Yes,Yes,Competition,Yes,Positive,None,Medium
RCT28091,Rituximab,Anti-CD20,Crossover,None,Phase 2,279,9,Every 3 weeks,85,18-65,40% M/60% F,0-1,0,0,Normal,Neutropenia,Dermatological,Blood,Severe,4,22.81,No,Yes,Discontinuation,Dose adjustment,21,2,No,Delay,Yes,No,No,Competition,,None,Gender,High
RCT90880,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,241,6,Monthly,177,18-75,40% M/60% F,0-2,2,3,Mild impairment,Fatigue,Gastrointestinal,Hepatic,Moderate,1,3.66,No,Yes,Supportive care,Patient education,19,33,Yes,None,Yes,Yes,Yes,Safety,,Negative,None,Low
RCT33624,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,44,4,Monthly,85,≥18,40% M/60% F,0-2,4,2,Normal,Nausea,Hematological,Skin,Mild,2,9.66,No,No,Discontinuation,Monitoring,16,49,Yes,Delay,Yes,Yes,No,Competition,No,Negative,None,Medium
RCT42075,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,97,6,Weekly,93,≥18,60% M/40% F,1-2,0,3,Moderate impairment,Neutropenia,Cardiac,Gastrointestinal,Mild,2,26.82,Yes,No,Discontinuation,Patient education,22,31,No,Discontinuation,Yes,Yes,Yes,Efficacy,Yes,Unknown,Prior treatments,High
RCT82364,Cetuximab,Anti-EGFR,Single-arm,None,Phase 3,70,15,Every 3 weeks,89,18-65,60% M/40% F,0-1,5,0,Mild impairment,Rash,Cardiac,Cardiac,Moderate,3,21.23,Yes,No,Discontinuation,Patient education,4,43,No,Discontinuation,No,Yes,Yes,Competition,No,Positive,Prior treatments,Medium
RCT30884,Rituximab,Anti-CD20,Randomized,Placebo,Phase 1,171,11,Bi-weekly,34,18-65,50% M/50% F,0-1,3,0,Moderate impairment,Fatigue,Dermatological,Cardiac,Severe,4,7.2,Yes,Yes,Supportive care,Dose adjustment,6,40,Yes,Discontinuation,No,No,Yes,Safety,,None,Gender,Low
RCT80598,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,154,2,Every 3 weeks,117,18-65,50% M/50% F,0-1,2,0,Mild impairment,Rash,Hepatic,Cardiac,Severe,3,25.33,Yes,No,Supportive care,Premedication,16,13,Yes,Reduction,Yes,Yes,No,Regulatory,No,Negative,None,Medium
RCT67994,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 2,250,4,Monthly,102,21-85,60% M/40% F,0-1,1,3,Mild impairment,Infusion reaction,Cardiac,Skin,Severe,2,12.77,No,No,Supportive care,Patient education,21,7,No,Discontinuation,Yes,No,No,Efficacy,Yes,Unknown,Gender,Low
RCT18060,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,126,9,Every 3 weeks,39,≥18,40% M/60% F,1-2,5,0,Mild impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,1,18.79,Yes,Yes,Supportive care,Premedication,20,56,No,None,No,Yes,No,,Yes,None,None,High
RCT98391,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,167,14,Weekly,83,18-65,40% M/60% F,0-1,1,3,Moderate impairment,Infusion reaction,Hematological,Skin,Severe,1,21.77,No,Yes,Discontinuation,Monitoring,26,60,No,Reduction,No,No,No,Regulatory,Yes,Negative,ECOG,Low
RCT47847,Rituximab,Anti-CD20,Single-arm,None,Phase 1,139,12,Monthly,93,18-75,50% M/50% F,0-2,1,3,Normal,Nausea,Hepatic,Hepatic,Moderate,4,21.06,No,Yes,Dose reduction,Dose adjustment,13,33,No,None,No,Yes,No,Regulatory,Yes,Positive,Gender,Unknown
RCT71689,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,139,15,Bi-weekly,93,18-65,40% M/60% F,1-2,1,0,Moderate impairment,Nausea,Hematological,Gastrointestinal,Severe,5,23.1,Yes,No,Supportive care,Patient education,10,17,Yes,None,Yes,Yes,Yes,Regulatory,No,Unknown,None,Low
RCT68655,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 2,164,6,Bi-weekly,178,18-75,60% M/40% F,0-2,3,3,Moderate impairment,Nausea,Gastrointestinal,Skin,Severe,2,14.57,Yes,No,Treatment hold,Patient education,11,58,No,Delay,Yes,Yes,No,Safety,Yes,Negative,Prior treatments,Low
RCT77779,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,221,5,Every 3 weeks,66,18-75,60% M/40% F,0-2,2,1,Normal,Fatigue,Hematological,Skin,Moderate,3,17.77,Yes,No,Treatment hold,Monitoring,25,20,No,Delay,No,No,Yes,,,Positive,ECOG,High
RCT23015,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 2,282,15,Every 3 weeks,114,≥18,40% M/60% F,0-1,2,0,Mild impairment,Rash,Hematological,Skin,Severe,4,15.53,No,Yes,Discontinuation,Dose adjustment,9,39,Yes,Reduction,No,No,Yes,Regulatory,No,Unknown,ECOG,High
RCT84965,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,38,3,Weekly,104,21-85,40% M/60% F,1-2,3,3,Normal,Neutropenia,Gastrointestinal,Blood,Mild,5,22.14,Yes,No,Supportive care,Premedication,9,8,No,Reduction,No,No,Yes,Competition,No,None,Age,Low
RCT47200,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,199,7,Bi-weekly,54,18-65,60% M/40% F,0-2,4,1,Mild impairment,Neutropenia,Gastrointestinal,Blood,Mild,3,27.11,Yes,No,Discontinuation,Premedication,15,31,Yes,Delay,No,Yes,Yes,Efficacy,,Unknown,Prior treatments,Unknown
RCT81050,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,223,7,Weekly,55,≥18,50% M/50% F,0-2,3,0,Moderate impairment,Nausea,Dermatological,Cardiac,Severe,1,28.0,Yes,No,Dose reduction,Premedication,15,35,Yes,None,No,No,Yes,Regulatory,,None,ECOG,Medium
RCT94718,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 3,123,14,Weekly,64,≥18,60% M/40% F,0-1,1,2,Mild impairment,Fatigue,Cardiac,Skin,Moderate,2,16.66,Yes,No,Treatment hold,Monitoring,10,2,Yes,Delay,No,Yes,No,Efficacy,,Positive,Prior treatments,Medium
RCT65108,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,41,1,Every 3 weeks,62,18-75,60% M/40% F,0-1,4,3,Normal,Fatigue,Hepatic,Skin,Moderate,5,18.36,No,No,Treatment hold,Premedication,12,60,Yes,Discontinuation,No,Yes,Yes,Efficacy,Yes,Unknown,Age,Low
RCT98028,Rituximab,Anti-CD20,Crossover,None,Phase 3,69,1,Bi-weekly,56,≥18,40% M/60% F,0-2,0,2,Mild impairment,Neutropenia,Gastrointestinal,Blood,Moderate,5,29.94,No,No,Dose reduction,Premedication,8,12,Yes,Delay,No,No,Yes,,No,Negative,Prior treatments,High
RCT36156,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,208,1,Weekly,53,21-85,50% M/50% F,0-2,2,2,Moderate impairment,Fatigue,Cardiac,Hepatic,Severe,2,7.07,No,No,Treatment hold,Patient education,20,46,Yes,Delay,No,No,No,Safety,Yes,None,ECOG,High
RCT86014,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 2,132,14,Weekly,111,21-85,50% M/50% F,1-2,3,1,Normal,Rash,Hepatic,Blood,Moderate,1,28.14,No,No,Dose reduction,Patient education,13,60,Yes,Discontinuation,Yes,Yes,No,,,Unknown,Prior treatments,Medium
RCT61501,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 3,177,2,Monthly,99,18-75,50% M/50% F,0-2,3,2,Mild impairment,Nausea,Hematological,Skin,Mild,4,29.08,Yes,Yes,Discontinuation,Dose adjustment,18,16,No,Discontinuation,No,No,Yes,,,Positive,Age,Unknown
RCT74974,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 3,96,15,Bi-weekly,148,18-65,60% M/40% F,0-2,2,0,Normal,Neutropenia,Dermatological,Blood,Severe,4,26.48,No,No,Treatment hold,Premedication,26,40,No,None,No,No,Yes,Regulatory,No,None,None,Unknown
RCT57059,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,166,12,Monthly,151,18-65,50% M/50% F,1-2,3,1,Moderate impairment,Infusion reaction,Cardiac,Hepatic,Mild,5,29.52,No,Yes,Discontinuation,Monitoring,4,52,Yes,Reduction,Yes,No,Yes,Safety,Yes,Unknown,ECOG,Medium
RCT86664,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 3,139,4,Weekly,174,≥18,50% M/50% F,0-1,0,2,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,1,20.73,No,Yes,Dose reduction,Premedication,21,32,No,Delay,Yes,No,Yes,,Yes,None,Age,Medium
RCT29393,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,284,12,Monthly,57,21-85,40% M/60% F,1-2,0,1,Mild impairment,Nausea,Hepatic,Cardiac,Severe,1,9.48,No,Yes,Treatment hold,Monitoring,3,11,No,Delay,Yes,Yes,No,Regulatory,,Unknown,ECOG,Low
RCT63982,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,139,15,Every 3 weeks,35,≥18,50% M/50% F,0-2,4,2,Normal,Fatigue,Gastrointestinal,Blood,Severe,1,6.17,No,Yes,Dose reduction,Patient education,8,39,No,Delay,No,No,Yes,Regulatory,Yes,None,Gender,Unknown
RCT65730,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,91,7,Weekly,108,≥18,50% M/50% F,0-2,3,3,Moderate impairment,Neutropenia,Cardiac,Blood,Mild,4,15.42,Yes,No,Supportive care,Patient education,26,4,Yes,Delay,No,Yes,No,Safety,,Negative,Prior treatments,High
RCT53954,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,201,10,Weekly,87,18-65,40% M/60% F,1-2,2,1,Moderate impairment,Infusion reaction,Cardiac,Cardiac,Moderate,4,14.89,No,No,Dose reduction,Patient education,21,44,No,Reduction,Yes,No,Yes,,,Negative,ECOG,Unknown
RCT89010,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,279,11,Monthly,34,18-75,60% M/40% F,0-1,2,0,Moderate impairment,Nausea,Cardiac,Hepatic,Severe,3,13.3,No,Yes,Treatment hold,Patient education,21,60,No,Delay,No,Yes,No,Efficacy,No,Negative,None,Medium
RCT10807,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,202,8,Monthly,66,18-75,50% M/50% F,0-2,3,3,Normal,Fatigue,Dermatological,Skin,Mild,4,29.95,Yes,No,Discontinuation,Dose adjustment,5,48,No,Reduction,No,Yes,Yes,Regulatory,No,None,Age,Medium
RCT45347,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,60,7,Monthly,171,18-65,40% M/60% F,0-2,1,1,Mild impairment,Infusion reaction,Gastrointestinal,Skin,Moderate,4,2.28,Yes,No,Discontinuation,Dose adjustment,21,27,No,Reduction,No,Yes,No,Safety,,None,Age,Medium
RCT50255,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,74,4,Monthly,59,21-85,40% M/60% F,1-2,1,2,Normal,Infusion reaction,Gastrointestinal,Cardiac,Mild,5,9.94,No,No,Supportive care,Premedication,2,46,Yes,None,Yes,Yes,Yes,Competition,No,None,Age,Medium
RCT50384,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,133,8,Bi-weekly,108,18-75,50% M/50% F,0-1,2,1,Moderate impairment,Fatigue,Dermatological,Cardiac,Severe,1,24.48,Yes,Yes,Discontinuation,Monitoring,5,59,Yes,Discontinuation,No,No,No,Safety,,Unknown,ECOG,Medium
RCT87588,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,217,1,Bi-weekly,150,18-65,50% M/50% F,0-2,1,3,Mild impairment,Nausea,Cardiac,Blood,Mild,4,15.55,Yes,Yes,Dose reduction,Dose adjustment,18,40,Yes,Reduction,No,Yes,No,Competition,,Unknown,Gender,Medium
RCT77449,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,183,1,Monthly,169,21-85,60% M/40% F,1-2,5,1,Moderate impairment,Infusion reaction,Gastrointestinal,Blood,Severe,4,21.54,No,No,Discontinuation,Dose adjustment,11,32,No,Delay,No,Yes,No,Competition,No,None,ECOG,Medium
RCT79275,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,181,7,Every 3 weeks,125,18-75,40% M/60% F,1-2,0,0,Normal,Infusion reaction,Cardiac,Skin,Mild,2,22.02,No,No,Dose reduction,Premedication,22,29,No,Discontinuation,No,Yes,Yes,Regulatory,,Positive,Age,Unknown
RCT38122,Cetuximab,Anti-EGFR,Single-arm,None,Phase 3,85,11,Bi-weekly,75,18-75,40% M/60% F,0-1,3,1,Normal,Infusion reaction,Cardiac,Blood,Severe,2,6.35,Yes,Yes,Dose reduction,Patient education,11,6,No,Reduction,Yes,No,No,,Yes,Positive,Age,Low
RCT50077,Rituximab,Anti-CD20,Randomized,None,Phase 1,38,6,Weekly,107,≥18,40% M/60% F,0-1,5,3,Mild impairment,Infusion reaction,Hepatic,Skin,Severe,5,21.69,No,No,Discontinuation,Patient education,17,48,Yes,Reduction,No,No,Yes,Regulatory,,Unknown,ECOG,Low
RCT91245,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,160,7,Monthly,57,18-65,60% M/40% F,0-2,4,3,Mild impairment,Neutropenia,Gastrointestinal,Hepatic,Severe,2,17.98,No,Yes,Treatment hold,Premedication,16,34,Yes,None,Yes,No,No,Efficacy,No,Negative,Prior treatments,Low
RCT46165,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 1,290,2,Bi-weekly,153,18-75,40% M/60% F,0-2,1,1,Mild impairment,Fatigue,Hematological,Gastrointestinal,Moderate,3,17.15,No,No,Treatment hold,Monitoring,18,33,Yes,Delay,Yes,Yes,No,Safety,,Positive,ECOG,Low
RCT68970,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,207,5,Bi-weekly,66,18-75,50% M/50% F,1-2,1,0,Moderate impairment,Nausea,Dermatological,Cardiac,Severe,1,6.56,No,No,Treatment hold,Dose adjustment,1,52,No,Reduction,No,No,Yes,Efficacy,Yes,Unknown,None,High
RCT19588,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 3,94,6,Bi-weekly,115,≥18,50% M/50% F,0-2,5,1,Normal,Rash,Hepatic,Skin,Severe,2,6.77,Yes,Yes,Supportive care,Dose adjustment,26,9,No,Delay,Yes,No,Yes,,Yes,None,ECOG,Medium
RCT66963,Rituximab,Anti-CD20,Crossover,None,Phase 3,80,6,Every 3 weeks,75,18-65,60% M/40% F,0-1,0,0,Mild impairment,Nausea,Dermatological,Hepatic,Severe,4,8.19,Yes,Yes,Treatment hold,Premedication,15,44,No,Delay,Yes,Yes,Yes,Efficacy,No,Positive,Gender,Medium
RCT46436,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 2,209,7,Monthly,120,18-65,40% M/60% F,0-1,1,2,Moderate impairment,Fatigue,Hepatic,Blood,Severe,5,11.94,No,Yes,Treatment hold,Dose adjustment,23,11,No,None,No,Yes,No,Efficacy,Yes,Positive,Age,Unknown
RCT42439,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,231,3,Every 3 weeks,40,21-85,40% M/60% F,0-2,1,3,Moderate impairment,Neutropenia,Cardiac,Hepatic,Severe,4,7.4,Yes,Yes,Discontinuation,Premedication,15,6,No,Delay,No,Yes,No,Safety,,Negative,ECOG,Unknown
RCT20868,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,52,5,Weekly,164,≥18,40% M/60% F,0-2,1,2,Moderate impairment,Rash,Gastrointestinal,Gastrointestinal,Severe,5,8.87,Yes,Yes,Dose reduction,Patient education,13,40,No,None,No,No,No,Efficacy,Yes,None,ECOG,High
RCT79507,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,29,3,Monthly,68,18-65,60% M/40% F,0-1,4,2,Moderate impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Moderate,3,28.6,No,Yes,Treatment hold,Dose adjustment,25,60,Yes,Discontinuation,No,Yes,No,Efficacy,Yes,Negative,Gender,High
RCT98433,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,101,8,Bi-weekly,84,21-85,50% M/50% F,0-2,0,3,Normal,Nausea,Hematological,Cardiac,Moderate,4,14.57,No,No,Discontinuation,Dose adjustment,20,14,No,Reduction,Yes,Yes,Yes,Competition,,Positive,ECOG,Unknown
RCT89658,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 2,219,5,Monthly,145,18-65,60% M/40% F,0-2,0,0,Moderate impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,5,26.58,Yes,No,Supportive care,Patient education,11,19,Yes,None,No,Yes,No,Safety,,Unknown,ECOG,Medium
RCT97669,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 1,41,8,Monthly,39,18-65,40% M/60% F,0-2,3,2,Moderate impairment,Nausea,Gastrointestinal,Skin,Mild,5,17.87,Yes,No,Supportive care,Patient education,8,14,No,Reduction,No,Yes,No,Regulatory,,Positive,Gender,Low
RCT38853,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,235,15,Bi-weekly,128,18-65,40% M/60% F,0-2,5,2,Normal,Rash,Gastrointestinal,Gastrointestinal,Mild,2,15.06,Yes,Yes,Discontinuation,Monitoring,21,33,No,Delay,Yes,Yes,Yes,,Yes,Negative,Prior treatments,Low
RCT73623,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,157,12,Weekly,55,18-65,40% M/60% F,0-1,0,0,Moderate impairment,Infusion reaction,Cardiac,Cardiac,Severe,3,20.77,Yes,No,Treatment hold,Dose adjustment,14,51,Yes,Discontinuation,No,Yes,No,,No,Negative,None,Medium
RCT83600,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,295,4,Bi-weekly,134,18-65,50% M/50% F,0-2,2,0,Moderate impairment,Infusion reaction,Hematological,Skin,Moderate,1,23.63,No,No,Dose reduction,Dose adjustment,1,23,No,None,No,Yes,Yes,,Yes,Negative,ECOG,High
RCT56922,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 2,271,4,Bi-weekly,59,21-85,40% M/60% F,0-1,5,3,Normal,Infusion reaction,Gastrointestinal,Blood,Severe,3,22.16,Yes,Yes,Discontinuation,Monitoring,11,46,No,Delay,Yes,No,No,Competition,No,None,ECOG,Low
RCT70384,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,114,5,Monthly,132,18-65,60% M/40% F,1-2,5,1,Mild impairment,Rash,Hepatic,Skin,Severe,1,13.41,No,Yes,Treatment hold,Monitoring,19,29,No,None,Yes,Yes,Yes,Regulatory,Yes,Negative,Age,High
RCT53989,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,187,10,Weekly,126,18-75,50% M/50% F,0-2,5,0,Mild impairment,Infusion reaction,Gastrointestinal,Cardiac,Moderate,3,3.44,Yes,No,Treatment hold,Monitoring,7,55,No,Discontinuation,Yes,No,No,Regulatory,Yes,Positive,ECOG,High
RCT63154,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 3,220,3,Monthly,106,21-85,50% M/50% F,0-1,1,1,Moderate impairment,Neutropenia,Hematological,Gastrointestinal,Severe,4,21.0,Yes,No,Discontinuation,Premedication,8,50,Yes,None,No,Yes,Yes,Competition,No,Positive,None,Low
RCT78615,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,224,13,Bi-weekly,43,18-65,50% M/50% F,1-2,0,1,Normal,Neutropenia,Hematological,Skin,Moderate,3,25.97,No,No,Supportive care,Dose adjustment,28,38,Yes,Delay,Yes,No,No,,,None,None,High
RCT25940,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,74,6,Every 3 weeks,86,21-85,40% M/60% F,0-1,0,1,Moderate impairment,Rash,Hematological,Skin,Mild,5,26.04,Yes,Yes,Treatment hold,Patient education,12,60,Yes,None,Yes,Yes,No,Safety,,Unknown,Age,High
RCT86173,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 1,176,4,Weekly,64,21-85,50% M/50% F,0-2,5,2,Normal,Infusion reaction,Hepatic,Hepatic,Moderate,4,16.67,No,Yes,Supportive care,Premedication,5,12,Yes,None,Yes,No,No,Safety,No,Positive,ECOG,High
RCT97732,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 3,131,5,Monthly,165,21-85,60% M/40% F,1-2,3,0,Moderate impairment,Neutropenia,Hematological,Cardiac,Mild,4,21.05,No,Yes,Dose reduction,Patient education,14,54,No,Reduction,No,Yes,Yes,Safety,No,Negative,Age,Medium
RCT67279,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,292,15,Monthly,180,18-75,40% M/60% F,1-2,2,2,Mild impairment,Neutropenia,Hepatic,Cardiac,Mild,1,10.35,Yes,Yes,Treatment hold,Premedication,5,15,No,Reduction,No,No,Yes,,Yes,Unknown,Prior treatments,Medium
RCT71545,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,182,14,Monthly,72,18-65,50% M/50% F,0-2,5,0,Normal,Neutropenia,Hematological,Skin,Severe,4,2.03,Yes,No,Discontinuation,Monitoring,25,59,No,None,Yes,No,No,,,Unknown,Gender,Unknown
RCT11926,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,223,9,Weekly,96,21-85,40% M/60% F,0-2,4,3,Mild impairment,Neutropenia,Hematological,Blood,Mild,2,15.87,No,Yes,Dose reduction,Dose adjustment,22,39,Yes,Delay,No,No,No,,No,Negative,ECOG,Unknown
RCT13806,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,176,10,Weekly,154,18-75,40% M/60% F,0-2,5,3,Mild impairment,Fatigue,Gastrointestinal,Gastrointestinal,Severe,4,14.39,No,No,Supportive care,Premedication,13,39,Yes,Discontinuation,No,No,Yes,,Yes,Negative,Prior treatments,High
RCT43798,Bevacizumab,Anti-VEGF,Crossover,None,Phase 1,232,6,Every 3 weeks,151,21-85,50% M/50% F,1-2,5,3,Moderate impairment,Nausea,Dermatological,Hepatic,Mild,4,24.12,No,No,Dose reduction,Patient education,4,57,Yes,Reduction,No,No,Yes,Efficacy,No,Unknown,ECOG,Unknown
RCT71779,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 3,268,12,Weekly,163,21-85,50% M/50% F,1-2,4,1,Moderate impairment,Infusion reaction,Hepatic,Hepatic,Mild,2,14.71,Yes,Yes,Supportive care,Monitoring,28,59,No,Delay,No,No,No,Efficacy,No,Unknown,Gender,High
RCT58130,Rituximab,Anti-CD20,Single-arm,None,Phase 1,260,4,Bi-weekly,134,18-65,40% M/60% F,0-1,5,0,Mild impairment,Fatigue,Hepatic,Blood,Moderate,1,2.51,Yes,No,Treatment hold,Premedication,14,8,Yes,Reduction,Yes,Yes,Yes,Competition,,None,ECOG,Medium
RCT93634,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 2,78,10,Bi-weekly,161,18-75,50% M/50% F,0-2,0,0,Moderate impairment,Infusion reaction,Hematological,Skin,Mild,4,14.43,Yes,Yes,Supportive care,Monitoring,10,39,Yes,Discontinuation,Yes,No,Yes,Safety,No,None,ECOG,Low
RCT95223,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,240,3,Bi-weekly,164,18-75,40% M/60% F,1-2,3,0,Mild impairment,Infusion reaction,Dermatological,Gastrointestinal,Moderate,1,3.88,Yes,Yes,Dose reduction,Patient education,15,44,No,Reduction,Yes,No,Yes,,Yes,Negative,Age,High
RCT24150,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,183,13,Every 3 weeks,177,21-85,60% M/40% F,1-2,0,0,Moderate impairment,Infusion reaction,Gastrointestinal,Gastrointestinal,Severe,4,21.19,Yes,Yes,Discontinuation,Monitoring,18,58,No,Delay,No,No,Yes,,Yes,Positive,Gender,Low
RCT37459,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 3,233,6,Monthly,86,18-75,50% M/50% F,1-2,4,0,Mild impairment,Neutropenia,Hematological,Skin,Severe,4,29.33,No,No,Supportive care,Monitoring,7,5,No,Reduction,No,Yes,No,Regulatory,Yes,Negative,Prior treatments,Medium
RCT16651,Rituximab,Anti-CD20,Randomized,None,Phase 2,166,1,Bi-weekly,150,21-85,40% M/60% F,1-2,5,0,Moderate impairment,Fatigue,Hematological,Blood,Mild,1,25.29,No,No,Discontinuation,Dose adjustment,15,33,Yes,Discontinuation,Yes,Yes,Yes,Competition,,Negative,Prior treatments,Low
RCT34034,Trastuzumab,Anti-HER2,Single-arm,None,Phase 1,52,6,Bi-weekly,96,≥18,40% M/60% F,1-2,2,0,Normal,Infusion reaction,Hematological,Gastrointestinal,Severe,4,26.42,No,No,Treatment hold,Patient education,14,46,Yes,Delay,No,No,Yes,Competition,,Negative,Gender,Medium
RCT87478,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 3,96,6,Monthly,87,≥18,60% M/40% F,1-2,2,1,Moderate impairment,Infusion reaction,Gastrointestinal,Gastrointestinal,Mild,3,23.38,Yes,Yes,Treatment hold,Patient education,17,4,Yes,Delay,Yes,Yes,Yes,Safety,,None,None,High
RCT20181,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,192,7,Weekly,32,21-85,40% M/60% F,1-2,5,1,Normal,Nausea,Hepatic,Skin,Mild,4,24.47,Yes,Yes,Dose reduction,Premedication,17,23,No,Discontinuation,Yes,Yes,Yes,Regulatory,Yes,Positive,ECOG,Low
RCT54964,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 1,237,6,Monthly,58,21-85,60% M/40% F,0-2,0,1,Mild impairment,Nausea,Hepatic,Gastrointestinal,Severe,5,19.01,Yes,No,Treatment hold,Patient education,19,9,Yes,None,No,Yes,No,,No,None,Gender,Medium
RCT68550,Rituximab,Anti-CD20,Randomized,None,Phase 2,218,3,Every 3 weeks,97,21-85,50% M/50% F,0-1,1,2,Mild impairment,Nausea,Cardiac,Blood,Mild,2,7.13,No,Yes,Treatment hold,Dose adjustment,17,18,Yes,Delay,No,No,Yes,Competition,,Positive,Age,Unknown
RCT39797,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,229,1,Monthly,44,18-75,40% M/60% F,0-1,1,2,Mild impairment,Rash,Hematological,Blood,Moderate,5,14.62,No,No,Treatment hold,Dose adjustment,23,55,No,Delay,Yes,No,No,,Yes,Positive,ECOG,Unknown
RCT43596,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 3,265,10,Bi-weekly,106,≥18,50% M/50% F,1-2,4,3,Mild impairment,Fatigue,Hepatic,Gastrointestinal,Moderate,4,26.42,No,Yes,Dose reduction,Premedication,7,36,Yes,None,Yes,No,No,,Yes,Positive,Prior treatments,High
RCT94050,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 1,254,14,Bi-weekly,132,21-85,60% M/40% F,0-1,4,3,Normal,Fatigue,Gastrointestinal,Skin,Mild,1,15.49,Yes,No,Supportive care,Monitoring,5,27,Yes,None,No,No,Yes,Safety,Yes,None,Gender,Low
RCT93270,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,88,7,Every 3 weeks,125,21-85,50% M/50% F,0-2,2,0,Moderate impairment,Infusion reaction,Gastrointestinal,Skin,Mild,1,24.35,No,Yes,Dose reduction,Premedication,23,54,No,Reduction,Yes,No,Yes,,Yes,Negative,Prior treatments,Medium
RCT48782,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,169,7,Weekly,38,≥18,60% M/40% F,0-1,2,1,Mild impairment,Nausea,Hematological,Blood,Mild,4,3.73,No,Yes,Treatment hold,Premedication,8,9,No,Discontinuation,Yes,Yes,No,Safety,No,Positive,Prior treatments,Medium
RCT25719,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 3,57,5,Monthly,91,18-65,60% M/40% F,0-1,0,1,Mild impairment,Infusion reaction,Gastrointestinal,Skin,Mild,4,17.03,No,Yes,Supportive care,Premedication,20,42,Yes,None,No,No,No,,No,Unknown,Prior treatments,High
RCT89420,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,253,3,Bi-weekly,133,≥18,40% M/60% F,1-2,4,0,Mild impairment,Neutropenia,Cardiac,Cardiac,Severe,4,12.72,No,No,Treatment hold,Dose adjustment,11,58,No,None,Yes,No,No,Safety,Yes,Unknown,None,Unknown
RCT12117,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 2,79,6,Every 3 weeks,161,21-85,60% M/40% F,0-1,5,2,Normal,Nausea,Cardiac,Hepatic,Moderate,3,25.43,Yes,Yes,Dose reduction,Premedication,7,50,Yes,Reduction,No,Yes,Yes,,Yes,Negative,None,Low
RCT36332,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,164,6,Weekly,73,18-65,60% M/40% F,0-2,5,2,Moderate impairment,Neutropenia,Gastrointestinal,Cardiac,Severe,1,16.95,Yes,Yes,Discontinuation,Patient education,28,13,No,None,Yes,No,No,Competition,,Positive,Prior treatments,Low
RCT53410,Rituximab,Anti-CD20,Crossover,None,Phase 2,113,4,Bi-weekly,87,≥18,40% M/60% F,0-2,1,3,Mild impairment,Infusion reaction,Cardiac,Cardiac,Mild,5,2.19,No,Yes,Supportive care,Patient education,8,10,No,Delay,No,No,No,Competition,No,Negative,Gender,High
RCT22917,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,236,15,Every 3 weeks,171,≥18,50% M/50% F,0-1,5,2,Normal,Nausea,Cardiac,Hepatic,Mild,4,18.23,Yes,No,Dose reduction,Patient education,19,30,No,Discontinuation,No,No,Yes,Efficacy,,Unknown,Gender,Unknown
RCT42023,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,218,10,Every 3 weeks,56,21-85,40% M/60% F,0-1,2,3,Moderate impairment,Fatigue,Hepatic,Hepatic,Moderate,5,20.94,No,No,Treatment hold,Dose adjustment,25,48,No,Delay,Yes,Yes,No,Regulatory,,Unknown,Gender,Medium
RCT15898,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,224,4,Weekly,109,≥18,60% M/40% F,0-1,1,2,Moderate impairment,Neutropenia,Gastrointestinal,Skin,Moderate,5,13.0,No,Yes,Supportive care,Dose adjustment,28,27,Yes,Discontinuation,Yes,Yes,Yes,Regulatory,No,Unknown,ECOG,Medium
RCT92220,Cetuximab,Anti-EGFR,Randomized,None,Phase 1,109,11,Monthly,134,18-65,60% M/40% F,0-1,5,2,Normal,Infusion reaction,Cardiac,Gastrointestinal,Severe,1,16.6,No,No,Dose reduction,Premedication,28,46,No,None,No,Yes,Yes,Safety,,Negative,Age,Low
RCT31053,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,155,3,Bi-weekly,164,18-75,40% M/60% F,0-2,0,3,Mild impairment,Rash,Gastrointestinal,Gastrointestinal,Mild,2,14.56,Yes,Yes,Dose reduction,Premedication,3,13,Yes,None,No,Yes,Yes,Competition,No,Negative,Gender,High
RCT70125,Trastuzumab,Anti-HER2,Single-arm,None,Phase 1,293,8,Every 3 weeks,142,18-75,60% M/40% F,0-2,1,0,Mild impairment,Fatigue,Hematological,Gastrointestinal,Mild,3,5.17,Yes,No,Treatment hold,Premedication,26,46,Yes,Discontinuation,Yes,Yes,No,Competition,,Unknown,Gender,Low
RCT57390,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,212,10,Every 3 weeks,55,18-75,40% M/60% F,1-2,1,1,Normal,Nausea,Hepatic,Cardiac,Moderate,4,25.94,No,Yes,Treatment hold,Dose adjustment,18,12,No,Reduction,Yes,No,Yes,Safety,Yes,None,Gender,Unknown
RCT91286,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,194,5,Weekly,86,18-65,50% M/50% F,0-2,4,1,Mild impairment,Fatigue,Gastrointestinal,Blood,Severe,5,5.39,Yes,No,Treatment hold,Premedication,15,53,No,Discontinuation,No,No,Yes,Competition,,Unknown,ECOG,Medium
RCT90173,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,170,3,Every 3 weeks,35,18-65,50% M/50% F,0-1,0,0,Normal,Rash,Hematological,Gastrointestinal,Moderate,5,6.38,No,Yes,Discontinuation,Monitoring,10,19,No,None,No,Yes,No,Competition,No,Negative,ECOG,Low
RCT65695,Rituximab,Anti-CD20,Randomized,Placebo,Phase 1,281,10,Monthly,180,≥18,50% M/50% F,1-2,5,2,Normal,Nausea,Gastrointestinal,Hepatic,Severe,3,15.18,No,No,Treatment hold,Dose adjustment,19,17,Yes,Discontinuation,No,No,Yes,Regulatory,,None,Prior treatments,Low
RCT84961,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 1,116,8,Monthly,85,18-65,50% M/50% F,0-1,1,2,Moderate impairment,Infusion reaction,Dermatological,Cardiac,Moderate,1,20.66,No,Yes,Supportive care,Dose adjustment,15,47,Yes,Delay,No,No,Yes,Efficacy,Yes,Negative,Age,High
RCT17084,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 2,69,6,Every 3 weeks,48,18-65,60% M/40% F,0-2,0,0,Normal,Fatigue,Cardiac,Skin,Severe,5,20.23,No,No,Supportive care,Patient education,24,22,No,None,Yes,Yes,No,,,None,Age,Low
RCT74291,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 2,252,10,Weekly,134,21-85,50% M/50% F,0-1,5,3,Moderate impairment,Infusion reaction,Hematological,Cardiac,Mild,1,25.42,Yes,Yes,Supportive care,Premedication,6,57,Yes,Discontinuation,No,No,Yes,Efficacy,,None,Gender,Unknown
RCT52320,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,281,4,Bi-weekly,41,18-65,60% M/40% F,0-1,0,0,Normal,Fatigue,Gastrointestinal,Skin,Moderate,3,3.69,No,Yes,Supportive care,Premedication,19,23,Yes,Discontinuation,No,Yes,No,Efficacy,Yes,Negative,ECOG,Medium
RCT14884,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 3,95,6,Every 3 weeks,74,21-85,50% M/50% F,0-1,3,2,Moderate impairment,Neutropenia,Cardiac,Blood,Severe,2,26.51,Yes,No,Supportive care,Premedication,21,4,Yes,Delay,No,Yes,No,Regulatory,No,Positive,None,Medium
RCT48196,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 1,183,15,Bi-weekly,157,18-65,50% M/50% F,1-2,3,1,Normal,Neutropenia,Hematological,Gastrointestinal,Severe,3,10.91,No,Yes,Dose reduction,Patient education,15,19,Yes,Reduction,Yes,Yes,Yes,Regulatory,,Positive,Age,High
RCT14289,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,184,10,Weekly,179,18-65,50% M/50% F,1-2,1,3,Normal,Fatigue,Cardiac,Blood,Mild,3,13.31,Yes,Yes,Discontinuation,Monitoring,15,34,No,Discontinuation,No,No,Yes,Regulatory,No,Negative,None,Medium
RCT40956,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,277,6,Monthly,125,21-85,60% M/40% F,0-1,0,0,Moderate impairment,Nausea,Dermatological,Blood,Moderate,2,17.42,No,No,Discontinuation,Patient education,19,30,No,Delay,Yes,No,Yes,,No,Negative,None,Low
RCT87436,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,222,8,Weekly,59,21-85,60% M/40% F,0-1,3,3,Mild impairment,Fatigue,Cardiac,Blood,Severe,1,19.02,Yes,Yes,Dose reduction,Premedication,11,39,Yes,Reduction,Yes,No,No,Regulatory,,Positive,Prior treatments,Unknown
RCT61037,Rituximab,Anti-CD20,Single-arm,None,Phase 1,174,8,Every 3 weeks,60,≥18,40% M/60% F,1-2,4,1,Moderate impairment,Rash,Cardiac,Gastrointestinal,Severe,3,22.61,No,No,Treatment hold,Dose adjustment,16,11,No,None,No,Yes,Yes,Regulatory,Yes,Positive,None,Low
RCT22270,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,276,2,Weekly,36,18-75,50% M/50% F,0-2,1,2,Normal,Fatigue,Gastrointestinal,Blood,Moderate,4,7.3,Yes,No,Discontinuation,Monitoring,14,58,No,Reduction,No,Yes,Yes,Safety,Yes,Unknown,Age,Low
RCT53493,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 2,101,2,Bi-weekly,35,18-75,50% M/50% F,0-1,1,0,Moderate impairment,Neutropenia,Dermatological,Hepatic,Severe,2,21.97,Yes,Yes,Supportive care,Patient education,7,25,Yes,Reduction,No,Yes,Yes,Efficacy,Yes,Negative,ECOG,Unknown
RCT45804,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,252,14,Every 3 weeks,40,≥18,40% M/60% F,1-2,3,2,Mild impairment,Fatigue,Hepatic,Hepatic,Moderate,4,1.6,No,Yes,Supportive care,Dose adjustment,22,59,No,None,No,No,No,Competition,Yes,Positive,ECOG,Unknown
RCT60604,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,238,13,Bi-weekly,57,18-65,50% M/50% F,0-1,2,2,Mild impairment,Rash,Dermatological,Skin,Mild,2,21.83,Yes,No,Treatment hold,Dose adjustment,25,50,No,None,No,Yes,No,Regulatory,,Unknown,Prior treatments,High
RCT69950,Rituximab,Anti-CD20,Randomized,None,Phase 3,261,9,Monthly,150,18-65,50% M/50% F,1-2,5,1,Moderate impairment,Rash,Gastrointestinal,Gastrointestinal,Severe,1,27.27,Yes,Yes,Discontinuation,Patient education,16,28,No,Discontinuation,Yes,No,No,,No,Unknown,Gender,Low
RCT49972,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,162,2,Bi-weekly,98,21-85,40% M/60% F,1-2,2,2,Normal,Rash,Hematological,Hepatic,Moderate,5,28.45,Yes,No,Discontinuation,Dose adjustment,8,24,Yes,Delay,No,No,Yes,Regulatory,No,Positive,Age,High
RCT40975,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,300,12,Weekly,31,18-65,60% M/40% F,0-1,3,0,Mild impairment,Nausea,Hematological,Gastrointestinal,Mild,2,11.56,No,No,Supportive care,Patient education,16,39,Yes,Reduction,Yes,No,Yes,Regulatory,No,Positive,Age,High
RCT45668,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,119,9,Every 3 weeks,123,18-75,40% M/60% F,0-1,3,0,Normal,Fatigue,Hematological,Cardiac,Severe,3,19.8,Yes,Yes,Discontinuation,Patient education,20,40,Yes,Discontinuation,No,Yes,No,Safety,Yes,Unknown,Prior treatments,High
RCT99420,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 1,113,2,Weekly,180,18-75,40% M/60% F,1-2,3,3,Mild impairment,Rash,Hematological,Blood,Moderate,2,1.26,No,No,Treatment hold,Monitoring,22,10,Yes,Reduction,No,No,Yes,Efficacy,No,None,None,High
RCT73607,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,159,2,Every 3 weeks,91,≥18,60% M/40% F,0-1,5,2,Moderate impairment,Fatigue,Cardiac,Gastrointestinal,Mild,3,21.27,No,Yes,Treatment hold,Dose adjustment,11,41,Yes,None,Yes,Yes,Yes,Competition,,Positive,Gender,Low
RCT21502,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,149,12,Every 3 weeks,114,18-75,60% M/40% F,0-1,3,0,Normal,Neutropenia,Dermatological,Hepatic,Severe,4,18.43,Yes,No,Discontinuation,Monitoring,10,23,Yes,Discontinuation,Yes,Yes,No,Regulatory,,Unknown,ECOG,Unknown
RCT37308,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 3,156,6,Every 3 weeks,119,18-75,40% M/60% F,0-2,3,2,Mild impairment,Rash,Gastrointestinal,Hepatic,Mild,5,27.57,Yes,Yes,Supportive care,Premedication,11,43,No,None,Yes,No,No,Regulatory,Yes,None,None,Unknown
RCT25855,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 2,134,15,Every 3 weeks,73,≥18,40% M/60% F,0-2,4,2,Mild impairment,Rash,Hepatic,Cardiac,Severe,1,2.92,Yes,No,Treatment hold,Monitoring,7,20,No,Discontinuation,Yes,No,No,Efficacy,Yes,None,Gender,Unknown
RCT49218,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,95,11,Every 3 weeks,159,≥18,50% M/50% F,0-2,2,2,Normal,Fatigue,Dermatological,Hepatic,Severe,5,15.61,Yes,No,Supportive care,Dose adjustment,23,1,Yes,None,Yes,Yes,No,Efficacy,,None,ECOG,High
RCT97420,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 3,187,13,Monthly,69,18-65,40% M/60% F,1-2,0,2,Mild impairment,Neutropenia,Dermatological,Hepatic,Mild,5,18.02,No,No,Supportive care,Dose adjustment,11,3,No,Reduction,Yes,No,Yes,,Yes,Positive,Age,Unknown
RCT53132,Trastuzumab,Anti-HER2,Single-arm,None,Phase 1,72,7,Every 3 weeks,73,21-85,40% M/60% F,0-1,3,2,Normal,Nausea,Cardiac,Hepatic,Moderate,4,13.89,Yes,No,Dose reduction,Patient education,9,2,No,Discontinuation,No,Yes,No,Regulatory,,Unknown,Age,Medium
RCT80091,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,58,11,Every 3 weeks,144,≥18,50% M/50% F,0-1,3,2,Mild impairment,Neutropenia,Hematological,Hepatic,Severe,3,7.73,Yes,No,Dose reduction,Monitoring,7,8,Yes,Discontinuation,No,Yes,Yes,Efficacy,,Positive,Prior treatments,Medium
RCT79854,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,186,10,Monthly,132,≥18,50% M/50% F,0-1,2,3,Moderate impairment,Infusion reaction,Cardiac,Hepatic,Mild,2,22.74,No,Yes,Treatment hold,Dose adjustment,25,27,No,None,Yes,No,Yes,Regulatory,,Positive,Age,Low
RCT90643,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,147,15,Monthly,69,18-65,40% M/60% F,0-2,5,3,Mild impairment,Infusion reaction,Hepatic,Gastrointestinal,Mild,2,24.37,Yes,Yes,Treatment hold,Dose adjustment,21,22,No,Delay,Yes,Yes,Yes,,No,Negative,ECOG,Low
RCT66770,Rituximab,Anti-CD20,Single-arm,None,Phase 3,34,4,Every 3 weeks,81,≥18,60% M/40% F,0-2,5,0,Moderate impairment,Infusion reaction,Gastrointestinal,Hepatic,Severe,1,25.35,Yes,No,Dose reduction,Patient education,20,4,No,Reduction,Yes,No,Yes,Regulatory,No,None,Prior treatments,Low
RCT41727,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 3,22,9,Bi-weekly,71,18-65,60% M/40% F,0-1,2,1,Mild impairment,Neutropenia,Hematological,Hepatic,Mild,2,22.07,No,No,Discontinuation,Patient education,10,2,Yes,Discontinuation,Yes,No,Yes,Regulatory,No,Positive,ECOG,Unknown
RCT58070,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,250,15,Every 3 weeks,97,18-65,40% M/60% F,1-2,4,2,Moderate impairment,Neutropenia,Gastrointestinal,Skin,Severe,5,16.0,No,Yes,Supportive care,Premedication,23,37,Yes,Discontinuation,No,Yes,No,,,Unknown,Prior treatments,Medium
RCT59474,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,82,2,Weekly,109,21-85,50% M/50% F,1-2,2,3,Moderate impairment,Nausea,Hepatic,Cardiac,Severe,3,18.14,Yes,Yes,Supportive care,Monitoring,22,24,No,Discontinuation,Yes,No,No,Competition,No,Negative,Gender,Low
RCT45056,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 2,243,12,Weekly,150,18-65,60% M/40% F,0-2,3,1,Mild impairment,Rash,Dermatological,Blood,Moderate,2,19.66,No,No,Dose reduction,Premedication,12,4,No,Delay,Yes,Yes,Yes,Competition,,Negative,Gender,Unknown
RCT32970,Rituximab,Anti-CD20,Randomized,Placebo,Phase 1,57,15,Bi-weekly,37,18-75,40% M/60% F,0-1,2,1,Normal,Infusion reaction,Gastrointestinal,Cardiac,Severe,1,10.03,No,Yes,Dose reduction,Dose adjustment,14,29,No,Discontinuation,No,No,Yes,Regulatory,No,Unknown,Prior treatments,High
RCT67672,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,248,5,Every 3 weeks,103,18-75,50% M/50% F,1-2,4,1,Moderate impairment,Fatigue,Hepatic,Hepatic,Moderate,1,11.16,Yes,No,Supportive care,Monitoring,18,36,No,None,Yes,No,Yes,Regulatory,,Positive,ECOG,Low
RCT15576,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,242,5,Weekly,39,21-85,40% M/60% F,1-2,0,3,Normal,Rash,Gastrointestinal,Hepatic,Moderate,3,16.21,No,No,Dose reduction,Monitoring,3,38,Yes,Delay,Yes,Yes,No,Safety,,Unknown,Gender,Unknown
RCT25543,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 1,103,11,Weekly,113,21-85,60% M/40% F,0-1,3,1,Mild impairment,Infusion reaction,Hepatic,Skin,Severe,5,9.38,Yes,Yes,Discontinuation,Monitoring,17,38,No,Delay,Yes,Yes,Yes,Safety,No,Positive,Age,Low
RCT11507,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,61,12,Bi-weekly,161,≥18,60% M/40% F,1-2,0,2,Mild impairment,Fatigue,Cardiac,Skin,Moderate,3,4.97,No,No,Dose reduction,Monitoring,8,37,Yes,Discontinuation,Yes,Yes,Yes,Safety,Yes,None,None,High
RCT51205,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,299,7,Weekly,101,≥18,60% M/40% F,1-2,5,2,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Moderate,2,15.93,Yes,Yes,Dose reduction,Patient education,12,10,Yes,Delay,Yes,No,Yes,Efficacy,,Unknown,Age,Low
RCT53483,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 2,42,2,Every 3 weeks,110,≥18,50% M/50% F,0-2,3,2,Mild impairment,Neutropenia,Gastrointestinal,Skin,Severe,2,3.55,No,No,Supportive care,Dose adjustment,2,15,No,Delay,Yes,Yes,Yes,,,None,None,High
RCT62256,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,211,10,Monthly,89,21-85,60% M/40% F,0-1,2,2,Moderate impairment,Nausea,Hepatic,Gastrointestinal,Moderate,1,24.64,Yes,No,Discontinuation,Dose adjustment,15,25,No,Delay,No,No,Yes,Regulatory,,Positive,None,Unknown
RCT15294,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,173,15,Every 3 weeks,47,18-65,50% M/50% F,1-2,4,0,Moderate impairment,Rash,Cardiac,Skin,Severe,4,4.99,Yes,No,Supportive care,Premedication,16,18,Yes,Delay,No,Yes,Yes,Safety,Yes,Unknown,Prior treatments,High
RCT82637,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,36,2,Bi-weekly,36,18-65,40% M/60% F,0-2,4,0,Moderate impairment,Neutropenia,Hematological,Hepatic,Severe,2,15.51,No,No,Treatment hold,Premedication,16,46,Yes,None,Yes,Yes,Yes,Efficacy,No,Positive,Gender,Unknown
RCT29793,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,187,10,Bi-weekly,96,18-75,60% M/40% F,0-1,1,3,Mild impairment,Neutropenia,Hematological,Skin,Severe,1,23.07,Yes,Yes,Discontinuation,Premedication,21,35,Yes,None,No,No,No,Efficacy,No,Negative,Gender,Medium
RCT95800,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,119,1,Every 3 weeks,102,18-75,50% M/50% F,1-2,5,3,Normal,Infusion reaction,Hepatic,Hepatic,Moderate,5,15.02,No,Yes,Dose reduction,Dose adjustment,13,11,Yes,Reduction,Yes,No,Yes,Competition,,Negative,Gender,Medium
RCT58138,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,51,5,Every 3 weeks,164,21-85,40% M/60% F,0-1,1,3,Normal,Fatigue,Dermatological,Cardiac,Mild,4,18.61,Yes,No,Dose reduction,Premedication,14,10,Yes,Delay,Yes,Yes,Yes,Efficacy,,None,None,Low
RCT84992,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,27,14,Weekly,95,21-85,40% M/60% F,0-2,5,2,Normal,Fatigue,Cardiac,Blood,Mild,4,15.9,No,Yes,Discontinuation,Monitoring,19,19,No,Delay,No,Yes,Yes,Efficacy,,Unknown,None,High
RCT90834,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,259,6,Bi-weekly,104,18-65,60% M/40% F,0-2,5,3,Normal,Rash,Hepatic,Skin,Moderate,1,21.21,No,Yes,Dose reduction,Patient education,16,42,No,Discontinuation,No,No,No,,,None,Age,Medium
RCT72658,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,94,3,Bi-weekly,108,18-65,50% M/50% F,0-1,2,3,Moderate impairment,Nausea,Hepatic,Blood,Mild,3,27.42,No,No,Discontinuation,Patient education,5,41,No,Discontinuation,Yes,Yes,No,Safety,,Negative,Age,Low
RCT93231,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,127,13,Every 3 weeks,74,≥18,40% M/60% F,1-2,5,1,Moderate impairment,Nausea,Cardiac,Blood,Mild,1,28.27,Yes,Yes,Discontinuation,Monitoring,17,60,Yes,None,Yes,No,No,,No,Unknown,Prior treatments,High
RCT66135,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,250,1,Every 3 weeks,114,21-85,40% M/60% F,0-2,5,1,Mild impairment,Nausea,Hepatic,Hepatic,Mild,1,16.7,Yes,Yes,Supportive care,Patient education,25,42,No,Reduction,No,Yes,No,Regulatory,No,Negative,Gender,Low
RCT34378,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,158,8,Weekly,46,≥18,40% M/60% F,1-2,1,0,Normal,Rash,Hematological,Hepatic,Moderate,1,6.18,Yes,Yes,Dose reduction,Patient education,27,34,No,Reduction,Yes,Yes,Yes,Efficacy,No,Negative,ECOG,Low
RCT36832,Cetuximab,Anti-EGFR,Crossover,None,Phase 3,128,4,Bi-weekly,65,21-85,40% M/60% F,0-2,2,0,Moderate impairment,Nausea,Hepatic,Gastrointestinal,Moderate,2,5.18,No,Yes,Dose reduction,Monitoring,24,32,No,Discontinuation,No,No,No,Regulatory,Yes,Unknown,Age,Unknown
RCT13205,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,43,12,Monthly,71,18-75,60% M/40% F,1-2,1,1,Mild impairment,Rash,Gastrointestinal,Gastrointestinal,Moderate,2,2.46,Yes,Yes,Treatment hold,Premedication,26,3,Yes,None,No,Yes,Yes,,No,Unknown,None,High
RCT30554,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 3,92,10,Every 3 weeks,65,18-75,60% M/40% F,0-2,1,0,Moderate impairment,Fatigue,Gastrointestinal,Blood,Moderate,4,7.65,Yes,Yes,Supportive care,Dose adjustment,13,20,No,Delay,No,No,Yes,Safety,,Unknown,Gender,Low
RCT23962,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,267,14,Bi-weekly,61,21-85,40% M/60% F,0-2,0,3,Normal,Neutropenia,Dermatological,Blood,Severe,2,19.09,Yes,No,Discontinuation,Patient education,21,46,Yes,Reduction,No,Yes,No,,No,Positive,None,Low
RCT99292,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,155,14,Bi-weekly,87,≥18,50% M/50% F,0-2,3,1,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Moderate,4,16.15,No,Yes,Treatment hold,Premedication,15,3,No,Discontinuation,Yes,No,Yes,Safety,No,Unknown,Age,Unknown
RCT56515,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,140,13,Bi-weekly,133,≥18,40% M/60% F,0-1,0,1,Mild impairment,Fatigue,Cardiac,Cardiac,Mild,2,22.97,No,Yes,Supportive care,Patient education,8,42,No,None,No,No,No,Efficacy,,None,Prior treatments,Low
RCT77641,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,165,6,Bi-weekly,137,18-65,50% M/50% F,0-2,4,3,Mild impairment,Infusion reaction,Hepatic,Hepatic,Moderate,4,18.08,No,No,Supportive care,Premedication,27,3,Yes,Delay,No,Yes,Yes,,Yes,Unknown,None,Unknown
RCT37914,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,131,4,Weekly,123,21-85,40% M/60% F,1-2,5,0,Mild impairment,Infusion reaction,Dermatological,Blood,Moderate,4,4.67,No,Yes,Discontinuation,Monitoring,9,1,Yes,Reduction,Yes,No,Yes,Regulatory,Yes,Unknown,Age,Low
RCT60145,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,23,1,Every 3 weeks,130,≥18,40% M/60% F,0-1,1,3,Moderate impairment,Nausea,Cardiac,Cardiac,Severe,2,10.86,No,No,Dose reduction,Dose adjustment,7,45,No,Reduction,No,No,No,Competition,No,Unknown,Age,Medium
RCT87298,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,201,7,Bi-weekly,180,21-85,60% M/40% F,0-1,4,2,Mild impairment,Neutropenia,Hematological,Blood,Moderate,4,13.04,No,No,Discontinuation,Dose adjustment,25,2,Yes,Discontinuation,No,No,Yes,,,Negative,Age,High
RCT12955,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,93,9,Bi-weekly,93,18-65,50% M/50% F,1-2,4,2,Normal,Nausea,Hepatic,Blood,Severe,4,10.76,No,Yes,Supportive care,Premedication,28,22,No,Delay,No,No,No,Competition,,Positive,Prior treatments,Low
RCT97816,Rituximab,Anti-CD20,Crossover,None,Phase 3,89,4,Bi-weekly,35,18-75,50% M/50% F,0-2,0,1,Moderate impairment,Neutropenia,Cardiac,Skin,Severe,2,10.47,No,No,Supportive care,Monitoring,25,25,Yes,None,Yes,Yes,No,Safety,Yes,None,None,High
RCT32286,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,140,3,Bi-weekly,176,18-65,40% M/60% F,0-1,5,0,Normal,Fatigue,Hepatic,Skin,Moderate,5,24.31,Yes,Yes,Dose reduction,Patient education,3,20,Yes,Discontinuation,No,Yes,Yes,Efficacy,Yes,None,None,Unknown
RCT14175,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,162,14,Bi-weekly,152,21-85,50% M/50% F,0-2,3,3,Mild impairment,Fatigue,Hepatic,Gastrointestinal,Mild,5,15.57,Yes,Yes,Supportive care,Patient education,5,32,No,Discontinuation,No,No,Yes,Competition,No,Negative,None,Low
RCT19719,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 3,91,4,Every 3 weeks,148,18-75,50% M/50% F,1-2,5,3,Moderate impairment,Neutropenia,Hematological,Skin,Mild,1,16.51,Yes,Yes,Treatment hold,Patient education,25,38,No,Discontinuation,Yes,Yes,No,Efficacy,Yes,None,Gender,High
RCT39656,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,261,14,Every 3 weeks,89,21-85,50% M/50% F,1-2,4,1,Mild impairment,Fatigue,Hepatic,Cardiac,Severe,3,24.07,Yes,No,Discontinuation,Dose adjustment,14,29,No,Reduction,Yes,No,No,Safety,No,None,Gender,High
RCT15434,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,50,5,Weekly,73,18-65,60% M/40% F,0-1,5,1,Normal,Fatigue,Hematological,Gastrointestinal,Moderate,3,1.06,Yes,Yes,Discontinuation,Premedication,15,20,No,Reduction,No,No,No,Safety,No,Positive,Prior treatments,High
RCT92342,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 3,299,2,Weekly,151,≥18,50% M/50% F,0-2,3,1,Mild impairment,Rash,Hepatic,Skin,Mild,4,13.14,Yes,Yes,Supportive care,Monitoring,5,54,Yes,Reduction,Yes,Yes,Yes,Safety,No,Negative,Age,High
RCT58321,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,202,8,Weekly,173,18-65,60% M/40% F,0-1,2,1,Mild impairment,Fatigue,Cardiac,Skin,Mild,1,24.7,No,No,Supportive care,Monitoring,25,2,No,Delay,No,No,No,,,Positive,ECOG,Low
RCT78625,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 3,67,5,Weekly,176,18-65,60% M/40% F,0-2,5,0,Normal,Nausea,Gastrointestinal,Cardiac,Severe,5,5.13,Yes,Yes,Discontinuation,Dose adjustment,13,42,No,Discontinuation,No,No,No,Efficacy,,Positive,Prior treatments,Low
RCT66029,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 3,223,2,Weekly,100,21-85,50% M/50% F,0-1,1,1,Moderate impairment,Nausea,Hepatic,Hepatic,Mild,5,5.14,Yes,No,Supportive care,Premedication,20,43,Yes,Reduction,Yes,Yes,Yes,Regulatory,No,Unknown,None,High
RCT47664,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,196,5,Every 3 weeks,132,21-85,50% M/50% F,0-2,4,0,Normal,Neutropenia,Gastrointestinal,Skin,Severe,4,11.29,Yes,No,Discontinuation,Patient education,23,6,No,Delay,Yes,No,Yes,Competition,Yes,None,Prior treatments,High
RCT29545,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,59,13,Weekly,130,≥18,60% M/40% F,1-2,0,2,Moderate impairment,Rash,Gastrointestinal,Cardiac,Mild,2,4.06,No,Yes,Discontinuation,Dose adjustment,8,25,No,Discontinuation,No,No,No,Efficacy,No,None,Gender,High
RCT13320,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 1,164,13,Every 3 weeks,82,21-85,40% M/60% F,1-2,0,3,Mild impairment,Nausea,Gastrointestinal,Gastrointestinal,Moderate,3,7.81,No,No,Supportive care,Monitoring,22,3,Yes,Delay,Yes,No,No,Efficacy,,Unknown,None,Unknown
RCT71083,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 2,283,9,Every 3 weeks,166,18-75,50% M/50% F,0-1,0,0,Mild impairment,Fatigue,Gastrointestinal,Blood,Mild,3,18.43,No,No,Supportive care,Premedication,8,38,No,Delay,No,No,Yes,Safety,No,Positive,None,Unknown
RCT98561,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 2,240,8,Monthly,88,21-85,60% M/40% F,1-2,0,3,Mild impairment,Rash,Hematological,Blood,Severe,3,16.9,Yes,Yes,Treatment hold,Monitoring,10,23,Yes,Discontinuation,Yes,No,Yes,Regulatory,Yes,None,ECOG,Medium
RCT65950,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 1,132,12,Monthly,85,18-65,60% M/40% F,0-1,0,3,Normal,Rash,Hepatic,Blood,Mild,4,3.59,No,Yes,Discontinuation,Dose adjustment,23,45,Yes,None,Yes,No,No,Safety,No,Positive,Gender,Medium
RCT58311,Trastuzumab,Anti-HER2,Randomized,None,Phase 3,140,13,Bi-weekly,84,18-65,60% M/40% F,1-2,0,2,Moderate impairment,Nausea,Hematological,Skin,Moderate,5,9.67,Yes,Yes,Dose reduction,Patient education,18,34,Yes,Delay,No,No,Yes,Safety,,Unknown,None,Unknown
RCT67498,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 3,160,13,Bi-weekly,94,21-85,50% M/50% F,1-2,4,3,Moderate impairment,Infusion reaction,Cardiac,Blood,Moderate,5,19.92,Yes,No,Dose reduction,Monitoring,13,51,No,Reduction,Yes,No,No,Efficacy,,None,None,Low
RCT81311,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,169,5,Weekly,96,21-85,50% M/50% F,0-2,5,0,Mild impairment,Infusion reaction,Cardiac,Cardiac,Moderate,3,10.74,No,No,Discontinuation,Dose adjustment,28,43,Yes,Delay,No,Yes,Yes,Regulatory,No,Negative,Prior treatments,High
RCT65586,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,273,4,Weekly,166,18-75,50% M/50% F,1-2,5,2,Moderate impairment,Neutropenia,Cardiac,Hepatic,Severe,5,9.01,Yes,No,Discontinuation,Patient education,6,54,No,Discontinuation,Yes,No,No,Regulatory,Yes,Positive,ECOG,High
RCT20413,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,99,1,Bi-weekly,131,18-75,50% M/50% F,1-2,0,1,Mild impairment,Rash,Cardiac,Gastrointestinal,Mild,3,28.29,No,No,Discontinuation,Patient education,4,56,Yes,None,Yes,No,No,,No,Positive,Prior treatments,High
RCT34282,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 1,56,12,Weekly,30,18-75,60% M/40% F,0-2,3,1,Moderate impairment,Rash,Gastrointestinal,Hepatic,Mild,4,23.93,No,Yes,Supportive care,Dose adjustment,8,7,Yes,None,No,No,No,Efficacy,No,None,ECOG,Low
RCT39232,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,234,7,Weekly,156,18-65,60% M/40% F,0-2,3,0,Moderate impairment,Infusion reaction,Gastrointestinal,Hepatic,Severe,3,2.8,Yes,No,Treatment hold,Patient education,10,34,No,Delay,Yes,Yes,No,Safety,No,Unknown,Gender,Medium
RCT98089,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 2,73,1,Weekly,88,≥18,60% M/40% F,0-2,1,1,Normal,Infusion reaction,Dermatological,Skin,Severe,4,17.02,Yes,No,Supportive care,Dose adjustment,18,51,No,Reduction,No,No,Yes,,Yes,Positive,Prior treatments,Unknown
RCT88507,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,159,8,Monthly,50,21-85,60% M/40% F,1-2,2,0,Mild impairment,Neutropenia,Hepatic,Hepatic,Severe,3,4.17,No,No,Discontinuation,Patient education,1,47,Yes,Discontinuation,No,Yes,Yes,Competition,Yes,Unknown,Age,Unknown
RCT62873,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,56,8,Every 3 weeks,135,≥18,60% M/40% F,1-2,2,3,Moderate impairment,Nausea,Cardiac,Gastrointestinal,Mild,3,23.24,No,No,Discontinuation,Premedication,1,24,No,Discontinuation,No,No,No,Regulatory,Yes,Negative,ECOG,High
RCT17646,Trastuzumab,Anti-HER2,Single-arm,None,Phase 3,28,8,Monthly,62,≥18,50% M/50% F,1-2,1,2,Moderate impairment,Infusion reaction,Dermatological,Hepatic,Mild,5,2.95,No,No,Treatment hold,Monitoring,28,24,Yes,None,No,No,Yes,Safety,Yes,Positive,Gender,Unknown
RCT12337,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,76,13,Bi-weekly,152,18-75,40% M/60% F,0-2,4,3,Moderate impairment,Rash,Cardiac,Skin,Severe,2,20.45,Yes,Yes,Treatment hold,Monitoring,12,41,Yes,Delay,Yes,Yes,No,Efficacy,No,Positive,ECOG,Low
RCT80578,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,168,6,Weekly,129,≥18,60% M/40% F,0-1,4,3,Mild impairment,Rash,Cardiac,Skin,Moderate,3,22.38,Yes,No,Dose reduction,Premedication,28,5,Yes,Reduction,No,No,Yes,Safety,Yes,None,Gender,Unknown
RCT78661,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 2,133,15,Monthly,96,≥18,60% M/40% F,0-2,3,3,Normal,Nausea,Hematological,Hepatic,Mild,1,15.41,Yes,No,Dose reduction,Patient education,1,12,Yes,Delay,No,No,No,Competition,,Negative,Gender,Low
RCT13646,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,289,14,Every 3 weeks,76,≥18,40% M/60% F,0-1,4,0,Moderate impairment,Neutropenia,Hematological,Blood,Moderate,5,20.4,Yes,Yes,Treatment hold,Dose adjustment,3,24,Yes,None,Yes,Yes,No,Efficacy,,Positive,Gender,Unknown
RCT99818,Trastuzumab,Anti-HER2,Crossover,None,Phase 1,266,11,Weekly,80,18-65,40% M/60% F,0-1,1,0,Mild impairment,Infusion reaction,Dermatological,Hepatic,Moderate,1,20.25,Yes,No,Dose reduction,Monitoring,17,55,Yes,Discontinuation,No,Yes,No,Efficacy,Yes,None,Gender,Unknown
RCT23996,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,282,5,Monthly,167,21-85,60% M/40% F,1-2,0,1,Mild impairment,Neutropenia,Hematological,Cardiac,Mild,4,1.31,No,Yes,Discontinuation,Patient education,15,44,No,Reduction,Yes,No,No,Competition,No,None,Age,Medium
RCT82120,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,270,4,Bi-weekly,104,≥18,40% M/60% F,0-1,1,2,Mild impairment,Fatigue,Gastrointestinal,Hepatic,Mild,5,20.69,Yes,No,Supportive care,Patient education,3,59,Yes,Reduction,No,No,Yes,,,Negative,ECOG,Unknown
RCT71986,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 3,206,8,Bi-weekly,89,≥18,60% M/40% F,0-1,2,0,Normal,Fatigue,Hematological,Skin,Moderate,4,7.74,No,Yes,Supportive care,Dose adjustment,24,26,No,Reduction,Yes,No,No,Efficacy,,Positive,Gender,High
RCT60526,Rituximab,Anti-CD20,Randomized,None,Phase 1,52,10,Weekly,180,≥18,50% M/50% F,1-2,5,3,Mild impairment,Fatigue,Cardiac,Hepatic,Severe,1,18.26,Yes,Yes,Supportive care,Patient education,12,40,Yes,Delay,No,Yes,Yes,Efficacy,,Unknown,Prior treatments,Low
RCT55091,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,117,4,Weekly,82,18-75,50% M/50% F,1-2,3,2,Mild impairment,Fatigue,Dermatological,Blood,Mild,1,23.92,No,No,Treatment hold,Monitoring,4,20,No,Discontinuation,Yes,No,No,Regulatory,,None,Gender,Medium
RCT79893,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,297,4,Monthly,164,18-65,60% M/40% F,0-2,0,0,Moderate impairment,Rash,Hematological,Blood,Severe,1,5.74,Yes,No,Treatment hold,Premedication,26,38,Yes,Delay,Yes,Yes,No,Safety,No,Unknown,None,High
RCT25413,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,146,10,Every 3 weeks,143,21-85,40% M/60% F,1-2,1,3,Mild impairment,Infusion reaction,Cardiac,Skin,Severe,3,6.44,Yes,Yes,Treatment hold,Dose adjustment,15,12,No,Reduction,Yes,Yes,No,Regulatory,,None,Age,Unknown
RCT10561,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 2,87,5,Monthly,134,18-75,60% M/40% F,0-1,1,0,Mild impairment,Nausea,Cardiac,Blood,Moderate,2,6.18,No,Yes,Discontinuation,Patient education,21,13,Yes,Delay,Yes,No,Yes,Efficacy,No,Positive,Age,Low
RCT51412,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 3,281,2,Weekly,79,18-65,50% M/50% F,0-2,5,3,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Mild,1,13.16,No,Yes,Discontinuation,Patient education,25,58,No,Reduction,Yes,Yes,Yes,Competition,,Negative,Age,Unknown
RCT68559,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 1,216,3,Bi-weekly,142,21-85,40% M/60% F,0-2,1,2,Moderate impairment,Rash,Dermatological,Blood,Moderate,4,4.87,Yes,Yes,Discontinuation,Premedication,4,57,Yes,Discontinuation,Yes,No,No,Regulatory,Yes,Negative,ECOG,Unknown
RCT31546,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 1,246,13,Monthly,136,21-85,40% M/60% F,0-2,5,1,Mild impairment,Nausea,Dermatological,Gastrointestinal,Moderate,2,29.83,No,No,Treatment hold,Monitoring,7,23,No,Delay,No,No,No,Competition,Yes,Negative,Prior treatments,Low
RCT60069,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,217,4,Monthly,106,18-75,40% M/60% F,1-2,0,1,Moderate impairment,Nausea,Hepatic,Gastrointestinal,Moderate,4,1.42,No,No,Treatment hold,Premedication,3,20,Yes,Discontinuation,Yes,Yes,Yes,Safety,Yes,Positive,None,Unknown
RCT76493,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 3,155,15,Bi-weekly,79,18-75,50% M/50% F,0-1,4,2,Mild impairment,Neutropenia,Gastrointestinal,Blood,Mild,3,2.74,Yes,Yes,Discontinuation,Dose adjustment,15,19,No,Discontinuation,No,Yes,No,,No,Positive,Prior treatments,Low
RCT92860,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,83,8,Every 3 weeks,119,≥18,40% M/60% F,1-2,4,3,Moderate impairment,Rash,Hepatic,Blood,Moderate,4,4.59,No,Yes,Dose reduction,Premedication,16,57,No,None,Yes,Yes,No,Competition,Yes,Positive,Gender,High
RCT72536,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,116,5,Every 3 weeks,38,18-75,40% M/60% F,0-1,0,1,Normal,Nausea,Hepatic,Blood,Mild,2,14.51,No,No,Supportive care,Monitoring,14,41,No,Delay,No,No,No,Safety,,None,ECOG,Medium
RCT12631,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,88,7,Every 3 weeks,162,18-75,60% M/40% F,1-2,4,1,Moderate impairment,Rash,Cardiac,Skin,Mild,4,14.95,Yes,Yes,Discontinuation,Premedication,24,49,Yes,Delay,No,No,No,Efficacy,No,Unknown,Prior treatments,Low
RCT15618,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,170,15,Bi-weekly,137,18-65,40% M/60% F,0-1,1,2,Moderate impairment,Nausea,Dermatological,Blood,Severe,1,7.3,No,No,Dose reduction,Patient education,10,37,Yes,Reduction,Yes,Yes,No,,No,None,None,High
RCT64684,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 3,72,14,Bi-weekly,66,18-75,40% M/60% F,0-2,1,3,Mild impairment,Nausea,Cardiac,Gastrointestinal,Mild,4,25.91,No,Yes,Discontinuation,Dose adjustment,1,1,Yes,None,Yes,Yes,Yes,Safety,Yes,None,Gender,Low
RCT15393,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 3,268,6,Bi-weekly,45,18-65,50% M/50% F,0-1,5,2,Mild impairment,Rash,Hematological,Hepatic,Mild,4,7.01,Yes,Yes,Discontinuation,Monitoring,1,25,No,Discontinuation,Yes,No,Yes,Efficacy,Yes,None,Prior treatments,High
RCT88942,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,168,15,Monthly,123,18-65,60% M/40% F,1-2,3,2,Moderate impairment,Nausea,Dermatological,Blood,Severe,4,29.34,Yes,Yes,Dose reduction,Patient education,7,48,Yes,None,No,Yes,No,Efficacy,,Positive,Age,Low
RCT76158,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 3,181,10,Bi-weekly,81,≥18,50% M/50% F,1-2,3,1,Normal,Nausea,Gastrointestinal,Cardiac,Moderate,2,14.87,No,Yes,Dose reduction,Dose adjustment,24,53,Yes,Delay,No,No,No,Regulatory,Yes,None,None,High
RCT89706,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,209,5,Every 3 weeks,108,18-65,60% M/40% F,0-2,3,0,Moderate impairment,Rash,Dermatological,Gastrointestinal,Severe,3,26.9,No,No,Supportive care,Patient education,28,39,Yes,Reduction,No,No,No,Efficacy,No,None,ECOG,Unknown
RCT11024,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 2,122,10,Weekly,177,21-85,40% M/60% F,1-2,1,3,Normal,Fatigue,Dermatological,Skin,Mild,1,23.57,No,No,Discontinuation,Dose adjustment,27,45,Yes,Discontinuation,Yes,No,No,,,None,Prior treatments,High
RCT24097,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,117,1,Monthly,149,21-85,50% M/50% F,0-1,3,2,Normal,Neutropenia,Dermatological,Skin,Mild,2,12.9,Yes,Yes,Dose reduction,Dose adjustment,9,52,No,Reduction,No,No,No,,No,Positive,Gender,Low
RCT87373,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,270,6,Bi-weekly,52,18-65,60% M/40% F,1-2,3,0,Mild impairment,Rash,Hematological,Gastrointestinal,Mild,2,17.09,No,No,Dose reduction,Patient education,4,33,Yes,None,No,No,No,,No,Unknown,Age,High
RCT48306,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 1,87,10,Every 3 weeks,143,18-75,40% M/60% F,0-1,1,3,Normal,Rash,Hepatic,Skin,Mild,5,10.66,No,Yes,Treatment hold,Monitoring,18,15,No,None,Yes,No,Yes,Regulatory,,Negative,Gender,High
RCT68775,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,63,1,Monthly,172,≥18,60% M/40% F,0-2,3,1,Normal,Infusion reaction,Hepatic,Blood,Moderate,2,28.98,No,No,Supportive care,Patient education,15,36,Yes,None,No,Yes,No,Regulatory,,Positive,None,Unknown
RCT62743,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,225,12,Monthly,175,18-75,50% M/50% F,0-2,5,0,Moderate impairment,Neutropenia,Hematological,Cardiac,Mild,1,26.65,Yes,Yes,Discontinuation,Monitoring,17,2,Yes,Reduction,No,Yes,No,Regulatory,No,Unknown,ECOG,Medium
RCT75916,Rituximab,Anti-CD20,Randomized,None,Phase 1,267,7,Bi-weekly,170,18-65,60% M/40% F,0-2,5,3,Normal,Infusion reaction,Cardiac,Blood,Moderate,5,1.72,Yes,Yes,Dose reduction,Monitoring,13,45,No,Delay,No,Yes,No,Competition,,None,Gender,Medium
RCT95490,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 2,86,10,Weekly,107,≥18,50% M/50% F,0-2,1,3,Moderate impairment,Fatigue,Hepatic,Gastrointestinal,Moderate,3,26.56,No,Yes,Discontinuation,Patient education,3,23,Yes,Delay,Yes,No,No,Competition,Yes,Negative,ECOG,Unknown
RCT23513,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,252,15,Every 3 weeks,115,18-65,40% M/60% F,0-1,3,1,Moderate impairment,Neutropenia,Dermatological,Gastrointestinal,Mild,1,18.69,Yes,Yes,Treatment hold,Dose adjustment,7,27,Yes,Delay,No,No,Yes,Regulatory,,Negative,Prior treatments,High
RCT34455,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,282,7,Weekly,97,≥18,50% M/50% F,0-1,1,1,Mild impairment,Fatigue,Hepatic,Blood,Severe,3,6.48,Yes,Yes,Discontinuation,Dose adjustment,25,53,Yes,None,Yes,No,Yes,Efficacy,Yes,Positive,Gender,Unknown
RCT72895,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 1,110,1,Every 3 weeks,47,18-75,40% M/60% F,0-2,0,1,Mild impairment,Nausea,Hematological,Gastrointestinal,Moderate,4,12.97,Yes,Yes,Treatment hold,Dose adjustment,27,22,No,Delay,Yes,Yes,No,Safety,Yes,Positive,ECOG,High
RCT73624,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,300,10,Every 3 weeks,44,18-75,50% M/50% F,0-1,1,3,Moderate impairment,Neutropenia,Hepatic,Skin,Severe,1,18.22,No,No,Dose reduction,Monitoring,22,23,No,Discontinuation,Yes,Yes,Yes,Safety,Yes,None,ECOG,Low
RCT72525,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,227,8,Bi-weekly,43,18-65,40% M/60% F,0-1,1,2,Normal,Neutropenia,Hepatic,Gastrointestinal,Moderate,4,25.85,Yes,Yes,Supportive care,Dose adjustment,21,41,No,Discontinuation,Yes,Yes,Yes,Regulatory,Yes,Positive,Age,Medium
RCT32482,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,50,3,Every 3 weeks,163,≥18,50% M/50% F,1-2,0,3,Moderate impairment,Nausea,Gastrointestinal,Gastrointestinal,Moderate,3,16.09,No,No,Treatment hold,Patient education,14,33,No,Delay,Yes,No,Yes,,No,Negative,Prior treatments,Medium
RCT24647,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 2,214,11,Every 3 weeks,101,18-75,50% M/50% F,0-2,0,0,Moderate impairment,Nausea,Hematological,Gastrointestinal,Mild,2,28.74,Yes,No,Discontinuation,Premedication,11,19,Yes,Delay,No,Yes,No,Competition,,Positive,Prior treatments,Low
RCT40609,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,299,9,Every 3 weeks,32,21-85,50% M/50% F,0-1,2,0,Normal,Neutropenia,Gastrointestinal,Skin,Severe,3,16.45,No,Yes,Treatment hold,Dose adjustment,24,26,No,None,Yes,No,No,Competition,No,Negative,Age,High
RCT13631,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 3,285,2,Bi-weekly,131,≥18,50% M/50% F,0-1,2,0,Normal,Nausea,Gastrointestinal,Hepatic,Severe,4,14.16,No,Yes,Dose reduction,Premedication,21,47,Yes,None,No,Yes,Yes,,Yes,Unknown,Gender,Medium
RCT58258,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,292,14,Every 3 weeks,151,18-65,50% M/50% F,0-1,3,0,Mild impairment,Fatigue,Hepatic,Gastrointestinal,Severe,2,26.48,No,Yes,Treatment hold,Dose adjustment,14,47,No,None,Yes,No,No,Safety,,Negative,Gender,Unknown
RCT26081,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 3,233,11,Bi-weekly,115,18-65,50% M/50% F,0-2,0,0,Mild impairment,Infusion reaction,Cardiac,Cardiac,Severe,3,17.86,Yes,No,Supportive care,Premedication,16,8,No,Reduction,Yes,Yes,No,Competition,Yes,Positive,None,Low
RCT49057,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,143,10,Monthly,162,21-85,40% M/60% F,1-2,2,2,Normal,Nausea,Cardiac,Blood,Severe,1,19.9,No,No,Supportive care,Patient education,28,31,No,Discontinuation,No,No,No,,,None,Prior treatments,Low
RCT37791,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 2,262,11,Monthly,95,21-85,40% M/60% F,1-2,1,1,Mild impairment,Fatigue,Gastrointestinal,Cardiac,Mild,4,24.53,Yes,Yes,Supportive care,Patient education,24,20,Yes,None,Yes,No,No,Efficacy,Yes,Positive,None,Medium
RCT47501,Rituximab,Anti-CD20,Crossover,None,Phase 2,187,12,Monthly,86,18-75,60% M/40% F,1-2,0,1,Mild impairment,Rash,Hematological,Hepatic,Severe,3,8.46,No,Yes,Discontinuation,Patient education,21,8,Yes,Discontinuation,No,Yes,No,Regulatory,Yes,Positive,None,Unknown
RCT64779,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,72,6,Every 3 weeks,51,18-65,50% M/50% F,0-1,3,2,Normal,Neutropenia,Hematological,Gastrointestinal,Severe,3,22.6,No,Yes,Supportive care,Monitoring,27,8,Yes,None,Yes,Yes,No,Safety,No,Negative,Prior treatments,Low
RCT31541,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,296,9,Weekly,153,≥18,40% M/60% F,0-2,0,2,Mild impairment,Rash,Hepatic,Blood,Mild,2,8.88,Yes,Yes,Treatment hold,Premedication,5,33,Yes,Discontinuation,No,Yes,No,Efficacy,,Negative,Prior treatments,High
RCT53646,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,192,15,Bi-weekly,79,18-65,50% M/50% F,0-1,4,1,Moderate impairment,Infusion reaction,Hematological,Cardiac,Severe,4,10.75,Yes,Yes,Discontinuation,Dose adjustment,10,6,No,Delay,Yes,No,No,Safety,Yes,None,Gender,Medium
RCT86375,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 2,240,5,Monthly,71,21-85,60% M/40% F,1-2,0,0,Normal,Rash,Gastrointestinal,Hepatic,Mild,5,16.38,Yes,Yes,Supportive care,Monitoring,17,42,No,Delay,Yes,Yes,No,,No,Positive,ECOG,Low
RCT65143,Rituximab,Anti-CD20,Single-arm,None,Phase 1,293,6,Monthly,122,18-75,40% M/60% F,0-1,2,3,Mild impairment,Nausea,Dermatological,Skin,Mild,4,9.33,No,Yes,Supportive care,Dose adjustment,8,10,No,Reduction,No,No,Yes,,Yes,Positive,Gender,Medium
RCT76067,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 2,210,15,Monthly,118,≥18,40% M/60% F,0-1,5,3,Moderate impairment,Fatigue,Cardiac,Skin,Severe,4,8.56,Yes,No,Discontinuation,Dose adjustment,17,17,No,Reduction,Yes,No,No,Regulatory,No,None,ECOG,Medium
RCT76045,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,184,4,Bi-weekly,72,≥18,40% M/60% F,1-2,3,0,Mild impairment,Neutropenia,Cardiac,Hepatic,Moderate,1,25.66,No,Yes,Discontinuation,Monitoring,11,13,Yes,Discontinuation,Yes,No,No,Competition,Yes,Unknown,ECOG,High
RCT51610,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,237,11,Weekly,85,≥18,40% M/60% F,0-1,0,3,Mild impairment,Infusion reaction,Hematological,Skin,Mild,1,19.2,Yes,No,Discontinuation,Dose adjustment,23,21,No,Reduction,Yes,No,Yes,,Yes,Positive,ECOG,High
RCT18801,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 3,109,3,Monthly,93,18-75,40% M/60% F,0-1,5,0,Moderate impairment,Fatigue,Cardiac,Gastrointestinal,Mild,1,5.87,No,No,Dose reduction,Patient education,27,7,Yes,Delay,No,No,No,Efficacy,No,Positive,Prior treatments,Low
RCT64149,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,177,3,Every 3 weeks,120,18-65,40% M/60% F,1-2,0,0,Normal,Neutropenia,Dermatological,Gastrointestinal,Mild,1,25.47,No,Yes,Supportive care,Patient education,13,60,Yes,Reduction,Yes,Yes,No,Safety,,Positive,Gender,Medium
RCT72829,Trastuzumab,Anti-HER2,Randomized,None,Phase 3,125,14,Bi-weekly,126,18-65,60% M/40% F,0-2,2,1,Mild impairment,Rash,Hepatic,Skin,Severe,2,7.9,Yes,No,Dose reduction,Patient education,2,59,Yes,None,Yes,No,No,Regulatory,No,Unknown,None,Medium
RCT21106,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 2,61,6,Monthly,62,18-75,60% M/40% F,1-2,3,0,Moderate impairment,Infusion reaction,Hematological,Gastrointestinal,Mild,5,1.79,No,Yes,Dose reduction,Patient education,16,20,No,None,No,No,Yes,Safety,Yes,Negative,ECOG,High
RCT56914,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,138,12,Monthly,63,≥18,60% M/40% F,0-1,5,2,Moderate impairment,Nausea,Hematological,Gastrointestinal,Moderate,4,26.11,No,No,Dose reduction,Dose adjustment,27,36,No,Reduction,No,Yes,Yes,Competition,,Unknown,Gender,High
RCT72359,Cetuximab,Anti-EGFR,Single-arm,None,Phase 3,251,13,Bi-weekly,88,21-85,50% M/50% F,0-2,2,3,Mild impairment,Rash,Gastrointestinal,Gastrointestinal,Moderate,3,14.17,No,No,Supportive care,Monitoring,19,47,Yes,None,Yes,No,Yes,Safety,No,Negative,Age,Low
RCT55972,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,238,11,Bi-weekly,139,18-65,60% M/40% F,0-2,0,0,Moderate impairment,Neutropenia,Hepatic,Blood,Moderate,5,2.54,Yes,No,Supportive care,Premedication,17,2,Yes,Reduction,No,Yes,Yes,Safety,Yes,None,Gender,Unknown
RCT25798,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,118,2,Weekly,31,18-65,50% M/50% F,0-1,3,1,Mild impairment,Fatigue,Hematological,Blood,Moderate,3,29.95,No,Yes,Dose reduction,Monitoring,11,34,Yes,Discontinuation,Yes,No,Yes,,,Negative,Gender,Medium
RCT62136,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 1,255,15,Weekly,40,≥18,50% M/50% F,0-2,3,1,Normal,Nausea,Cardiac,Blood,Mild,3,2.33,No,Yes,Supportive care,Patient education,13,55,Yes,Reduction,Yes,No,Yes,Regulatory,No,Positive,Gender,Low
RCT38483,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 3,291,5,Monthly,119,≥18,60% M/40% F,1-2,0,2,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Mild,5,2.51,No,No,Discontinuation,Premedication,12,40,No,Discontinuation,No,Yes,No,,No,None,Gender,Medium
RCT39473,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,255,8,Monthly,170,≥18,40% M/60% F,1-2,2,0,Moderate impairment,Nausea,Cardiac,Blood,Mild,4,24.25,Yes,Yes,Supportive care,Patient education,23,58,Yes,Delay,No,Yes,No,Regulatory,Yes,Unknown,Gender,Unknown
RCT95619,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,300,9,Weekly,53,18-75,50% M/50% F,0-2,2,0,Normal,Neutropenia,Cardiac,Gastrointestinal,Moderate,2,20.89,No,Yes,Treatment hold,Premedication,3,37,Yes,Discontinuation,No,Yes,Yes,Competition,,Negative,None,Low
RCT32756,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,178,13,Monthly,176,21-85,40% M/60% F,0-1,0,1,Normal,Fatigue,Cardiac,Cardiac,Severe,4,1.74,No,Yes,Dose reduction,Dose adjustment,25,11,Yes,Discontinuation,No,No,No,Efficacy,No,Positive,Prior treatments,High
RCT13504,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 2,234,10,Weekly,74,18-65,60% M/40% F,1-2,5,2,Normal,Fatigue,Hematological,Blood,Moderate,1,28.08,Yes,Yes,Dose reduction,Monitoring,28,42,Yes,Delay,Yes,No,No,Competition,No,None,Gender,High
RCT45347,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,119,6,Monthly,62,≥18,60% M/40% F,0-1,3,2,Normal,Neutropenia,Hepatic,Skin,Moderate,2,22.62,No,No,Treatment hold,Patient education,24,28,No,None,No,Yes,No,,No,Negative,None,Medium
RCT67955,Cetuximab,Anti-EGFR,Single-arm,None,Phase 1,225,13,Monthly,84,21-85,40% M/60% F,0-2,3,2,Moderate impairment,Fatigue,Dermatological,Skin,Severe,4,18.77,No,No,Treatment hold,Monitoring,11,24,Yes,Reduction,No,Yes,Yes,Safety,No,Unknown,Prior treatments,Medium
RCT61258,Rituximab,Anti-CD20,Randomized,None,Phase 2,196,5,Bi-weekly,105,18-75,60% M/40% F,1-2,2,1,Normal,Infusion reaction,Hepatic,Blood,Severe,2,20.19,No,No,Dose reduction,Monitoring,22,26,No,Discontinuation,Yes,Yes,Yes,Efficacy,Yes,None,None,Medium
RCT36966,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,214,12,Bi-weekly,93,21-85,60% M/40% F,0-2,1,2,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Moderate,5,13.26,No,Yes,Supportive care,Patient education,16,5,No,None,No,No,Yes,Regulatory,No,Positive,None,Unknown
RCT29062,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,221,8,Every 3 weeks,147,≥18,50% M/50% F,0-2,5,1,Moderate impairment,Fatigue,Gastrointestinal,Skin,Moderate,5,14.23,Yes,No,Discontinuation,Premedication,13,40,Yes,Delay,Yes,Yes,No,Competition,,Unknown,ECOG,Medium
RCT27133,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,249,14,Monthly,169,18-65,50% M/50% F,0-1,2,0,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,1,29.92,No,No,Supportive care,Patient education,19,25,Yes,None,Yes,Yes,No,Competition,Yes,Negative,Age,Low
RCT27147,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 3,286,6,Weekly,95,21-85,60% M/40% F,0-1,2,0,Mild impairment,Infusion reaction,Dermatological,Blood,Severe,1,16.12,No,No,Discontinuation,Patient education,25,32,Yes,Reduction,No,Yes,Yes,Safety,No,Negative,None,High
RCT19032,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 3,113,9,Bi-weekly,176,21-85,50% M/50% F,0-1,2,3,Mild impairment,Nausea,Dermatological,Gastrointestinal,Mild,4,21.88,No,Yes,Dose reduction,Premedication,2,56,No,None,Yes,Yes,No,Regulatory,Yes,Positive,Prior treatments,Unknown
RCT31009,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,238,10,Every 3 weeks,159,18-65,50% M/50% F,1-2,3,0,Mild impairment,Nausea,Hematological,Gastrointestinal,Moderate,3,21.43,Yes,Yes,Dose reduction,Dose adjustment,14,49,Yes,None,Yes,Yes,No,Efficacy,,Unknown,Gender,High
RCT65788,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,97,2,Bi-weekly,37,18-75,50% M/50% F,0-1,2,2,Moderate impairment,Neutropenia,Hepatic,Skin,Mild,2,25.68,No,Yes,Treatment hold,Patient education,7,42,No,Reduction,Yes,Yes,Yes,Competition,Yes,Unknown,None,Low
RCT82093,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,110,2,Bi-weekly,128,21-85,60% M/40% F,0-1,0,0,Moderate impairment,Nausea,Cardiac,Gastrointestinal,Moderate,4,20.88,Yes,No,Dose reduction,Patient education,2,43,No,Delay,Yes,No,Yes,Safety,No,Unknown,Age,High
RCT34689,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 3,123,2,Bi-weekly,152,21-85,50% M/50% F,1-2,2,0,Mild impairment,Rash,Cardiac,Cardiac,Severe,5,3.53,No,No,Discontinuation,Premedication,9,52,No,Reduction,No,No,Yes,Safety,Yes,Positive,Age,Unknown
RCT32428,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,120,13,Monthly,41,18-75,40% M/60% F,1-2,1,3,Moderate impairment,Neutropenia,Hematological,Gastrointestinal,Mild,5,17.83,Yes,Yes,Treatment hold,Patient education,11,30,Yes,Delay,Yes,Yes,Yes,Regulatory,Yes,None,Gender,Medium
RCT25987,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,24,3,Weekly,82,18-75,40% M/60% F,0-2,1,0,Moderate impairment,Nausea,Hepatic,Gastrointestinal,Severe,5,5.91,Yes,No,Dose reduction,Dose adjustment,2,6,No,Discontinuation,No,No,Yes,Efficacy,,None,ECOG,Medium
RCT17628,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 2,46,11,Every 3 weeks,180,18-75,40% M/60% F,1-2,4,3,Normal,Fatigue,Gastrointestinal,Cardiac,Moderate,3,6.17,Yes,No,Supportive care,Premedication,12,55,Yes,Discontinuation,Yes,No,Yes,Regulatory,Yes,Unknown,None,High
RCT24070,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,103,3,Weekly,68,≥18,50% M/50% F,0-2,1,0,Moderate impairment,Infusion reaction,Cardiac,Cardiac,Severe,2,29.55,No,No,Dose reduction,Monitoring,1,18,Yes,Delay,Yes,No,No,Efficacy,No,Unknown,Prior treatments,Low
RCT14402,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,96,8,Bi-weekly,36,21-85,50% M/50% F,1-2,0,3,Mild impairment,Infusion reaction,Hematological,Hepatic,Mild,4,9.23,Yes,Yes,Supportive care,Monitoring,1,6,No,Discontinuation,Yes,Yes,No,Efficacy,Yes,Negative,Prior treatments,High
RCT43192,Rituximab,Anti-CD20,Randomized,None,Phase 2,161,10,Monthly,120,18-75,50% M/50% F,0-2,5,1,Normal,Neutropenia,Dermatological,Gastrointestinal,Moderate,2,1.62,Yes,Yes,Discontinuation,Dose adjustment,27,6,Yes,None,No,No,No,,Yes,Positive,None,High
RCT21427,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 1,22,4,Every 3 weeks,123,21-85,60% M/40% F,1-2,5,0,Moderate impairment,Neutropenia,Hematological,Skin,Severe,2,14.38,Yes,Yes,Discontinuation,Monitoring,4,53,Yes,Reduction,Yes,No,No,,,Positive,None,Medium
RCT64730,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 3,299,14,Every 3 weeks,162,≥18,40% M/60% F,0-1,4,0,Moderate impairment,Neutropenia,Dermatological,Cardiac,Severe,4,23.59,Yes,Yes,Treatment hold,Monitoring,9,33,Yes,Delay,No,Yes,No,,No,Unknown,Gender,High
RCT43779,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,34,7,Every 3 weeks,33,≥18,50% M/50% F,0-1,4,1,Mild impairment,Fatigue,Hematological,Gastrointestinal,Severe,1,10.49,Yes,No,Treatment hold,Premedication,10,3,Yes,Delay,Yes,Yes,No,,,Unknown,ECOG,Medium
RCT37155,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,147,6,Weekly,142,21-85,50% M/50% F,0-2,1,0,Mild impairment,Infusion reaction,Cardiac,Gastrointestinal,Mild,4,19.5,Yes,No,Treatment hold,Dose adjustment,9,43,No,Discontinuation,No,No,Yes,Competition,No,Negative,None,Medium
RCT79871,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 2,282,9,Monthly,151,≥18,60% M/40% F,0-1,0,0,Mild impairment,Infusion reaction,Hepatic,Gastrointestinal,Mild,2,12.11,Yes,Yes,Supportive care,Premedication,21,47,Yes,None,No,Yes,Yes,,Yes,Unknown,Prior treatments,High
RCT20845,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,289,14,Every 3 weeks,130,18-75,50% M/50% F,0-1,1,3,Moderate impairment,Neutropenia,Hepatic,Blood,Moderate,3,29.83,No,Yes,Discontinuation,Premedication,25,25,Yes,Reduction,No,Yes,No,Regulatory,No,Negative,ECOG,Medium
RCT67719,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,237,10,Monthly,157,18-75,60% M/40% F,1-2,2,1,Moderate impairment,Rash,Cardiac,Cardiac,Severe,3,25.56,Yes,No,Discontinuation,Monitoring,3,43,No,Discontinuation,No,No,Yes,Competition,Yes,Positive,ECOG,Unknown
RCT22354,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,205,2,Weekly,49,18-75,60% M/40% F,0-1,1,2,Moderate impairment,Nausea,Cardiac,Blood,Moderate,3,16.62,No,No,Supportive care,Patient education,25,38,No,Delay,No,No,No,Safety,No,Negative,Prior treatments,Unknown
RCT63128,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,87,15,Bi-weekly,66,18-65,50% M/50% F,0-2,2,3,Mild impairment,Infusion reaction,Dermatological,Cardiac,Mild,3,27.1,Yes,No,Treatment hold,Monitoring,20,53,No,Delay,Yes,Yes,No,Regulatory,Yes,Unknown,Gender,Medium
RCT88523,Rituximab,Anti-CD20,Single-arm,None,Phase 2,297,5,Monthly,162,21-85,50% M/50% F,0-2,3,1,Normal,Nausea,Cardiac,Skin,Mild,4,13.65,No,Yes,Supportive care,Dose adjustment,22,29,Yes,Discontinuation,Yes,No,Yes,Safety,No,None,None,Unknown
RCT13410,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,131,15,Every 3 weeks,127,≥18,50% M/50% F,0-2,0,0,Mild impairment,Nausea,Dermatological,Gastrointestinal,Mild,4,17.87,No,No,Discontinuation,Premedication,22,1,No,None,No,Yes,No,,,None,Prior treatments,High
RCT77033,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 1,173,9,Monthly,85,18-65,50% M/50% F,0-2,4,1,Normal,Nausea,Cardiac,Hepatic,Moderate,5,1.56,Yes,No,Treatment hold,Patient education,5,12,Yes,Delay,Yes,No,Yes,Competition,Yes,Unknown,ECOG,Medium
RCT28591,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,262,1,Bi-weekly,93,18-65,50% M/50% F,1-2,0,0,Normal,Nausea,Cardiac,Gastrointestinal,Moderate,4,17.31,Yes,No,Treatment hold,Patient education,13,38,Yes,Reduction,Yes,Yes,Yes,Competition,,Negative,Gender,Low
RCT89102,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,211,1,Every 3 weeks,147,≥18,50% M/50% F,1-2,4,0,Moderate impairment,Rash,Dermatological,Cardiac,Mild,5,9.87,Yes,Yes,Treatment hold,Premedication,19,56,Yes,Discontinuation,No,Yes,No,Competition,,None,Gender,Medium
RCT24259,Rituximab,Anti-CD20,Crossover,None,Phase 2,293,10,Every 3 weeks,57,21-85,60% M/40% F,0-2,2,3,Normal,Rash,Gastrointestinal,Hepatic,Moderate,5,25.39,Yes,No,Supportive care,Dose adjustment,23,25,Yes,Reduction,No,Yes,Yes,Regulatory,No,None,Gender,High
RCT96706,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,164,5,Weekly,77,18-75,60% M/40% F,1-2,5,1,Mild impairment,Rash,Gastrointestinal,Cardiac,Moderate,1,13.55,Yes,No,Dose reduction,Premedication,12,22,Yes,Discontinuation,Yes,Yes,No,Safety,No,Unknown,Age,Low
RCT45878,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 2,132,2,Every 3 weeks,132,≥18,50% M/50% F,1-2,0,3,Normal,Neutropenia,Dermatological,Hepatic,Mild,5,12.13,Yes,Yes,Supportive care,Patient education,16,5,Yes,None,No,No,Yes,,No,Positive,Gender,Low
RCT60378,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,240,15,Every 3 weeks,124,≥18,40% M/60% F,0-1,5,1,Normal,Rash,Hematological,Gastrointestinal,Moderate,1,23.09,No,Yes,Treatment hold,Premedication,1,45,No,Delay,Yes,Yes,Yes,Competition,No,None,Prior treatments,High
RCT52337,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,122,12,Monthly,55,21-85,50% M/50% F,0-2,1,1,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,4,22.8,No,Yes,Supportive care,Patient education,2,24,Yes,Reduction,No,Yes,Yes,Competition,,None,Age,Low
RCT12356,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,70,14,Weekly,54,18-65,50% M/50% F,0-2,1,2,Mild impairment,Fatigue,Gastrointestinal,Gastrointestinal,Mild,2,24.89,Yes,Yes,Discontinuation,Patient education,19,57,Yes,Reduction,Yes,No,No,Safety,Yes,Negative,Age,Low
RCT65092,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,96,2,Bi-weekly,154,21-85,50% M/50% F,0-2,0,2,Moderate impairment,Nausea,Cardiac,Cardiac,Moderate,2,9.26,No,Yes,Treatment hold,Patient education,19,44,No,Delay,No,Yes,No,Regulatory,No,None,Prior treatments,Low
RCT24685,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,82,15,Every 3 weeks,152,≥18,40% M/60% F,0-1,1,0,Moderate impairment,Infusion reaction,Gastrointestinal,Skin,Mild,2,28.99,Yes,No,Supportive care,Monitoring,25,55,Yes,Reduction,Yes,No,No,Efficacy,No,Negative,Age,Medium
RCT66744,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,157,6,Weekly,84,18-65,50% M/50% F,1-2,5,1,Mild impairment,Fatigue,Cardiac,Blood,Severe,1,10.08,No,Yes,Treatment hold,Dose adjustment,19,17,Yes,Reduction,No,No,No,Safety,Yes,Unknown,ECOG,Medium
RCT27623,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,175,2,Every 3 weeks,75,18-75,40% M/60% F,0-2,5,2,Normal,Neutropenia,Dermatological,Cardiac,Mild,2,23.7,No,No,Treatment hold,Dose adjustment,7,14,No,Reduction,No,Yes,No,Competition,,None,Gender,Medium
RCT44527,Rituximab,Anti-CD20,Crossover,Placebo,Phase 3,290,8,Bi-weekly,160,18-75,40% M/60% F,1-2,1,1,Mild impairment,Rash,Hematological,Hepatic,Severe,1,24.38,Yes,No,Dose reduction,Patient education,19,48,No,Reduction,Yes,No,Yes,,No,Unknown,Age,Unknown
RCT20649,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,218,13,Every 3 weeks,53,18-75,60% M/40% F,0-1,1,0,Normal,Neutropenia,Hepatic,Hepatic,Severe,5,5.65,Yes,No,Supportive care,Premedication,25,34,Yes,None,No,Yes,No,Efficacy,Yes,Positive,Prior treatments,Unknown
RCT48281,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 2,168,11,Monthly,137,21-85,50% M/50% F,0-1,0,0,Normal,Rash,Dermatological,Hepatic,Severe,3,20.48,No,Yes,Treatment hold,Patient education,28,24,Yes,None,Yes,Yes,Yes,Regulatory,,Positive,Prior treatments,Low
RCT70533,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 2,76,5,Every 3 weeks,122,18-65,60% M/40% F,1-2,0,0,Mild impairment,Neutropenia,Dermatological,Hepatic,Moderate,2,16.19,No,Yes,Discontinuation,Dose adjustment,4,30,No,Discontinuation,Yes,No,Yes,Regulatory,No,Positive,None,Medium
RCT31360,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,117,12,Weekly,81,18-65,40% M/60% F,0-2,0,1,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Moderate,2,5.33,No,Yes,Treatment hold,Dose adjustment,5,39,No,Delay,Yes,No,No,Regulatory,No,Positive,Age,Low
RCT66980,Rituximab,Anti-CD20,Randomized,None,Phase 1,156,1,Every 3 weeks,112,21-85,50% M/50% F,1-2,0,1,Mild impairment,Rash,Dermatological,Blood,Mild,3,25.36,No,Yes,Supportive care,Monitoring,3,51,Yes,Delay,Yes,No,No,Safety,No,None,Age,High
RCT40044,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,179,12,Weekly,179,21-85,60% M/40% F,1-2,4,1,Moderate impairment,Neutropenia,Hepatic,Skin,Mild,3,4.11,Yes,Yes,Supportive care,Premedication,12,60,Yes,None,No,Yes,Yes,,Yes,Negative,Gender,High
RCT39196,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 2,61,4,Every 3 weeks,68,18-65,40% M/60% F,1-2,4,2,Mild impairment,Rash,Cardiac,Hepatic,Moderate,3,5.86,No,No,Supportive care,Premedication,26,29,No,None,Yes,No,No,Regulatory,,Positive,Prior treatments,High
RCT46408,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,60,8,Bi-weekly,41,18-65,60% M/40% F,1-2,1,2,Moderate impairment,Fatigue,Gastrointestinal,Blood,Severe,2,27.24,Yes,Yes,Treatment hold,Monitoring,22,3,Yes,Delay,Yes,Yes,No,Efficacy,No,Unknown,None,High
RCT63925,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 2,101,7,Bi-weekly,178,≥18,40% M/60% F,0-1,0,0,Mild impairment,Neutropenia,Cardiac,Blood,Severe,1,6.22,No,Yes,Treatment hold,Dose adjustment,6,10,No,Delay,No,Yes,Yes,Regulatory,,Positive,None,Medium
RCT46812,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,226,13,Monthly,137,18-75,60% M/40% F,0-1,3,3,Normal,Infusion reaction,Dermatological,Hepatic,Moderate,2,6.72,Yes,No,Supportive care,Patient education,16,43,No,Discontinuation,Yes,Yes,No,,No,None,Prior treatments,Low
RCT91289,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,154,12,Monthly,113,≥18,60% M/40% F,1-2,2,0,Moderate impairment,Infusion reaction,Cardiac,Cardiac,Mild,4,9.92,Yes,Yes,Discontinuation,Patient education,11,57,Yes,Discontinuation,Yes,Yes,Yes,Competition,,None,Age,Low
RCT16801,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 1,47,5,Weekly,162,18-75,50% M/50% F,1-2,4,2,Normal,Neutropenia,Hematological,Hepatic,Moderate,4,17.28,No,No,Discontinuation,Premedication,23,52,Yes,None,Yes,No,Yes,Regulatory,,Positive,Gender,High
RCT67662,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,196,9,Every 3 weeks,167,18-75,40% M/60% F,0-2,5,2,Normal,Nausea,Cardiac,Hepatic,Moderate,3,2.45,No,Yes,Discontinuation,Monitoring,24,17,Yes,Delay,Yes,No,Yes,Competition,,Positive,None,High
RCT51166,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,177,12,Bi-weekly,115,18-65,40% M/60% F,0-1,0,2,Normal,Neutropenia,Gastrointestinal,Blood,Mild,5,21.98,Yes,Yes,Dose reduction,Premedication,7,42,Yes,Discontinuation,No,No,No,Regulatory,No,Negative,ECOG,Medium
RCT81222,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 3,232,11,Weekly,44,18-75,50% M/50% F,1-2,3,0,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Moderate,3,16.65,No,Yes,Discontinuation,Premedication,10,13,Yes,None,No,Yes,Yes,Efficacy,,Positive,ECOG,Unknown
RCT68393,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,104,2,Monthly,32,18-65,50% M/50% F,0-2,5,2,Mild impairment,Rash,Dermatological,Gastrointestinal,Moderate,5,16.0,No,No,Treatment hold,Dose adjustment,1,21,No,Reduction,Yes,No,Yes,Competition,Yes,None,Age,Medium
RCT35939,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,62,13,Bi-weekly,165,18-75,50% M/50% F,0-1,2,2,Normal,Infusion reaction,Hematological,Skin,Severe,1,9.62,Yes,Yes,Supportive care,Premedication,24,43,Yes,Reduction,Yes,No,No,Regulatory,No,Unknown,None,Medium
RCT44185,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 2,292,5,Weekly,99,18-65,60% M/40% F,0-2,1,2,Mild impairment,Neutropenia,Cardiac,Gastrointestinal,Moderate,2,25.82,No,No,Discontinuation,Dose adjustment,6,23,Yes,Reduction,No,Yes,Yes,Safety,Yes,Negative,Age,High
RCT62289,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,148,3,Monthly,113,18-75,50% M/50% F,1-2,4,0,Normal,Fatigue,Hepatic,Gastrointestinal,Moderate,2,27.74,Yes,Yes,Treatment hold,Monitoring,26,28,No,Reduction,No,Yes,Yes,Competition,No,Positive,Prior treatments,Unknown
RCT31845,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,20,2,Every 3 weeks,69,18-75,40% M/60% F,0-1,0,1,Moderate impairment,Neutropenia,Hematological,Gastrointestinal,Moderate,5,19.84,Yes,Yes,Dose reduction,Monitoring,13,28,Yes,None,Yes,Yes,No,Regulatory,,Unknown,None,Medium
RCT33552,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,105,5,Weekly,111,18-65,40% M/60% F,0-1,0,3,Mild impairment,Neutropenia,Cardiac,Hepatic,Severe,5,25.53,No,No,Dose reduction,Monitoring,14,50,Yes,Discontinuation,Yes,No,Yes,Regulatory,Yes,None,Gender,Low
RCT10274,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 1,150,13,Monthly,150,18-65,40% M/60% F,1-2,5,1,Normal,Infusion reaction,Hepatic,Cardiac,Mild,2,25.23,No,No,Treatment hold,Patient education,8,14,Yes,Discontinuation,Yes,Yes,No,Efficacy,,Unknown,Gender,Low
RCT88585,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 2,260,3,Every 3 weeks,142,21-85,50% M/50% F,1-2,4,3,Normal,Fatigue,Gastrointestinal,Gastrointestinal,Moderate,3,19.7,No,No,Dose reduction,Dose adjustment,12,19,No,None,No,Yes,Yes,Regulatory,Yes,Unknown,None,Medium
RCT84550,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 3,292,10,Bi-weekly,79,18-65,40% M/60% F,1-2,5,1,Normal,Nausea,Dermatological,Skin,Mild,2,15.02,No,No,Discontinuation,Monitoring,23,26,Yes,Discontinuation,No,No,No,,,Positive,ECOG,Unknown
RCT11381,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,186,13,Every 3 weeks,83,18-75,50% M/50% F,0-2,5,3,Moderate impairment,Fatigue,Hepatic,Gastrointestinal,Mild,1,9.36,No,Yes,Discontinuation,Patient education,12,39,No,Discontinuation,No,Yes,No,,No,Positive,Gender,Unknown
RCT76096,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 2,218,10,Monthly,127,18-65,50% M/50% F,0-2,1,3,Normal,Infusion reaction,Hepatic,Hepatic,Moderate,3,12.0,Yes,Yes,Dose reduction,Dose adjustment,27,3,Yes,Reduction,No,No,Yes,Competition,,Positive,ECOG,High
RCT75538,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 3,172,10,Weekly,95,18-75,60% M/40% F,0-1,4,2,Mild impairment,Infusion reaction,Gastrointestinal,Skin,Mild,1,14.68,Yes,No,Supportive care,Dose adjustment,11,11,Yes,None,Yes,Yes,Yes,Regulatory,,None,Gender,Low
RCT84910,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 3,209,1,Bi-weekly,76,18-75,50% M/50% F,0-2,4,0,Mild impairment,Infusion reaction,Hepatic,Cardiac,Mild,4,3.73,Yes,No,Dose reduction,Premedication,12,59,No,None,No,Yes,Yes,Efficacy,,Negative,ECOG,High
RCT99302,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,40,2,Every 3 weeks,113,≥18,40% M/60% F,0-2,4,3,Moderate impairment,Rash,Cardiac,Gastrointestinal,Moderate,2,22.16,Yes,No,Supportive care,Premedication,22,41,Yes,Reduction,Yes,Yes,No,,No,None,Age,Medium
RCT18078,Rituximab,Anti-CD20,Crossover,Placebo,Phase 3,52,2,Weekly,158,≥18,40% M/60% F,0-1,3,0,Mild impairment,Fatigue,Cardiac,Skin,Moderate,3,27.98,Yes,No,Treatment hold,Patient education,7,35,Yes,Delay,No,No,No,Safety,No,None,Age,Medium
RCT21812,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 2,277,2,Every 3 weeks,93,≥18,60% M/40% F,0-2,0,1,Mild impairment,Fatigue,Gastrointestinal,Skin,Mild,2,24.92,Yes,Yes,Dose reduction,Premedication,11,27,No,Delay,No,Yes,Yes,,No,Negative,Prior treatments,Unknown
RCT72616,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,233,12,Weekly,112,≥18,40% M/60% F,0-1,0,1,Normal,Fatigue,Hematological,Hepatic,Severe,3,12.73,No,No,Treatment hold,Dose adjustment,14,60,No,Discontinuation,No,No,No,Safety,,Negative,Gender,Low
RCT55695,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,265,1,Bi-weekly,117,18-75,40% M/60% F,0-1,0,1,Mild impairment,Neutropenia,Hematological,Gastrointestinal,Mild,3,15.41,Yes,Yes,Discontinuation,Monitoring,13,41,No,None,No,Yes,Yes,,No,Unknown,Prior treatments,Unknown
RCT46751,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,208,4,Weekly,97,18-65,40% M/60% F,1-2,5,1,Normal,Neutropenia,Cardiac,Gastrointestinal,Moderate,5,28.77,No,Yes,Supportive care,Patient education,24,11,No,Delay,Yes,Yes,Yes,Efficacy,No,None,Prior treatments,Unknown
RCT99807,Rituximab,Anti-CD20,Randomized,Placebo,Phase 3,76,11,Weekly,94,18-75,40% M/60% F,1-2,2,0,Moderate impairment,Fatigue,Hepatic,Blood,Severe,4,3.67,Yes,Yes,Supportive care,Patient education,10,44,Yes,Discontinuation,Yes,Yes,No,Efficacy,,Unknown,Age,Medium
RCT30330,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,275,2,Monthly,176,≥18,40% M/60% F,1-2,0,1,Moderate impairment,Infusion reaction,Gastrointestinal,Blood,Mild,3,27.35,No,Yes,Treatment hold,Dose adjustment,18,10,No,Discontinuation,Yes,Yes,Yes,Regulatory,Yes,None,None,Unknown
RCT25500,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 3,174,8,Weekly,93,21-85,50% M/50% F,0-2,4,3,Moderate impairment,Infusion reaction,Dermatological,Skin,Moderate,2,7.43,Yes,Yes,Supportive care,Monitoring,10,40,No,Reduction,Yes,Yes,Yes,Competition,No,None,Gender,Low
RCT51767,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 1,58,15,Weekly,171,18-65,60% M/40% F,1-2,2,3,Mild impairment,Fatigue,Hematological,Hepatic,Mild,1,29.05,Yes,No,Discontinuation,Monitoring,24,55,Yes,Reduction,No,Yes,No,Regulatory,No,None,Age,Medium
RCT44792,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 1,199,13,Every 3 weeks,50,21-85,60% M/40% F,0-1,1,3,Moderate impairment,Rash,Hepatic,Cardiac,Severe,2,18.56,Yes,No,Supportive care,Monitoring,11,25,No,None,No,Yes,Yes,Efficacy,No,Negative,None,Medium
RCT12693,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,96,8,Bi-weekly,83,≥18,50% M/50% F,1-2,3,2,Mild impairment,Nausea,Cardiac,Hepatic,Moderate,2,23.07,Yes,Yes,Discontinuation,Monitoring,2,34,Yes,None,No,No,Yes,Safety,No,None,Prior treatments,Unknown
RCT45570,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,73,10,Monthly,155,18-65,40% M/60% F,0-1,5,1,Mild impairment,Infusion reaction,Dermatological,Cardiac,Severe,4,26.86,No,No,Discontinuation,Premedication,6,10,No,Delay,No,Yes,Yes,Competition,No,Unknown,Prior treatments,High
RCT95754,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,51,12,Bi-weekly,112,18-65,40% M/60% F,1-2,1,1,Moderate impairment,Rash,Dermatological,Cardiac,Moderate,4,6.75,No,No,Treatment hold,Patient education,23,54,Yes,None,Yes,Yes,Yes,Safety,Yes,Negative,None,High
RCT40592,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,186,14,Bi-weekly,154,21-85,50% M/50% F,1-2,3,2,Normal,Nausea,Dermatological,Skin,Mild,3,14.82,Yes,Yes,Discontinuation,Premedication,2,21,Yes,Reduction,Yes,Yes,Yes,,Yes,Unknown,Prior treatments,High
RCT99142,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 2,299,10,Every 3 weeks,33,21-85,60% M/40% F,0-1,0,0,Normal,Nausea,Gastrointestinal,Cardiac,Mild,2,18.92,Yes,Yes,Dose reduction,Premedication,22,28,Yes,None,No,No,No,Regulatory,Yes,Negative,Age,Unknown
RCT76504,Rituximab,Anti-CD20,Single-arm,None,Phase 1,210,5,Monthly,69,18-65,60% M/40% F,0-2,3,0,Normal,Neutropenia,Hepatic,Skin,Severe,4,27.24,Yes,No,Supportive care,Premedication,14,28,Yes,Reduction,Yes,No,No,Regulatory,No,Positive,Gender,Low
RCT70493,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,35,15,Every 3 weeks,121,18-75,50% M/50% F,1-2,2,1,Mild impairment,Infusion reaction,Cardiac,Skin,Mild,4,22.03,Yes,Yes,Dose reduction,Monitoring,19,58,Yes,Delay,Yes,Yes,Yes,,,None,Gender,Medium
RCT56066,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 1,167,14,Weekly,59,18-75,40% M/60% F,1-2,4,1,Mild impairment,Fatigue,Gastrointestinal,Hepatic,Moderate,3,22.09,No,No,Treatment hold,Dose adjustment,14,4,Yes,Delay,Yes,Yes,No,,Yes,Negative,ECOG,Low
RCT78311,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 1,292,15,Every 3 weeks,131,18-65,40% M/60% F,1-2,5,0,Normal,Neutropenia,Cardiac,Blood,Moderate,4,20.2,No,Yes,Treatment hold,Premedication,8,43,Yes,Reduction,No,Yes,No,,,Positive,Prior treatments,Medium
RCT51194,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,90,4,Every 3 weeks,174,≥18,50% M/50% F,0-1,0,2,Normal,Nausea,Hematological,Cardiac,Severe,1,23.85,No,No,Treatment hold,Patient education,9,54,Yes,None,Yes,No,No,Competition,,Negative,Prior treatments,Low
RCT54386,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,127,9,Bi-weekly,90,18-75,60% M/40% F,0-2,4,2,Normal,Fatigue,Cardiac,Blood,Mild,2,20.15,Yes,No,Treatment hold,Patient education,15,39,Yes,Reduction,No,No,Yes,Competition,,Unknown,ECOG,Unknown
RCT98541,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,234,11,Monthly,75,18-75,50% M/50% F,0-1,3,3,Moderate impairment,Neutropenia,Hepatic,Cardiac,Moderate,1,24.7,Yes,Yes,Supportive care,Premedication,5,53,No,None,Yes,No,No,,No,Negative,Prior treatments,High
RCT39944,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,80,3,Weekly,144,18-75,60% M/40% F,0-1,2,3,Normal,Rash,Hepatic,Blood,Moderate,1,6.52,No,Yes,Treatment hold,Premedication,9,36,Yes,Reduction,Yes,No,No,,,Negative,Gender,Medium
RCT76440,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 1,208,9,Bi-weekly,158,18-75,40% M/60% F,0-1,0,3,Mild impairment,Neutropenia,Hepatic,Cardiac,Severe,4,21.53,No,Yes,Dose reduction,Premedication,11,32,No,None,No,Yes,No,,,None,None,Unknown
RCT92037,Cetuximab,Anti-EGFR,Single-arm,None,Phase 1,219,5,Every 3 weeks,103,18-65,60% M/40% F,0-1,4,2,Normal,Fatigue,Hematological,Hepatic,Mild,2,23.88,Yes,Yes,Discontinuation,Dose adjustment,3,29,Yes,Delay,Yes,Yes,Yes,Safety,,None,Prior treatments,Medium
RCT47296,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,225,7,Monthly,82,18-75,40% M/60% F,0-1,2,2,Moderate impairment,Rash,Dermatological,Blood,Moderate,4,17.15,Yes,Yes,Dose reduction,Patient education,6,42,Yes,Reduction,No,Yes,Yes,Regulatory,No,None,Gender,Unknown
RCT97941,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 1,199,2,Every 3 weeks,116,21-85,60% M/40% F,0-1,2,1,Mild impairment,Fatigue,Gastrointestinal,Cardiac,Moderate,5,3.1,No,No,Dose reduction,Patient education,13,29,Yes,Discontinuation,No,No,Yes,Safety,,Negative,ECOG,Low
RCT54915,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,254,12,Weekly,179,18-65,60% M/40% F,0-2,4,1,Moderate impairment,Neutropenia,Dermatological,Blood,Severe,5,25.68,Yes,Yes,Discontinuation,Monitoring,6,46,No,Delay,No,No,Yes,Competition,,Unknown,Prior treatments,Low
RCT75851,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 1,78,5,Monthly,63,18-65,40% M/60% F,0-2,5,3,Moderate impairment,Rash,Hepatic,Hepatic,Severe,5,21.26,Yes,Yes,Treatment hold,Dose adjustment,23,34,No,None,Yes,No,No,Regulatory,Yes,Negative,ECOG,Medium
RCT80251,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,28,9,Every 3 weeks,167,18-65,40% M/60% F,0-1,3,2,Mild impairment,Neutropenia,Hepatic,Blood,Mild,5,13.42,Yes,No,Dose reduction,Monitoring,7,3,Yes,Discontinuation,No,Yes,Yes,Safety,,Unknown,ECOG,Unknown
RCT96050,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,285,7,Every 3 weeks,47,21-85,40% M/60% F,0-2,2,0,Normal,Nausea,Cardiac,Cardiac,Moderate,2,18.53,Yes,No,Treatment hold,Premedication,16,19,No,Reduction,No,Yes,No,Regulatory,Yes,Unknown,Prior treatments,Unknown
RCT25129,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 1,250,13,Weekly,114,18-65,40% M/60% F,0-1,1,3,Normal,Nausea,Hematological,Blood,Severe,1,22.18,No,No,Supportive care,Monitoring,20,59,Yes,None,No,Yes,Yes,Safety,,None,ECOG,Low
RCT70540,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,189,8,Bi-weekly,143,18-65,40% M/60% F,0-2,4,1,Moderate impairment,Fatigue,Dermatological,Skin,Moderate,4,5.68,Yes,No,Treatment hold,Dose adjustment,4,24,Yes,None,Yes,Yes,Yes,Efficacy,No,Positive,Prior treatments,High
RCT31411,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,44,1,Monthly,99,18-75,40% M/60% F,1-2,5,2,Normal,Nausea,Hepatic,Hepatic,Mild,5,9.49,No,No,Supportive care,Monitoring,5,18,No,Delay,No,Yes,Yes,Safety,Yes,Negative,Age,High
RCT39282,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,68,14,Monthly,33,18-65,50% M/50% F,0-2,5,1,Mild impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,5,9.49,No,No,Supportive care,Dose adjustment,14,10,No,Delay,Yes,No,No,Competition,Yes,Unknown,Age,Low
RCT83091,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,235,14,Weekly,170,21-85,40% M/60% F,1-2,0,3,Moderate impairment,Nausea,Hematological,Cardiac,Moderate,4,10.78,Yes,Yes,Discontinuation,Dose adjustment,10,29,No,Delay,Yes,Yes,No,Safety,No,Unknown,None,High
RCT68050,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 2,259,4,Bi-weekly,59,21-85,50% M/50% F,0-2,1,3,Moderate impairment,Fatigue,Cardiac,Blood,Moderate,4,6.23,No,No,Treatment hold,Patient education,6,7,No,Reduction,No,Yes,Yes,Safety,,Positive,Prior treatments,Unknown
RCT15998,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 2,275,1,Every 3 weeks,147,≥18,50% M/50% F,0-2,1,2,Mild impairment,Neutropenia,Gastrointestinal,Cardiac,Mild,1,2.27,No,Yes,Supportive care,Dose adjustment,25,49,No,Discontinuation,Yes,No,No,Safety,,Unknown,Gender,Low
RCT56666,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,145,6,Monthly,127,18-75,40% M/60% F,1-2,1,3,Mild impairment,Nausea,Cardiac,Hepatic,Mild,2,18.8,No,No,Dose reduction,Dose adjustment,20,2,Yes,Discontinuation,No,No,No,Regulatory,Yes,None,Age,High
RCT26071,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,221,7,Monthly,166,21-85,60% M/40% F,0-1,1,2,Moderate impairment,Rash,Hepatic,Hepatic,Mild,5,18.74,No,No,Dose reduction,Monitoring,13,49,No,Delay,Yes,Yes,No,Regulatory,No,Positive,Gender,Medium
RCT88116,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 2,229,9,Every 3 weeks,82,21-85,40% M/60% F,0-2,0,3,Normal,Nausea,Gastrointestinal,Hepatic,Severe,5,20.67,Yes,No,Supportive care,Dose adjustment,7,50,No,None,No,Yes,No,Efficacy,No,Positive,Gender,Medium
RCT33410,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 2,204,13,Monthly,67,≥18,40% M/60% F,1-2,2,2,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Moderate,1,14.78,No,Yes,Discontinuation,Patient education,10,37,No,Discontinuation,No,Yes,Yes,Safety,Yes,Unknown,Age,Low
RCT48883,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,24,1,Bi-weekly,43,18-75,50% M/50% F,0-2,2,0,Mild impairment,Rash,Cardiac,Cardiac,Mild,4,20.86,Yes,Yes,Treatment hold,Dose adjustment,18,18,Yes,Reduction,No,No,No,,Yes,Positive,Prior treatments,Low
RCT54782,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,211,8,Weekly,153,≥18,40% M/60% F,0-1,0,0,Mild impairment,Infusion reaction,Cardiac,Cardiac,Moderate,1,28.44,Yes,No,Treatment hold,Monitoring,6,7,No,None,No,Yes,Yes,Safety,,Unknown,ECOG,Medium
RCT65044,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 3,208,10,Every 3 weeks,58,18-75,50% M/50% F,0-1,1,1,Normal,Infusion reaction,Hepatic,Cardiac,Severe,1,19.69,No,No,Supportive care,Patient education,1,56,Yes,Discontinuation,No,Yes,Yes,Regulatory,Yes,Negative,ECOG,High
RCT81719,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,294,2,Weekly,147,18-65,40% M/60% F,0-1,1,2,Moderate impairment,Neutropenia,Dermatological,Skin,Mild,2,6.13,No,Yes,Supportive care,Dose adjustment,19,14,No,Delay,No,No,No,Efficacy,,Unknown,Prior treatments,Medium
RCT83912,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,23,10,Bi-weekly,180,≥18,40% M/60% F,1-2,2,2,Mild impairment,Neutropenia,Cardiac,Hepatic,Severe,2,8.58,No,Yes,Discontinuation,Monitoring,26,13,No,Reduction,Yes,Yes,Yes,Efficacy,No,Positive,None,High
RCT34056,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 3,39,15,Every 3 weeks,140,18-75,60% M/40% F,1-2,1,0,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,1,20.92,Yes,Yes,Discontinuation,Premedication,2,2,No,Discontinuation,Yes,Yes,Yes,,No,None,None,Medium
RCT50769,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,68,4,Monthly,44,21-85,40% M/60% F,0-2,0,0,Mild impairment,Neutropenia,Hematological,Blood,Severe,5,11.12,No,No,Supportive care,Patient education,25,17,Yes,Reduction,Yes,Yes,Yes,Regulatory,,Positive,None,Low
RCT46402,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,257,14,Every 3 weeks,61,18-65,40% M/60% F,0-2,4,1,Mild impairment,Neutropenia,Dermatological,Hepatic,Severe,3,28.29,Yes,Yes,Supportive care,Premedication,4,34,No,Delay,No,No,Yes,Competition,No,Negative,None,Low
RCT90191,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 2,221,1,Every 3 weeks,119,21-85,60% M/40% F,1-2,4,1,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Severe,2,7.76,Yes,Yes,Dose reduction,Premedication,7,30,Yes,None,Yes,Yes,Yes,Regulatory,,None,Prior treatments,Medium
RCT52525,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,47,2,Monthly,109,18-65,40% M/60% F,0-1,4,2,Moderate impairment,Rash,Hematological,Gastrointestinal,Mild,1,19.25,No,No,Discontinuation,Monitoring,8,8,Yes,Delay,Yes,No,Yes,Efficacy,No,None,ECOG,High
RCT21003,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,199,2,Weekly,79,21-85,60% M/40% F,1-2,0,2,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Severe,3,29.91,No,No,Supportive care,Monitoring,19,55,No,Delay,No,Yes,No,Efficacy,,None,None,High
RCT85185,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,116,6,Bi-weekly,74,≥18,40% M/60% F,1-2,4,3,Moderate impairment,Infusion reaction,Dermatological,Hepatic,Mild,5,22.29,No,No,Supportive care,Monitoring,26,14,Yes,Reduction,No,No,Yes,Regulatory,,Unknown,Age,Low
RCT54694,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 3,81,9,Monthly,151,18-65,60% M/40% F,1-2,3,1,Mild impairment,Infusion reaction,Hepatic,Blood,Mild,3,27.52,No,No,Dose reduction,Premedication,22,6,No,Reduction,No,No,No,Competition,Yes,Positive,ECOG,Low
RCT90255,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,187,13,Every 3 weeks,76,18-75,50% M/50% F,0-1,1,3,Moderate impairment,Fatigue,Hepatic,Gastrointestinal,Moderate,3,21.05,Yes,No,Treatment hold,Dose adjustment,22,52,Yes,Reduction,Yes,No,No,,No,Unknown,None,Low
RCT94622,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,199,3,Every 3 weeks,112,18-75,60% M/40% F,1-2,3,0,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Moderate,4,15.61,No,No,Discontinuation,Premedication,6,57,No,Discontinuation,No,Yes,No,,,Negative,Prior treatments,Low
RCT73289,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,219,11,Monthly,170,18-75,50% M/50% F,0-1,2,0,Normal,Nausea,Cardiac,Blood,Severe,4,24.6,Yes,Yes,Treatment hold,Monitoring,23,38,No,Delay,Yes,No,No,Competition,No,Negative,Age,Low
RCT36405,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,68,5,Bi-weekly,131,≥18,50% M/50% F,0-1,4,3,Normal,Rash,Cardiac,Hepatic,Mild,3,4.09,No,No,Supportive care,Premedication,26,18,Yes,Delay,No,No,No,Efficacy,Yes,Unknown,Gender,Unknown
RCT58090,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,197,7,Monthly,78,≥18,40% M/60% F,0-1,3,3,Moderate impairment,Neutropenia,Gastrointestinal,Cardiac,Severe,1,28.37,No,No,Treatment hold,Patient education,22,17,Yes,Reduction,Yes,No,No,Efficacy,,None,Gender,High
RCT69078,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 2,108,6,Every 3 weeks,103,21-85,40% M/60% F,0-1,1,2,Mild impairment,Rash,Cardiac,Hepatic,Severe,5,3.84,Yes,Yes,Dose reduction,Dose adjustment,26,60,No,Delay,Yes,No,No,Efficacy,,Positive,Age,Unknown
RCT47137,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,132,15,Monthly,103,≥18,60% M/40% F,0-2,4,2,Normal,Fatigue,Hepatic,Gastrointestinal,Moderate,3,9.72,No,Yes,Discontinuation,Patient education,9,27,Yes,None,Yes,Yes,No,Safety,No,None,Age,Unknown
RCT34685,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,193,15,Weekly,31,≥18,60% M/40% F,1-2,5,0,Normal,Rash,Hematological,Gastrointestinal,Severe,3,26.69,No,Yes,Dose reduction,Patient education,11,7,Yes,Delay,Yes,Yes,No,Efficacy,No,None,ECOG,High
RCT57885,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,80,8,Every 3 weeks,160,18-75,60% M/40% F,0-2,2,0,Mild impairment,Rash,Hematological,Cardiac,Moderate,2,16.67,Yes,Yes,Dose reduction,Patient education,28,43,No,Discontinuation,No,No,Yes,,Yes,Unknown,ECOG,Medium
RCT21197,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,100,7,Monthly,54,≥18,50% M/50% F,0-2,4,3,Normal,Neutropenia,Hepatic,Skin,Severe,1,18.04,Yes,Yes,Dose reduction,Patient education,25,44,No,Delay,No,No,Yes,Efficacy,No,Unknown,Gender,Unknown
RCT65193,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,256,1,Monthly,73,≥18,60% M/40% F,0-1,0,1,Moderate impairment,Infusion reaction,Hepatic,Blood,Mild,2,15.56,Yes,No,Discontinuation,Patient education,28,43,No,Delay,Yes,No,Yes,Safety,No,Negative,Gender,Low
RCT67933,Trastuzumab,Anti-HER2,Randomized,None,Phase 3,255,11,Every 3 weeks,98,21-85,50% M/50% F,0-2,2,0,Moderate impairment,Fatigue,Dermatological,Cardiac,Severe,3,25.11,No,No,Discontinuation,Monitoring,3,3,No,Discontinuation,Yes,Yes,No,,Yes,None,Gender,Unknown
RCT86849,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,71,12,Every 3 weeks,178,18-65,50% M/50% F,0-2,3,0,Moderate impairment,Neutropenia,Cardiac,Hepatic,Moderate,1,9.04,No,No,Discontinuation,Patient education,10,50,Yes,Reduction,No,No,Yes,,No,Positive,None,Unknown
RCT31128,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,132,13,Bi-weekly,49,21-85,60% M/40% F,1-2,1,3,Mild impairment,Fatigue,Cardiac,Hepatic,Severe,4,26.43,No,No,Dose reduction,Premedication,11,3,Yes,Reduction,Yes,Yes,No,Safety,,None,Age,Low
RCT43461,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,156,8,Every 3 weeks,94,≥18,60% M/40% F,0-2,1,3,Mild impairment,Rash,Hematological,Cardiac,Moderate,2,9.88,No,No,Dose reduction,Dose adjustment,17,47,No,Delay,No,Yes,No,,Yes,None,None,Medium
RCT34533,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,280,15,Weekly,108,≥18,60% M/40% F,0-1,2,3,Mild impairment,Nausea,Dermatological,Gastrointestinal,Mild,3,19.99,No,Yes,Discontinuation,Dose adjustment,23,33,Yes,Discontinuation,No,No,Yes,,,Positive,ECOG,High
RCT78021,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 1,107,11,Monthly,158,18-75,40% M/60% F,0-1,2,1,Moderate impairment,Fatigue,Dermatological,Hepatic,Mild,4,5.46,No,Yes,Supportive care,Dose adjustment,28,47,Yes,Delay,Yes,No,No,Safety,Yes,None,ECOG,Low
RCT56115,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,229,3,Bi-weekly,125,21-85,40% M/60% F,1-2,2,0,Normal,Infusion reaction,Cardiac,Blood,Severe,3,17.48,Yes,No,Treatment hold,Premedication,12,48,Yes,Delay,No,Yes,No,Efficacy,Yes,None,ECOG,Unknown
RCT85386,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 3,44,9,Weekly,75,21-85,50% M/50% F,0-2,0,1,Mild impairment,Nausea,Dermatological,Skin,Severe,4,21.3,No,Yes,Dose reduction,Premedication,10,16,No,Discontinuation,Yes,No,Yes,Efficacy,,Negative,Gender,High
RCT34391,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 3,186,5,Weekly,145,18-75,50% M/50% F,0-1,3,0,Moderate impairment,Nausea,Hematological,Blood,Severe,1,11.41,Yes,No,Supportive care,Patient education,13,26,No,Delay,Yes,No,Yes,Competition,No,Negative,None,Unknown
RCT82500,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,229,11,Bi-weekly,157,21-85,60% M/40% F,1-2,1,2,Mild impairment,Neutropenia,Cardiac,Blood,Mild,5,3.52,Yes,Yes,Dose reduction,Premedication,4,42,Yes,Delay,Yes,Yes,No,Regulatory,,Positive,Prior treatments,Low
RCT96418,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,37,14,Bi-weekly,67,18-65,50% M/50% F,1-2,0,3,Normal,Fatigue,Cardiac,Hepatic,Severe,2,13.44,No,Yes,Discontinuation,Monitoring,6,32,Yes,None,No,Yes,Yes,Competition,No,Unknown,None,Low
RCT38452,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 2,132,12,Bi-weekly,52,≥18,40% M/60% F,0-1,1,3,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Moderate,1,6.04,No,No,Treatment hold,Monitoring,9,6,Yes,Delay,Yes,No,Yes,Competition,No,Unknown,Prior treatments,Medium
RCT61407,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 2,295,14,Bi-weekly,119,≥18,60% M/40% F,0-1,3,1,Mild impairment,Infusion reaction,Hematological,Cardiac,Moderate,2,18.9,No,Yes,Treatment hold,Dose adjustment,5,41,No,Delay,Yes,No,Yes,Competition,No,None,Prior treatments,Unknown
RCT72538,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,26,5,Monthly,74,21-85,40% M/60% F,0-1,0,1,Moderate impairment,Infusion reaction,Hematological,Cardiac,Severe,3,3.87,Yes,Yes,Treatment hold,Patient education,2,10,No,None,Yes,Yes,No,Regulatory,No,Unknown,Gender,Medium
RCT67420,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,46,11,Monthly,112,18-65,40% M/60% F,0-1,0,1,Moderate impairment,Infusion reaction,Hematological,Skin,Mild,1,10.29,No,Yes,Discontinuation,Dose adjustment,7,22,No,Reduction,No,No,Yes,Safety,No,Negative,Gender,Low
RCT28888,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,54,2,Bi-weekly,103,≥18,40% M/60% F,1-2,1,0,Moderate impairment,Rash,Cardiac,Blood,Mild,1,19.93,No,No,Treatment hold,Monitoring,15,45,Yes,Delay,No,No,No,Safety,,Positive,None,Low
RCT68487,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,127,13,Every 3 weeks,78,18-65,40% M/60% F,0-1,5,1,Moderate impairment,Infusion reaction,Dermatological,Blood,Severe,2,8.03,No,No,Treatment hold,Dose adjustment,8,51,No,None,Yes,No,No,Regulatory,No,Unknown,ECOG,High
RCT80105,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,24,13,Every 3 weeks,35,21-85,60% M/40% F,0-2,1,1,Moderate impairment,Nausea,Cardiac,Gastrointestinal,Severe,4,2.75,Yes,Yes,Treatment hold,Patient education,25,41,Yes,Discontinuation,No,Yes,Yes,Safety,No,Unknown,Age,Low
RCT77199,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,156,10,Bi-weekly,63,≥18,50% M/50% F,0-1,0,3,Moderate impairment,Nausea,Hematological,Gastrointestinal,Severe,1,22.26,Yes,Yes,Discontinuation,Monitoring,17,29,Yes,Discontinuation,No,No,Yes,Competition,No,Positive,ECOG,High
RCT53490,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,152,1,Weekly,85,18-65,40% M/60% F,1-2,3,2,Normal,Rash,Hematological,Blood,Severe,3,6.83,Yes,Yes,Supportive care,Patient education,26,29,No,Delay,No,Yes,No,,Yes,Negative,None,Medium
RCT89318,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,269,6,Monthly,158,≥18,60% M/40% F,0-1,4,0,Mild impairment,Fatigue,Cardiac,Blood,Severe,3,19.12,Yes,Yes,Discontinuation,Monitoring,16,30,No,Delay,Yes,No,No,Efficacy,No,Positive,Age,Low
RCT58701,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,115,13,Bi-weekly,31,18-75,40% M/60% F,0-2,2,3,Normal,Rash,Dermatological,Blood,Mild,1,25.06,No,Yes,Dose reduction,Dose adjustment,11,38,Yes,Delay,Yes,Yes,No,,,Positive,None,Medium
RCT23951,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 1,287,9,Bi-weekly,108,18-65,50% M/50% F,0-1,1,0,Mild impairment,Neutropenia,Gastrointestinal,Skin,Severe,5,6.34,No,No,Treatment hold,Dose adjustment,3,59,No,None,No,No,No,Efficacy,,Unknown,Gender,Medium
RCT43318,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,259,10,Every 3 weeks,108,18-65,60% M/40% F,1-2,2,0,Normal,Infusion reaction,Hematological,Skin,Moderate,3,21.89,No,Yes,Supportive care,Monitoring,5,54,Yes,Reduction,No,Yes,Yes,Competition,No,Negative,Gender,High
RCT22978,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,289,3,Monthly,175,18-75,40% M/60% F,0-2,3,3,Normal,Rash,Dermatological,Blood,Mild,2,26.05,No,Yes,Dose reduction,Patient education,25,5,Yes,Discontinuation,Yes,Yes,Yes,,,Unknown,Gender,Unknown
RCT38410,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 1,59,14,Monthly,88,18-65,40% M/60% F,0-2,1,2,Mild impairment,Fatigue,Dermatological,Gastrointestinal,Severe,5,18.16,No,Yes,Supportive care,Patient education,19,40,No,Reduction,Yes,No,Yes,Competition,,Negative,Prior treatments,Low
RCT84256,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 3,254,7,Weekly,173,18-75,50% M/50% F,1-2,3,2,Moderate impairment,Fatigue,Hepatic,Skin,Moderate,1,17.35,Yes,No,Supportive care,Premedication,16,24,Yes,Discontinuation,No,No,Yes,Regulatory,No,Positive,None,Low
RCT29845,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,141,7,Weekly,155,21-85,60% M/40% F,0-1,1,2,Normal,Neutropenia,Cardiac,Hepatic,Mild,1,23.97,No,Yes,Treatment hold,Patient education,27,58,Yes,Discontinuation,Yes,No,No,Regulatory,,None,Age,Low
RCT15115,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 3,33,9,Every 3 weeks,57,21-85,40% M/60% F,0-1,3,1,Moderate impairment,Infusion reaction,Hematological,Cardiac,Moderate,2,14.29,No,No,Discontinuation,Patient education,22,16,No,None,Yes,No,No,Efficacy,No,Positive,None,Unknown
RCT77378,Rituximab,Anti-CD20,Single-arm,None,Phase 2,233,7,Bi-weekly,177,18-75,40% M/60% F,0-2,5,2,Mild impairment,Neutropenia,Gastrointestinal,Cardiac,Mild,2,22.78,Yes,Yes,Treatment hold,Dose adjustment,20,15,Yes,Discontinuation,Yes,No,Yes,Safety,No,None,ECOG,High
RCT94567,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 3,45,4,Weekly,102,18-75,50% M/50% F,1-2,5,3,Mild impairment,Fatigue,Gastrointestinal,Blood,Mild,4,9.28,No,Yes,Discontinuation,Patient education,22,3,No,None,No,No,Yes,,No,Negative,None,Unknown
RCT73304,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,222,5,Monthly,93,18-65,40% M/60% F,0-1,1,0,Mild impairment,Rash,Dermatological,Cardiac,Severe,5,14.75,Yes,No,Discontinuation,Monitoring,8,59,No,Delay,No,No,No,,No,Unknown,ECOG,High
RCT36277,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 3,127,8,Monthly,173,18-65,60% M/40% F,0-1,2,1,Moderate impairment,Fatigue,Gastrointestinal,Blood,Severe,2,29.16,Yes,Yes,Discontinuation,Premedication,20,12,Yes,Delay,No,Yes,No,,,Unknown,Gender,Medium
RCT28082,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,290,5,Every 3 weeks,30,≥18,40% M/60% F,1-2,5,0,Normal,Nausea,Hematological,Gastrointestinal,Severe,1,4.54,No,Yes,Dose reduction,Monitoring,22,8,No,None,No,Yes,Yes,Safety,No,Positive,Gender,Medium
RCT72848,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,242,12,Bi-weekly,147,≥18,50% M/50% F,0-1,4,0,Moderate impairment,Rash,Hematological,Blood,Severe,4,29.8,Yes,Yes,Discontinuation,Monitoring,13,18,No,Reduction,No,No,Yes,Safety,,None,ECOG,Low
RCT89678,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,220,9,Bi-weekly,36,18-65,40% M/60% F,1-2,2,3,Moderate impairment,Fatigue,Hematological,Gastrointestinal,Severe,3,18.78,No,Yes,Treatment hold,Patient education,18,12,Yes,None,No,No,Yes,,Yes,Negative,None,Medium
RCT29680,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,281,8,Weekly,108,18-65,40% M/60% F,0-2,4,2,Normal,Neutropenia,Hepatic,Hepatic,Severe,4,22.52,Yes,Yes,Treatment hold,Dose adjustment,25,35,Yes,Reduction,No,Yes,No,,Yes,Unknown,Age,Medium
RCT76943,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,242,7,Every 3 weeks,103,18-65,60% M/40% F,1-2,3,1,Normal,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,4,1.38,Yes,Yes,Discontinuation,Premedication,4,28,No,None,Yes,No,No,Competition,Yes,Negative,Age,Unknown
RCT75886,Cetuximab,Anti-EGFR,Randomized,None,Phase 1,65,9,Every 3 weeks,49,21-85,60% M/40% F,1-2,1,1,Normal,Nausea,Cardiac,Skin,Moderate,1,22.33,Yes,No,Treatment hold,Dose adjustment,8,43,Yes,Reduction,No,No,No,,No,None,None,Unknown
RCT12403,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,74,6,Bi-weekly,86,21-85,50% M/50% F,1-2,1,2,Moderate impairment,Neutropenia,Cardiac,Blood,Moderate,4,27.04,Yes,Yes,Discontinuation,Premedication,4,18,No,Delay,Yes,Yes,Yes,Competition,Yes,Negative,Age,Unknown
RCT30286,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,131,2,Monthly,71,18-65,60% M/40% F,0-2,5,3,Moderate impairment,Rash,Hematological,Cardiac,Mild,3,15.28,No,Yes,Supportive care,Dose adjustment,14,26,No,None,Yes,No,No,Efficacy,No,None,None,Medium
RCT76567,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,111,8,Monthly,46,21-85,50% M/50% F,0-1,3,2,Mild impairment,Infusion reaction,Hepatic,Blood,Severe,4,11.41,No,Yes,Treatment hold,Patient education,11,51,No,Discontinuation,Yes,Yes,Yes,Efficacy,No,None,Gender,Medium
RCT86389,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 1,177,2,Weekly,61,18-65,40% M/60% F,0-2,4,3,Mild impairment,Infusion reaction,Hepatic,Skin,Mild,3,6.02,Yes,Yes,Supportive care,Premedication,7,8,No,Delay,No,Yes,No,Regulatory,,Positive,Age,Low
RCT74387,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,290,14,Monthly,165,18-75,40% M/60% F,1-2,2,2,Normal,Rash,Cardiac,Hepatic,Moderate,3,26.66,No,No,Dose reduction,Premedication,4,35,No,Reduction,No,Yes,Yes,Safety,Yes,Positive,Prior treatments,Low
RCT60244,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 3,177,13,Weekly,115,18-75,40% M/60% F,1-2,5,0,Normal,Infusion reaction,Hepatic,Skin,Mild,2,22.31,Yes,Yes,Supportive care,Monitoring,25,48,No,Delay,Yes,No,No,Efficacy,,None,None,Unknown
RCT80167,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 3,137,15,Bi-weekly,52,21-85,50% M/50% F,1-2,0,1,Normal,Neutropenia,Gastrointestinal,Cardiac,Mild,5,17.39,No,Yes,Discontinuation,Dose adjustment,16,52,Yes,Reduction,No,Yes,Yes,Efficacy,No,Positive,Age,Low
RCT42746,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,28,15,Monthly,40,18-75,60% M/40% F,1-2,2,0,Mild impairment,Neutropenia,Dermatological,Hepatic,Severe,3,1.32,No,No,Supportive care,Dose adjustment,2,57,No,Reduction,No,No,No,Competition,Yes,Positive,Age,Unknown
RCT17839,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 2,296,1,Bi-weekly,91,≥18,50% M/50% F,1-2,2,2,Normal,Rash,Gastrointestinal,Gastrointestinal,Severe,2,9.43,Yes,Yes,Discontinuation,Monitoring,13,14,Yes,Reduction,No,No,Yes,Competition,Yes,None,Gender,Unknown
RCT98666,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,281,1,Monthly,34,21-85,50% M/50% F,0-2,2,2,Mild impairment,Fatigue,Hematological,Gastrointestinal,Moderate,5,9.71,No,No,Supportive care,Dose adjustment,1,41,Yes,Discontinuation,Yes,No,No,Efficacy,No,Unknown,Prior treatments,High
RCT28641,Rituximab,Anti-CD20,Randomized,None,Phase 2,163,12,Bi-weekly,173,18-65,50% M/50% F,0-1,4,0,Moderate impairment,Neutropenia,Hematological,Skin,Mild,1,11.98,Yes,Yes,Dose reduction,Premedication,12,11,Yes,Reduction,Yes,Yes,Yes,Competition,Yes,Unknown,None,Low
RCT16450,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,202,15,Weekly,165,18-75,60% M/40% F,1-2,0,3,Mild impairment,Nausea,Cardiac,Skin,Severe,3,5.79,Yes,Yes,Discontinuation,Patient education,17,33,No,None,No,Yes,Yes,Efficacy,No,Unknown,Prior treatments,Unknown
RCT42891,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 3,213,4,Monthly,171,≥18,50% M/50% F,0-2,4,0,Normal,Neutropenia,Gastrointestinal,Hepatic,Severe,5,15.72,No,No,Discontinuation,Dose adjustment,15,39,Yes,Reduction,No,No,No,Safety,No,None,Prior treatments,Low
RCT92253,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 1,194,8,Bi-weekly,75,≥18,60% M/40% F,0-1,5,0,Mild impairment,Rash,Hematological,Cardiac,Mild,3,18.35,Yes,No,Supportive care,Dose adjustment,21,26,Yes,Delay,Yes,No,Yes,Safety,,Positive,Prior treatments,Low
RCT87134,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 1,231,12,Every 3 weeks,144,≥18,40% M/60% F,1-2,3,2,Mild impairment,Nausea,Gastrointestinal,Hepatic,Severe,4,11.18,No,No,Discontinuation,Monitoring,8,14,Yes,Delay,No,Yes,No,Efficacy,No,Positive,ECOG,Low
RCT22459,Rituximab,Anti-CD20,Single-arm,None,Phase 3,251,7,Monthly,44,18-65,50% M/50% F,0-1,2,0,Mild impairment,Infusion reaction,Gastrointestinal,Skin,Severe,3,16.31,No,Yes,Supportive care,Dose adjustment,25,25,No,Reduction,Yes,Yes,Yes,Regulatory,Yes,None,Gender,High
RCT40058,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,261,8,Every 3 weeks,135,21-85,40% M/60% F,1-2,0,0,Moderate impairment,Fatigue,Hematological,Blood,Moderate,4,16.39,No,Yes,Treatment hold,Monitoring,17,22,No,Delay,Yes,No,No,Efficacy,Yes,Negative,Prior treatments,Medium
RCT34417,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,200,7,Weekly,45,18-75,50% M/50% F,0-2,5,2,Moderate impairment,Infusion reaction,Dermatological,Skin,Moderate,4,13.14,No,No,Discontinuation,Premedication,24,39,Yes,Delay,Yes,No,Yes,,No,Positive,None,Medium
RCT45287,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,243,13,Weekly,148,18-75,60% M/40% F,1-2,5,1,Moderate impairment,Fatigue,Hematological,Hepatic,Mild,1,20.03,Yes,Yes,Discontinuation,Dose adjustment,27,11,Yes,Delay,No,No,Yes,Regulatory,No,Unknown,Age,Medium
RCT21984,Cetuximab,Anti-EGFR,Single-arm,None,Phase 2,278,15,Every 3 weeks,85,21-85,50% M/50% F,0-2,1,0,Moderate impairment,Nausea,Hepatic,Cardiac,Severe,3,17.19,Yes,Yes,Treatment hold,Monitoring,12,31,Yes,Discontinuation,No,Yes,Yes,Efficacy,Yes,Negative,Prior treatments,Unknown
RCT36406,Rituximab,Anti-CD20,Randomized,None,Phase 3,145,10,Monthly,121,18-65,60% M/40% F,1-2,3,3,Normal,Fatigue,Hepatic,Gastrointestinal,Severe,5,14.84,Yes,No,Supportive care,Monitoring,17,7,No,Reduction,Yes,Yes,No,,,Unknown,None,Low
RCT96706,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,91,12,Monthly,52,18-65,50% M/50% F,0-2,5,0,Moderate impairment,Fatigue,Cardiac,Skin,Moderate,1,3.21,No,Yes,Dose reduction,Dose adjustment,18,54,No,None,No,Yes,Yes,Efficacy,No,Negative,Age,Unknown
RCT47896,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,27,14,Bi-weekly,166,21-85,60% M/40% F,0-2,0,3,Moderate impairment,Nausea,Cardiac,Gastrointestinal,Moderate,4,3.68,Yes,Yes,Discontinuation,Premedication,23,47,No,Discontinuation,No,Yes,No,Safety,No,Unknown,Gender,Unknown
RCT24146,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,232,5,Monthly,91,21-85,60% M/40% F,0-2,4,3,Mild impairment,Rash,Hematological,Hepatic,Severe,4,24.27,No,Yes,Dose reduction,Dose adjustment,16,43,No,Discontinuation,No,No,Yes,Efficacy,Yes,None,ECOG,High
RCT28780,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,20,8,Monthly,58,18-65,40% M/60% F,1-2,4,3,Normal,Infusion reaction,Hepatic,Gastrointestinal,Severe,3,8.36,Yes,No,Discontinuation,Monitoring,14,39,Yes,Delay,Yes,No,No,Competition,Yes,Unknown,Age,Low
RCT60835,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,133,12,Every 3 weeks,142,21-85,50% M/50% F,0-2,3,1,Moderate impairment,Rash,Gastrointestinal,Gastrointestinal,Mild,4,10.71,Yes,No,Treatment hold,Premedication,3,45,Yes,None,Yes,No,No,Efficacy,Yes,None,Prior treatments,Medium
RCT80313,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 1,84,8,Every 3 weeks,155,21-85,60% M/40% F,0-1,5,0,Mild impairment,Rash,Hepatic,Cardiac,Moderate,5,13.65,No,No,Treatment hold,Monitoring,28,30,Yes,Discontinuation,Yes,Yes,Yes,Safety,No,None,Prior treatments,Medium
RCT70404,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 3,229,15,Every 3 weeks,58,18-75,50% M/50% F,0-2,5,3,Moderate impairment,Nausea,Dermatological,Cardiac,Severe,3,11.21,Yes,Yes,Discontinuation,Premedication,15,55,Yes,Delay,Yes,No,Yes,Competition,,Positive,Gender,Unknown
RCT56831,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,142,4,Bi-weekly,103,21-85,60% M/40% F,0-2,0,3,Moderate impairment,Infusion reaction,Dermatological,Blood,Severe,4,12.24,No,No,Dose reduction,Dose adjustment,5,59,Yes,None,Yes,Yes,Yes,,,None,Gender,High
RCT79383,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,118,11,Monthly,129,18-65,50% M/50% F,1-2,4,0,Normal,Nausea,Hepatic,Hepatic,Mild,3,18.0,Yes,Yes,Supportive care,Patient education,3,12,Yes,Delay,Yes,Yes,Yes,Competition,Yes,None,Gender,Low
RCT84001,Rituximab,Anti-CD20,Crossover,None,Phase 1,205,9,Weekly,54,18-65,60% M/40% F,0-2,4,3,Moderate impairment,Fatigue,Dermatological,Cardiac,Mild,3,18.67,No,No,Discontinuation,Monitoring,22,22,Yes,Discontinuation,No,Yes,No,,No,None,Gender,Unknown
RCT66399,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 1,127,15,Every 3 weeks,40,18-65,60% M/40% F,0-1,4,1,Normal,Nausea,Hepatic,Skin,Moderate,5,8.8,Yes,No,Dose reduction,Patient education,28,23,Yes,None,Yes,No,Yes,Competition,No,Negative,ECOG,Low
RCT50813,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 1,274,15,Weekly,146,≥18,60% M/40% F,1-2,3,3,Moderate impairment,Infusion reaction,Hematological,Hepatic,Mild,1,29.13,Yes,No,Dose reduction,Monitoring,19,42,No,Delay,No,No,Yes,Competition,Yes,Negative,Age,High
RCT84392,Bevacizumab,Anti-VEGF,Randomized,None,Phase 2,94,9,Every 3 weeks,50,18-65,40% M/60% F,0-2,0,0,Mild impairment,Rash,Hematological,Blood,Mild,5,14.76,Yes,Yes,Supportive care,Premedication,7,40,No,None,Yes,Yes,No,,No,Positive,Prior treatments,Unknown
RCT32829,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,236,6,Monthly,164,18-75,50% M/50% F,0-1,3,3,Moderate impairment,Infusion reaction,Cardiac,Gastrointestinal,Mild,2,6.94,No,Yes,Supportive care,Dose adjustment,3,50,Yes,None,No,Yes,Yes,,No,Unknown,Prior treatments,Unknown
RCT12661,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,295,1,Every 3 weeks,64,21-85,50% M/50% F,0-1,4,2,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Moderate,4,17.03,No,No,Treatment hold,Monitoring,1,46,No,Delay,No,Yes,No,Competition,,Unknown,Age,Medium
RCT83291,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,167,13,Weekly,81,18-65,50% M/50% F,0-2,5,3,Moderate impairment,Neutropenia,Hematological,Skin,Severe,1,29.36,Yes,No,Dose reduction,Dose adjustment,1,32,No,Discontinuation,No,No,No,,,Positive,None,Unknown
RCT36304,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 3,124,12,Weekly,175,21-85,40% M/60% F,0-1,1,0,Moderate impairment,Neutropenia,Hematological,Gastrointestinal,Severe,3,11.46,No,No,Discontinuation,Premedication,10,10,No,Reduction,No,Yes,No,Regulatory,Yes,None,Age,High
RCT89939,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 2,177,3,Weekly,89,18-65,50% M/50% F,1-2,4,0,Moderate impairment,Infusion reaction,Dermatological,Cardiac,Moderate,4,2.71,Yes,Yes,Discontinuation,Monitoring,23,22,Yes,Discontinuation,Yes,No,No,Competition,,None,Prior treatments,Low
RCT97878,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 3,295,15,Bi-weekly,147,≥18,60% M/40% F,0-2,4,1,Moderate impairment,Nausea,Hematological,Cardiac,Moderate,2,26.22,Yes,Yes,Discontinuation,Monitoring,17,49,No,Delay,Yes,No,No,Competition,Yes,Positive,ECOG,Medium
RCT72107,Rituximab,Anti-CD20,Single-arm,None,Phase 3,225,1,Weekly,120,≥18,40% M/60% F,1-2,1,3,Normal,Rash,Hematological,Skin,Moderate,5,13.31,Yes,No,Discontinuation,Dose adjustment,6,35,Yes,Reduction,Yes,No,No,,Yes,Positive,Prior treatments,Unknown
RCT68389,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,151,10,Bi-weekly,50,18-75,40% M/60% F,1-2,3,3,Mild impairment,Infusion reaction,Hematological,Cardiac,Severe,1,3.91,Yes,Yes,Treatment hold,Patient education,26,30,Yes,Reduction,No,Yes,No,Regulatory,No,None,Gender,Low
RCT23565,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 3,163,12,Every 3 weeks,60,21-85,60% M/40% F,0-2,2,3,Mild impairment,Rash,Hematological,Skin,Moderate,4,26.45,No,Yes,Discontinuation,Patient education,17,34,No,None,Yes,Yes,No,Regulatory,No,None,ECOG,Low
RCT68647,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,177,11,Every 3 weeks,130,18-65,40% M/60% F,0-2,0,1,Mild impairment,Rash,Cardiac,Hepatic,Moderate,3,5.3,No,Yes,Supportive care,Premedication,4,54,No,Delay,No,No,Yes,Competition,No,Positive,Age,Medium
RCT88711,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 1,57,8,Bi-weekly,72,18-75,50% M/50% F,1-2,1,3,Normal,Neutropenia,Cardiac,Gastrointestinal,Mild,5,1.32,Yes,Yes,Dose reduction,Premedication,17,39,No,Reduction,No,Yes,Yes,Regulatory,Yes,Positive,None,Low
RCT37133,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,213,4,Bi-weekly,31,18-65,60% M/40% F,1-2,3,0,Moderate impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Mild,2,13.91,No,No,Dose reduction,Monitoring,28,54,No,Delay,No,No,Yes,,,Unknown,Gender,Unknown
RCT95953,Trastuzumab,Anti-HER2,Crossover,None,Phase 1,284,2,Weekly,153,21-85,60% M/40% F,1-2,4,0,Mild impairment,Nausea,Hematological,Cardiac,Mild,2,11.55,Yes,No,Discontinuation,Premedication,7,58,Yes,Reduction,Yes,Yes,No,Efficacy,Yes,None,Age,Low
RCT67898,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,236,13,Monthly,114,18-65,40% M/60% F,0-2,3,1,Normal,Infusion reaction,Dermatological,Skin,Mild,2,27.92,No,No,Dose reduction,Patient education,24,1,Yes,Delay,No,No,No,Efficacy,,Positive,Age,Unknown
RCT98405,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 3,165,6,Bi-weekly,65,18-65,50% M/50% F,0-1,3,0,Moderate impairment,Fatigue,Gastrointestinal,Gastrointestinal,Moderate,3,24.24,No,Yes,Treatment hold,Dose adjustment,21,48,Yes,None,No,Yes,No,Efficacy,No,Positive,Gender,Medium
RCT81864,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,67,12,Monthly,166,18-65,60% M/40% F,1-2,1,2,Mild impairment,Fatigue,Gastrointestinal,Skin,Mild,1,16.14,No,Yes,Discontinuation,Dose adjustment,11,51,No,Reduction,Yes,Yes,No,Competition,,Unknown,None,High
RCT72325,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,162,7,Weekly,37,18-65,50% M/50% F,0-1,5,1,Moderate impairment,Nausea,Hepatic,Cardiac,Severe,4,7.72,No,Yes,Discontinuation,Dose adjustment,7,1,No,Delay,Yes,Yes,No,Safety,No,Positive,Gender,Unknown
RCT61283,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 1,53,2,Weekly,111,≥18,50% M/50% F,1-2,1,3,Normal,Infusion reaction,Hematological,Skin,Moderate,5,20.44,Yes,Yes,Dose reduction,Patient education,20,41,Yes,Reduction,No,No,No,Regulatory,,Positive,Age,Medium
RCT55526,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 3,127,7,Every 3 weeks,166,21-85,40% M/60% F,1-2,2,1,Moderate impairment,Neutropenia,Gastrointestinal,Cardiac,Severe,1,28.17,Yes,No,Dose reduction,Dose adjustment,17,46,Yes,Discontinuation,No,Yes,Yes,Regulatory,,Unknown,Age,Low
RCT94999,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 3,236,13,Bi-weekly,162,21-85,50% M/50% F,0-2,5,0,Normal,Rash,Hepatic,Skin,Severe,1,23.95,No,No,Treatment hold,Dose adjustment,24,38,Yes,Delay,No,Yes,No,Safety,,Negative,ECOG,Medium
RCT87821,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,184,9,Every 3 weeks,70,18-65,40% M/60% F,1-2,5,3,Normal,Nausea,Dermatological,Cardiac,Moderate,5,2.9,No,No,Discontinuation,Dose adjustment,16,47,No,Discontinuation,Yes,Yes,No,,No,Positive,Age,Low
RCT45673,Rituximab,Anti-CD20,Crossover,None,Phase 3,40,9,Every 3 weeks,56,18-75,50% M/50% F,1-2,5,1,Normal,Infusion reaction,Cardiac,Hepatic,Moderate,3,8.94,Yes,Yes,Discontinuation,Premedication,13,48,No,None,No,Yes,No,Efficacy,,Unknown,Gender,Low
RCT28481,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,223,12,Monthly,80,≥18,40% M/60% F,1-2,1,0,Moderate impairment,Infusion reaction,Hematological,Gastrointestinal,Severe,2,25.71,Yes,Yes,Supportive care,Premedication,6,11,No,None,Yes,Yes,No,Safety,No,Unknown,Age,High
RCT24840,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 3,172,15,Bi-weekly,97,18-65,40% M/60% F,0-2,2,1,Moderate impairment,Fatigue,Hematological,Blood,Moderate,5,1.83,Yes,Yes,Treatment hold,Monitoring,1,51,No,Discontinuation,Yes,Yes,Yes,Regulatory,,Unknown,ECOG,High
RCT49107,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,226,6,Weekly,179,18-75,40% M/60% F,0-1,2,0,Normal,Rash,Hematological,Hepatic,Moderate,4,22.44,Yes,Yes,Dose reduction,Dose adjustment,5,32,Yes,None,No,Yes,Yes,Regulatory,Yes,Negative,None,Low
RCT33134,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,60,10,Weekly,30,21-85,50% M/50% F,1-2,0,3,Normal,Infusion reaction,Gastrointestinal,Hepatic,Severe,2,6.44,Yes,Yes,Discontinuation,Monitoring,27,60,Yes,Reduction,Yes,Yes,Yes,Efficacy,Yes,Positive,Gender,High
RCT22221,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,51,15,Every 3 weeks,53,21-85,40% M/60% F,0-2,2,3,Normal,Nausea,Hepatic,Blood,Severe,2,14.82,No,No,Treatment hold,Patient education,24,15,Yes,Discontinuation,No,Yes,Yes,Regulatory,,Negative,Gender,Low
RCT97503,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,210,7,Bi-weekly,36,18-65,50% M/50% F,1-2,2,1,Normal,Rash,Dermatological,Blood,Mild,2,27.05,No,Yes,Dose reduction,Premedication,6,18,Yes,Discontinuation,No,Yes,Yes,Competition,Yes,None,Gender,High
RCT72709,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,89,10,Monthly,166,18-65,40% M/60% F,1-2,5,1,Mild impairment,Rash,Gastrointestinal,Skin,Severe,1,2.83,No,No,Dose reduction,Monitoring,21,28,Yes,Delay,No,Yes,No,,No,None,Gender,Medium
RCT68614,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 3,198,7,Every 3 weeks,34,≥18,50% M/50% F,1-2,0,2,Moderate impairment,Fatigue,Hematological,Skin,Moderate,4,5.35,Yes,Yes,Discontinuation,Dose adjustment,19,57,No,Discontinuation,Yes,Yes,Yes,,,Positive,Gender,Unknown
RCT38499,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 1,124,12,Every 3 weeks,45,18-75,40% M/60% F,1-2,1,2,Moderate impairment,Fatigue,Gastrointestinal,Blood,Moderate,1,8.04,Yes,No,Supportive care,Patient education,2,52,No,Reduction,Yes,Yes,Yes,Efficacy,Yes,Unknown,None,Unknown
RCT97513,Rituximab,Anti-CD20,Crossover,None,Phase 1,143,1,Every 3 weeks,77,≥18,60% M/40% F,1-2,4,0,Normal,Rash,Gastrointestinal,Gastrointestinal,Moderate,4,18.12,Yes,No,Supportive care,Patient education,13,39,No,Discontinuation,Yes,No,No,Safety,No,Positive,Gender,Medium
RCT86276,Trastuzumab,Anti-HER2,Single-arm,None,Phase 3,259,12,Monthly,157,18-75,60% M/40% F,0-1,0,1,Mild impairment,Rash,Hematological,Gastrointestinal,Moderate,1,12.82,Yes,No,Supportive care,Premedication,4,12,No,Delay,No,Yes,No,Efficacy,No,Positive,Age,Medium
RCT34537,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,22,15,Weekly,157,18-75,60% M/40% F,0-1,5,3,Moderate impairment,Nausea,Hematological,Gastrointestinal,Severe,3,26.04,No,No,Supportive care,Dose adjustment,28,36,Yes,Delay,Yes,No,Yes,Efficacy,Yes,None,None,Unknown
RCT38853,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,253,13,Bi-weekly,68,18-65,60% M/40% F,0-1,3,0,Mild impairment,Nausea,Cardiac,Cardiac,Severe,3,1.56,Yes,No,Supportive care,Monitoring,10,43,No,Reduction,Yes,No,Yes,Safety,No,None,None,High
RCT84490,Cetuximab,Anti-EGFR,Randomized,None,Phase 1,91,13,Weekly,87,≥18,60% M/40% F,0-1,0,0,Normal,Nausea,Cardiac,Hepatic,Severe,3,11.23,No,Yes,Discontinuation,Dose adjustment,19,23,No,Discontinuation,Yes,No,Yes,Regulatory,No,None,ECOG,Unknown
RCT32205,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 3,123,6,Weekly,158,21-85,40% M/60% F,0-1,3,2,Mild impairment,Rash,Hematological,Blood,Mild,2,15.79,No,No,Treatment hold,Premedication,21,14,Yes,Reduction,Yes,No,No,,No,Unknown,None,High
RCT68560,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,77,9,Bi-weekly,67,21-85,40% M/60% F,1-2,2,2,Moderate impairment,Nausea,Hematological,Hepatic,Moderate,5,18.03,Yes,No,Supportive care,Premedication,28,35,No,None,No,No,No,,,Unknown,None,Low
RCT60519,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 3,132,10,Bi-weekly,150,18-65,50% M/50% F,1-2,4,2,Normal,Neutropenia,Gastrointestinal,Skin,Mild,1,2.26,No,Yes,Treatment hold,Dose adjustment,9,14,No,None,Yes,No,No,Safety,,Positive,Age,High
RCT84499,Bevacizumab,Anti-VEGF,Randomized,None,Phase 2,48,9,Every 3 weeks,130,18-75,40% M/60% F,0-1,0,2,Normal,Fatigue,Dermatological,Blood,Moderate,1,12.18,No,No,Supportive care,Dose adjustment,18,39,Yes,Reduction,Yes,No,No,Safety,Yes,Negative,None,Medium
RCT22713,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 2,209,2,Bi-weekly,58,21-85,40% M/60% F,1-2,0,0,Mild impairment,Fatigue,Hepatic,Blood,Severe,2,8.9,No,No,Supportive care,Patient education,3,34,Yes,Reduction,Yes,Yes,No,Efficacy,,None,ECOG,High
RCT13281,Rituximab,Anti-CD20,Single-arm,None,Phase 3,248,7,Weekly,121,18-65,60% M/40% F,0-2,0,2,Moderate impairment,Infusion reaction,Dermatological,Blood,Mild,2,19.91,No,No,Discontinuation,Patient education,19,56,No,Reduction,Yes,No,No,Safety,No,Negative,Age,Unknown
RCT46373,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 1,204,11,Monthly,143,21-85,50% M/50% F,1-2,1,2,Normal,Fatigue,Hepatic,Hepatic,Severe,5,5.12,No,No,Treatment hold,Patient education,22,54,Yes,None,Yes,Yes,Yes,Regulatory,Yes,None,Age,Low
RCT51550,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 2,250,7,Monthly,53,21-85,60% M/40% F,0-1,5,2,Mild impairment,Nausea,Gastrointestinal,Blood,Moderate,1,22.73,Yes,Yes,Dose reduction,Monitoring,26,33,No,Discontinuation,Yes,Yes,Yes,Safety,,Unknown,None,Medium
RCT21483,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,266,9,Monthly,118,18-75,60% M/40% F,1-2,3,1,Moderate impairment,Neutropenia,Gastrointestinal,Cardiac,Moderate,5,7.18,Yes,No,Treatment hold,Premedication,27,25,Yes,Discontinuation,No,Yes,Yes,Safety,Yes,None,Gender,Unknown
RCT18804,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,261,8,Monthly,86,21-85,50% M/50% F,1-2,0,0,Mild impairment,Fatigue,Gastrointestinal,Cardiac,Mild,3,26.56,Yes,No,Discontinuation,Monitoring,14,45,No,Delay,No,No,Yes,Regulatory,No,Positive,Age,Medium
RCT10331,Rituximab,Anti-CD20,Randomized,Placebo,Phase 3,204,12,Monthly,178,21-85,40% M/60% F,0-2,5,1,Moderate impairment,Infusion reaction,Hematological,Hepatic,Severe,3,19.09,Yes,Yes,Treatment hold,Dose adjustment,6,35,Yes,Discontinuation,No,No,No,,,None,ECOG,Medium
RCT77176,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 3,94,4,Bi-weekly,127,18-65,40% M/60% F,1-2,2,0,Mild impairment,Fatigue,Dermatological,Gastrointestinal,Severe,3,10.88,No,Yes,Treatment hold,Dose adjustment,28,41,No,Discontinuation,Yes,Yes,Yes,Competition,Yes,None,None,High
RCT55892,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 2,183,9,Weekly,34,≥18,60% M/40% F,0-2,2,2,Normal,Neutropenia,Cardiac,Cardiac,Mild,2,17.82,Yes,Yes,Discontinuation,Premedication,7,14,Yes,Reduction,No,No,No,Safety,Yes,Unknown,Age,Low
RCT52263,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 2,92,13,Monthly,115,18-65,50% M/50% F,1-2,4,2,Normal,Neutropenia,Cardiac,Cardiac,Mild,1,18.9,Yes,Yes,Dose reduction,Premedication,23,12,No,Delay,Yes,Yes,No,Regulatory,Yes,Unknown,Age,Medium
RCT24313,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,81,1,Every 3 weeks,171,18-75,50% M/50% F,0-1,3,1,Normal,Infusion reaction,Hematological,Gastrointestinal,Mild,2,22.7,No,Yes,Dose reduction,Dose adjustment,17,54,Yes,Delay,Yes,No,Yes,Regulatory,Yes,Unknown,None,Medium
RCT47514,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 1,20,6,Monthly,173,21-85,40% M/60% F,0-1,1,2,Normal,Infusion reaction,Hepatic,Skin,Severe,1,23.92,No,No,Treatment hold,Patient education,2,47,No,None,Yes,Yes,No,Regulatory,Yes,None,None,Unknown
RCT73455,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,282,5,Bi-weekly,69,18-75,60% M/40% F,0-1,1,1,Normal,Rash,Dermatological,Cardiac,Mild,4,24.45,No,No,Supportive care,Premedication,13,1,No,Reduction,Yes,Yes,Yes,Competition,No,Positive,Prior treatments,Medium
RCT60253,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,40,2,Every 3 weeks,113,18-65,60% M/40% F,0-1,3,2,Mild impairment,Infusion reaction,Hematological,Gastrointestinal,Mild,5,17.66,Yes,No,Dose reduction,Dose adjustment,10,37,No,Discontinuation,Yes,No,Yes,,No,None,Gender,High
RCT55631,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,131,15,Every 3 weeks,147,18-65,60% M/40% F,1-2,5,0,Mild impairment,Neutropenia,Hepatic,Blood,Mild,3,18.56,No,No,Discontinuation,Monitoring,23,33,Yes,Reduction,No,Yes,Yes,,Yes,Positive,Gender,High
RCT17309,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,195,15,Weekly,48,≥18,60% M/40% F,1-2,3,3,Normal,Infusion reaction,Hepatic,Skin,Mild,1,28.98,No,No,Supportive care,Patient education,23,46,No,Reduction,No,No,Yes,,,Positive,ECOG,Medium
RCT74970,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,58,3,Weekly,73,21-85,50% M/50% F,0-1,0,0,Moderate impairment,Fatigue,Gastrointestinal,Cardiac,Severe,3,2.14,Yes,No,Supportive care,Dose adjustment,27,34,Yes,None,No,No,No,Safety,Yes,Positive,Age,Medium
RCT45059,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 2,117,10,Weekly,116,18-75,50% M/50% F,0-2,4,1,Moderate impairment,Fatigue,Dermatological,Cardiac,Mild,1,22.21,Yes,Yes,Dose reduction,Premedication,7,42,No,Delay,No,No,No,Competition,No,Positive,None,High
RCT75949,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,191,7,Bi-weekly,102,18-65,50% M/50% F,1-2,2,1,Mild impairment,Nausea,Cardiac,Blood,Mild,5,17.25,Yes,Yes,Discontinuation,Premedication,14,27,No,Delay,Yes,No,Yes,Regulatory,No,None,Age,Medium
RCT95168,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,130,3,Monthly,170,18-65,40% M/60% F,1-2,4,0,Mild impairment,Fatigue,Dermatological,Gastrointestinal,Severe,2,10.38,Yes,No,Dose reduction,Premedication,8,16,No,None,Yes,No,No,Efficacy,No,Positive,None,Low
RCT74292,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 3,77,4,Every 3 weeks,44,≥18,60% M/40% F,0-2,1,1,Moderate impairment,Infusion reaction,Hematological,Skin,Mild,3,5.66,Yes,No,Discontinuation,Patient education,6,59,Yes,None,No,Yes,No,Competition,,Unknown,Gender,Unknown
RCT14262,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 3,66,1,Weekly,91,18-75,40% M/60% F,0-1,4,2,Normal,Fatigue,Cardiac,Hepatic,Moderate,4,13.72,No,Yes,Discontinuation,Dose adjustment,25,53,Yes,None,Yes,No,Yes,Safety,,Unknown,Gender,Medium
RCT53093,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,226,14,Weekly,44,≥18,50% M/50% F,1-2,3,2,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Severe,2,9.54,Yes,Yes,Dose reduction,Monitoring,2,25,No,None,No,Yes,No,,Yes,Positive,Prior treatments,Unknown
RCT75180,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,237,4,Weekly,50,18-65,40% M/60% F,0-2,0,2,Mild impairment,Infusion reaction,Gastrointestinal,Blood,Severe,5,19.38,No,No,Supportive care,Patient education,18,18,Yes,Reduction,Yes,Yes,Yes,Competition,Yes,Positive,ECOG,High
RCT36601,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 2,216,7,Bi-weekly,160,≥18,50% M/50% F,0-2,4,2,Moderate impairment,Rash,Hepatic,Skin,Moderate,3,24.14,No,No,Discontinuation,Monitoring,1,30,No,Delay,Yes,No,Yes,Safety,,Unknown,Age,High
RCT48047,Cetuximab,Anti-EGFR,Single-arm,None,Phase 3,151,2,Bi-weekly,160,≥18,40% M/60% F,0-2,1,1,Moderate impairment,Neutropenia,Hematological,Skin,Moderate,2,27.29,No,No,Treatment hold,Dose adjustment,12,14,No,Delay,No,No,No,Efficacy,,None,Gender,High
RCT16625,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 3,179,14,Bi-weekly,79,18-75,50% M/50% F,1-2,4,3,Mild impairment,Rash,Cardiac,Skin,Severe,2,11.06,Yes,Yes,Discontinuation,Dose adjustment,10,50,Yes,Reduction,No,Yes,Yes,Efficacy,No,Unknown,Prior treatments,Medium
RCT13313,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,105,14,Weekly,51,18-65,40% M/60% F,0-2,3,0,Normal,Rash,Dermatological,Cardiac,Moderate,5,17.91,No,Yes,Supportive care,Premedication,4,15,Yes,Delay,Yes,Yes,Yes,Competition,,Unknown,Gender,Low
RCT20587,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 2,122,11,Weekly,138,≥18,40% M/60% F,1-2,2,3,Mild impairment,Nausea,Dermatological,Gastrointestinal,Mild,1,23.93,No,No,Supportive care,Premedication,9,4,Yes,Discontinuation,No,No,No,Competition,Yes,Negative,Age,Low
RCT26762,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 2,79,14,Weekly,102,18-75,60% M/40% F,0-2,4,3,Mild impairment,Nausea,Gastrointestinal,Skin,Severe,2,22.31,Yes,Yes,Supportive care,Patient education,20,11,Yes,Reduction,No,No,No,Regulatory,Yes,Unknown,Prior treatments,Medium
RCT45773,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 2,126,5,Bi-weekly,171,18-65,50% M/50% F,1-2,1,3,Mild impairment,Infusion reaction,Hematological,Blood,Mild,4,11.19,No,No,Treatment hold,Patient education,9,46,Yes,None,Yes,No,Yes,,,None,None,Low
RCT70314,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 3,99,9,Weekly,89,≥18,60% M/40% F,0-1,4,2,Moderate impairment,Rash,Dermatological,Gastrointestinal,Severe,3,15.39,No,No,Treatment hold,Dose adjustment,4,45,No,Reduction,Yes,Yes,No,,,Unknown,Age,High
RCT88984,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,265,15,Monthly,167,≥18,60% M/40% F,1-2,1,3,Mild impairment,Neutropenia,Gastrointestinal,Gastrointestinal,Severe,1,7.82,No,Yes,Discontinuation,Premedication,6,39,No,Discontinuation,No,No,No,Regulatory,,Positive,ECOG,Unknown
RCT78462,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 1,242,13,Weekly,103,18-75,50% M/50% F,0-2,0,2,Moderate impairment,Neutropenia,Hematological,Blood,Severe,3,3.87,No,Yes,Discontinuation,Dose adjustment,23,50,No,Discontinuation,No,No,No,Competition,Yes,Negative,Prior treatments,Medium
RCT43269,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,256,9,Bi-weekly,176,21-85,60% M/40% F,1-2,5,0,Mild impairment,Nausea,Hematological,Blood,Severe,1,4.1,Yes,Yes,Treatment hold,Premedication,15,44,Yes,None,No,No,No,Regulatory,,Unknown,Gender,Medium
RCT67974,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,194,11,Every 3 weeks,92,18-75,40% M/60% F,0-1,4,1,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Severe,2,24.87,No,Yes,Supportive care,Dose adjustment,22,28,Yes,Reduction,No,Yes,No,Competition,,Positive,Prior treatments,Unknown
RCT33378,Rituximab,Anti-CD20,Crossover,Placebo,Phase 2,61,13,Every 3 weeks,126,21-85,40% M/60% F,0-2,1,0,Normal,Fatigue,Hematological,Hepatic,Mild,1,27.94,Yes,Yes,Treatment hold,Premedication,19,25,No,None,Yes,No,Yes,Regulatory,Yes,Unknown,Gender,High
RCT84514,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,149,8,Every 3 weeks,173,21-85,60% M/40% F,0-2,2,1,Mild impairment,Neutropenia,Gastrointestinal,Blood,Severe,4,12.28,No,Yes,Discontinuation,Monitoring,16,4,No,Reduction,No,No,Yes,Efficacy,,Unknown,Gender,Low
RCT96806,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,200,4,Every 3 weeks,31,21-85,50% M/50% F,0-2,0,2,Moderate impairment,Infusion reaction,Hepatic,Cardiac,Mild,1,11.33,Yes,No,Discontinuation,Premedication,26,55,Yes,Delay,No,Yes,Yes,,No,Positive,None,High
RCT52820,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 1,213,6,Weekly,105,21-85,60% M/40% F,0-1,2,1,Moderate impairment,Infusion reaction,Hepatic,Blood,Moderate,3,2.63,No,No,Dose reduction,Monitoring,6,18,No,Discontinuation,No,Yes,No,,No,Unknown,None,Medium
RCT42396,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,263,9,Bi-weekly,114,18-75,40% M/60% F,1-2,3,3,Moderate impairment,Infusion reaction,Gastrointestinal,Blood,Moderate,1,20.23,Yes,No,Dose reduction,Patient education,8,25,Yes,Discontinuation,Yes,Yes,Yes,Efficacy,No,None,None,Low
RCT21598,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 3,258,5,Bi-weekly,146,21-85,40% M/60% F,0-2,1,1,Normal,Fatigue,Hepatic,Hepatic,Mild,4,1.19,Yes,Yes,Supportive care,Monitoring,6,38,Yes,Reduction,Yes,Yes,Yes,Efficacy,,Negative,Gender,Medium
RCT44360,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 1,164,7,Weekly,100,21-85,40% M/60% F,1-2,3,3,Moderate impairment,Nausea,Gastrointestinal,Blood,Severe,5,13.74,Yes,Yes,Treatment hold,Monitoring,6,43,No,None,No,No,Yes,,Yes,Unknown,ECOG,Low
RCT99646,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,76,6,Monthly,78,18-65,60% M/40% F,1-2,5,2,Mild impairment,Infusion reaction,Hepatic,Skin,Severe,5,18.77,No,Yes,Supportive care,Monitoring,7,24,No,Reduction,Yes,No,No,Safety,,None,Gender,High
RCT48644,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,46,8,Monthly,129,18-65,50% M/50% F,1-2,0,3,Mild impairment,Fatigue,Hematological,Gastrointestinal,Moderate,4,22.69,Yes,No,Discontinuation,Monitoring,15,11,Yes,Discontinuation,Yes,Yes,Yes,,No,Positive,None,Unknown
RCT65789,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 2,119,12,Weekly,126,21-85,60% M/40% F,0-1,3,0,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Severe,5,16.93,No,No,Treatment hold,Dose adjustment,10,11,No,None,Yes,Yes,No,Efficacy,,Unknown,Prior treatments,Unknown
RCT71933,Rituximab,Anti-CD20,Crossover,None,Phase 2,252,3,Monthly,53,≥18,60% M/40% F,1-2,4,1,Mild impairment,Infusion reaction,Dermatological,Skin,Severe,3,2.86,No,Yes,Treatment hold,Premedication,8,52,Yes,None,Yes,Yes,Yes,Safety,Yes,Negative,Gender,Low
RCT37655,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,25,15,Every 3 weeks,166,≥18,40% M/60% F,0-2,1,1,Normal,Fatigue,Gastrointestinal,Gastrointestinal,Severe,1,3.11,Yes,No,Dose reduction,Monitoring,24,24,Yes,Discontinuation,Yes,No,Yes,Safety,Yes,Unknown,None,Medium
RCT39604,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,251,15,Bi-weekly,122,≥18,50% M/50% F,0-2,0,2,Normal,Neutropenia,Hepatic,Blood,Mild,2,11.83,Yes,No,Discontinuation,Monitoring,26,44,Yes,Reduction,Yes,No,Yes,Regulatory,No,None,Prior treatments,Medium
RCT54661,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,128,5,Every 3 weeks,161,≥18,60% M/40% F,0-2,2,3,Moderate impairment,Rash,Hepatic,Cardiac,Moderate,2,23.17,Yes,No,Dose reduction,Patient education,2,21,No,Reduction,Yes,No,Yes,Efficacy,,Positive,Gender,High
RCT52830,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 3,139,7,Monthly,91,18-75,50% M/50% F,1-2,4,2,Moderate impairment,Nausea,Cardiac,Blood,Mild,1,20.96,Yes,Yes,Supportive care,Monitoring,12,52,No,Discontinuation,No,Yes,No,Safety,No,Unknown,Gender,Low
RCT91571,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 3,285,6,Bi-weekly,52,18-65,60% M/40% F,0-1,2,3,Moderate impairment,Fatigue,Dermatological,Cardiac,Mild,5,20.26,Yes,Yes,Discontinuation,Patient education,3,4,No,Reduction,No,No,No,Regulatory,No,Unknown,Gender,Unknown
RCT89108,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,280,12,Every 3 weeks,48,≥18,40% M/60% F,1-2,2,2,Mild impairment,Nausea,Cardiac,Blood,Mild,4,7.3,No,Yes,Dose reduction,Patient education,5,22,No,Delay,Yes,No,Yes,Regulatory,,None,Gender,High
RCT34501,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 3,106,14,Bi-weekly,147,18-65,40% M/60% F,0-1,5,3,Normal,Fatigue,Hematological,Gastrointestinal,Moderate,5,29.59,No,Yes,Dose reduction,Monitoring,1,11,Yes,None,Yes,Yes,No,,No,Positive,None,Low
RCT24001,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,289,4,Every 3 weeks,56,18-65,60% M/40% F,0-1,2,1,Mild impairment,Infusion reaction,Dermatological,Gastrointestinal,Mild,3,6.42,Yes,Yes,Supportive care,Dose adjustment,12,6,Yes,Discontinuation,No,No,No,Efficacy,,None,None,High
RCT33446,Cetuximab,Anti-EGFR,Single-arm,None,Phase 3,28,12,Weekly,97,≥18,60% M/40% F,1-2,2,2,Normal,Neutropenia,Dermatological,Blood,Mild,4,22.41,No,No,Supportive care,Patient education,12,60,No,Reduction,Yes,No,No,Safety,Yes,Positive,ECOG,Medium
RCT48513,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 2,211,1,Weekly,34,≥18,40% M/60% F,0-2,2,1,Normal,Fatigue,Cardiac,Skin,Severe,2,16.75,No,No,Dose reduction,Monitoring,2,18,Yes,Reduction,No,No,Yes,Competition,,None,Gender,High
RCT95276,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 1,188,14,Bi-weekly,140,21-85,40% M/60% F,0-1,2,0,Moderate impairment,Rash,Gastrointestinal,Hepatic,Moderate,5,18.84,No,Yes,Discontinuation,Patient education,23,16,Yes,None,Yes,No,No,Safety,Yes,None,Age,Low
RCT20474,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 1,22,5,Monthly,94,18-65,60% M/40% F,0-2,5,3,Moderate impairment,Fatigue,Hepatic,Hepatic,Severe,1,14.08,Yes,No,Dose reduction,Dose adjustment,1,14,No,Reduction,Yes,No,No,Regulatory,Yes,Unknown,Gender,Medium
RCT55661,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,27,5,Weekly,68,21-85,60% M/40% F,0-1,0,0,Mild impairment,Infusion reaction,Cardiac,Hepatic,Mild,5,25.46,Yes,Yes,Discontinuation,Premedication,8,37,Yes,Reduction,No,Yes,Yes,,,Negative,ECOG,Low
RCT38838,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,273,10,Bi-weekly,159,21-85,60% M/40% F,0-2,0,3,Moderate impairment,Rash,Dermatological,Cardiac,Moderate,4,16.09,No,No,Dose reduction,Premedication,22,31,No,Delay,Yes,Yes,Yes,Safety,Yes,Unknown,None,High
RCT21534,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 1,130,6,Every 3 weeks,156,≥18,60% M/40% F,0-2,3,2,Moderate impairment,Rash,Dermatological,Gastrointestinal,Mild,2,21.05,Yes,Yes,Treatment hold,Monitoring,27,4,Yes,Delay,Yes,No,No,Competition,Yes,Negative,Prior treatments,Unknown
RCT33567,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 3,201,1,Bi-weekly,140,18-75,60% M/40% F,1-2,5,2,Normal,Fatigue,Cardiac,Hepatic,Mild,2,17.07,No,No,Supportive care,Monitoring,25,43,Yes,Delay,No,No,No,Competition,No,None,Gender,Medium
RCT71452,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,30,1,Bi-weekly,156,18-75,50% M/50% F,0-1,4,0,Moderate impairment,Rash,Dermatological,Skin,Severe,1,20.42,No,No,Supportive care,Patient education,5,12,Yes,Reduction,Yes,Yes,Yes,,,Negative,Prior treatments,Low
RCT50667,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,30,13,Weekly,176,21-85,40% M/60% F,1-2,2,0,Mild impairment,Infusion reaction,Hematological,Cardiac,Moderate,4,16.54,Yes,Yes,Discontinuation,Patient education,10,40,No,Delay,No,Yes,No,Efficacy,Yes,Unknown,ECOG,Low
RCT55688,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,36,5,Every 3 weeks,55,18-65,60% M/40% F,1-2,1,2,Moderate impairment,Fatigue,Hepatic,Skin,Severe,5,29.45,Yes,Yes,Dose reduction,Monitoring,13,32,No,Discontinuation,Yes,No,No,Regulatory,No,None,ECOG,Low
RCT71749,Rituximab,Anti-CD20,Randomized,Placebo,Phase 2,126,12,Every 3 weeks,83,18-65,50% M/50% F,0-1,0,1,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,2,2.67,No,Yes,Dose reduction,Monitoring,27,2,No,Discontinuation,Yes,No,Yes,Efficacy,Yes,None,Prior treatments,High
RCT68836,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,89,1,Bi-weekly,176,18-65,40% M/60% F,1-2,2,0,Normal,Nausea,Hematological,Skin,Mild,3,1.3,No,No,Discontinuation,Dose adjustment,25,34,Yes,Delay,Yes,No,No,Regulatory,No,Positive,Prior treatments,Unknown
RCT50534,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,131,5,Bi-weekly,56,21-85,40% M/60% F,0-1,3,2,Mild impairment,Neutropenia,Hematological,Blood,Severe,3,21.12,Yes,No,Discontinuation,Patient education,2,27,No,Reduction,No,No,Yes,Competition,,Unknown,Age,Low
RCT69839,Bevacizumab,Anti-VEGF,Randomized,None,Phase 2,139,6,Bi-weekly,119,18-65,40% M/60% F,0-1,5,0,Mild impairment,Nausea,Hematological,Hepatic,Severe,3,3.49,Yes,Yes,Dose reduction,Dose adjustment,4,20,Yes,None,No,No,No,Competition,Yes,None,Gender,Medium
RCT36796,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,129,11,Monthly,179,18-65,50% M/50% F,0-2,2,3,Normal,Neutropenia,Dermatological,Hepatic,Moderate,4,11.17,Yes,No,Discontinuation,Dose adjustment,6,14,No,Delay,No,No,No,Safety,,Positive,Age,Unknown
RCT15678,Rituximab,Anti-CD20,Crossover,None,Phase 3,230,2,Bi-weekly,91,21-85,60% M/40% F,0-2,0,0,Moderate impairment,Fatigue,Hepatic,Hepatic,Mild,2,18.6,No,Yes,Supportive care,Dose adjustment,19,53,Yes,Delay,Yes,Yes,No,Regulatory,No,None,ECOG,High
RCT67549,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,94,13,Weekly,126,≥18,50% M/50% F,0-1,0,0,Mild impairment,Infusion reaction,Hematological,Gastrointestinal,Severe,5,16.43,Yes,No,Discontinuation,Patient education,16,7,Yes,Discontinuation,Yes,No,Yes,,No,None,Age,Unknown
RCT21979,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 3,185,6,Monthly,57,≥18,40% M/60% F,0-2,0,3,Moderate impairment,Infusion reaction,Gastrointestinal,Skin,Moderate,3,16.11,Yes,Yes,Discontinuation,Dose adjustment,3,15,Yes,Delay,Yes,Yes,No,,Yes,Negative,ECOG,High
RCT31268,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,61,6,Bi-weekly,50,≥18,60% M/40% F,1-2,2,1,Mild impairment,Infusion reaction,Dermatological,Hepatic,Moderate,2,1.8,Yes,No,Dose reduction,Dose adjustment,15,20,Yes,Delay,No,Yes,Yes,Competition,No,Unknown,Gender,High
RCT48875,Cetuximab,Anti-EGFR,Crossover,None,Phase 3,279,2,Every 3 weeks,177,18-65,40% M/60% F,0-2,4,3,Mild impairment,Nausea,Hematological,Gastrointestinal,Mild,1,15.05,No,No,Treatment hold,Dose adjustment,25,20,Yes,Reduction,Yes,No,No,Competition,Yes,None,Gender,Unknown
RCT27890,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,119,6,Bi-weekly,130,18-75,60% M/40% F,0-1,2,3,Mild impairment,Rash,Hepatic,Hepatic,Severe,3,15.57,Yes,Yes,Supportive care,Premedication,19,50,Yes,None,No,No,No,Regulatory,No,None,None,High
RCT20969,Trastuzumab,Anti-HER2,Randomized,None,Phase 3,231,5,Bi-weekly,32,21-85,50% M/50% F,0-2,4,0,Mild impairment,Rash,Gastrointestinal,Gastrointestinal,Severe,5,21.9,Yes,No,Supportive care,Premedication,9,11,Yes,Discontinuation,No,No,Yes,,,None,Prior treatments,High
RCT98909,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,226,14,Weekly,57,18-75,50% M/50% F,0-2,5,2,Normal,Rash,Gastrointestinal,Cardiac,Mild,2,11.62,Yes,Yes,Treatment hold,Monitoring,6,3,Yes,Reduction,Yes,Yes,Yes,Efficacy,No,Negative,ECOG,Unknown
RCT42212,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,245,4,Every 3 weeks,144,18-65,40% M/60% F,0-2,3,2,Moderate impairment,Infusion reaction,Cardiac,Skin,Mild,4,1.53,Yes,Yes,Treatment hold,Patient education,10,32,Yes,None,Yes,No,No,Competition,No,Negative,None,High
RCT73452,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,27,9,Monthly,35,18-65,60% M/40% F,0-2,5,3,Mild impairment,Infusion reaction,Gastrointestinal,Blood,Severe,2,13.11,Yes,Yes,Supportive care,Premedication,22,51,No,Delay,Yes,Yes,Yes,Regulatory,No,Unknown,Gender,Unknown
RCT84645,Rituximab,Anti-CD20,Crossover,None,Phase 1,216,12,Monthly,146,18-75,50% M/50% F,0-1,0,0,Moderate impairment,Fatigue,Dermatological,Skin,Mild,4,19.57,Yes,Yes,Treatment hold,Monitoring,15,17,No,None,Yes,No,No,Safety,Yes,Negative,ECOG,High
RCT51120,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 1,35,1,Weekly,144,≥18,40% M/60% F,1-2,0,0,Mild impairment,Fatigue,Hepatic,Hepatic,Severe,5,26.59,Yes,Yes,Treatment hold,Premedication,3,24,Yes,Delay,No,Yes,Yes,,,Negative,None,Medium
RCT89212,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 2,118,3,Monthly,155,≥18,60% M/40% F,0-2,1,2,Normal,Rash,Dermatological,Skin,Mild,4,25.7,Yes,No,Discontinuation,Monitoring,7,7,No,Discontinuation,Yes,Yes,Yes,Competition,,Negative,None,High
RCT21907,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,69,9,Weekly,130,≥18,40% M/60% F,1-2,4,3,Mild impairment,Nausea,Gastrointestinal,Gastrointestinal,Severe,1,15.49,Yes,Yes,Treatment hold,Premedication,24,58,Yes,Reduction,No,Yes,Yes,Safety,Yes,Positive,Gender,Low
RCT78653,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,196,15,Every 3 weeks,35,≥18,60% M/40% F,0-1,0,1,Normal,Nausea,Hematological,Skin,Mild,5,20.05,Yes,No,Discontinuation,Patient education,3,16,No,Delay,Yes,No,No,Competition,No,None,Gender,High
RCT32097,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,120,11,Every 3 weeks,106,18-75,60% M/40% F,1-2,2,0,Mild impairment,Fatigue,Dermatological,Hepatic,Moderate,1,25.85,No,No,Treatment hold,Premedication,25,3,Yes,Reduction,Yes,Yes,No,Efficacy,No,Unknown,ECOG,High
RCT10329,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,111,4,Bi-weekly,130,≥18,50% M/50% F,1-2,1,2,Normal,Nausea,Hepatic,Blood,Moderate,3,5.98,Yes,Yes,Discontinuation,Patient education,12,26,No,Reduction,Yes,No,No,Competition,,None,Gender,Unknown
RCT41501,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 3,283,14,Every 3 weeks,116,18-75,40% M/60% F,0-2,4,3,Mild impairment,Infusion reaction,Hematological,Hepatic,Moderate,4,14.58,Yes,Yes,Dose reduction,Premedication,20,25,Yes,Reduction,Yes,Yes,No,,,Positive,Gender,Unknown
RCT42032,Bevacizumab,Anti-VEGF,Crossover,None,Phase 1,235,7,Every 3 weeks,87,18-75,60% M/40% F,0-2,1,1,Mild impairment,Fatigue,Hepatic,Cardiac,Severe,1,9.25,Yes,No,Treatment hold,Dose adjustment,3,33,Yes,None,Yes,No,No,Regulatory,No,Unknown,None,High
RCT21432,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 3,172,5,Weekly,160,18-75,50% M/50% F,0-2,4,2,Mild impairment,Infusion reaction,Hematological,Skin,Severe,5,7.26,No,No,Dose reduction,Premedication,25,52,No,None,No,Yes,Yes,Safety,Yes,Positive,Age,Unknown
RCT37658,Rituximab,Anti-CD20,Randomized,None,Phase 3,108,6,Monthly,127,18-65,60% M/40% F,0-1,2,2,Moderate impairment,Infusion reaction,Hepatic,Cardiac,Moderate,1,23.92,Yes,Yes,Supportive care,Monitoring,1,45,No,Discontinuation,No,Yes,Yes,Competition,Yes,None,ECOG,Unknown
RCT49891,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,128,2,Every 3 weeks,40,18-65,40% M/60% F,1-2,0,2,Moderate impairment,Rash,Hematological,Skin,Mild,3,8.16,No,Yes,Discontinuation,Dose adjustment,24,49,No,Discontinuation,Yes,No,No,Competition,No,Unknown,ECOG,Low
RCT20873,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,166,12,Bi-weekly,53,18-75,60% M/40% F,0-1,5,3,Normal,Rash,Gastrointestinal,Cardiac,Severe,5,27.73,Yes,Yes,Treatment hold,Dose adjustment,6,44,Yes,Discontinuation,No,Yes,Yes,Regulatory,Yes,None,None,Unknown
RCT98066,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,115,1,Bi-weekly,56,21-85,60% M/40% F,1-2,2,1,Mild impairment,Nausea,Gastrointestinal,Gastrointestinal,Mild,3,16.37,No,No,Treatment hold,Dose adjustment,11,14,No,Reduction,No,No,No,Regulatory,Yes,Positive,Prior treatments,Low
RCT95406,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,103,15,Weekly,178,18-75,50% M/50% F,0-1,0,0,Moderate impairment,Nausea,Gastrointestinal,Blood,Severe,3,28.68,Yes,Yes,Treatment hold,Monitoring,10,50,Yes,Discontinuation,Yes,No,Yes,Competition,,Negative,ECOG,Unknown
RCT27426,Rituximab,Anti-CD20,Randomized,None,Phase 2,152,15,Weekly,107,≥18,40% M/60% F,1-2,5,1,Moderate impairment,Nausea,Hematological,Cardiac,Severe,4,17.23,No,Yes,Supportive care,Monitoring,7,15,Yes,Delay,Yes,Yes,Yes,Regulatory,Yes,Unknown,ECOG,Medium
RCT29991,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,284,4,Monthly,85,18-75,60% M/40% F,1-2,5,3,Mild impairment,Fatigue,Cardiac,Hepatic,Moderate,5,29.72,Yes,Yes,Dose reduction,Premedication,21,49,No,Delay,Yes,Yes,Yes,Efficacy,Yes,Unknown,ECOG,Medium
RCT54476,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 1,61,10,Bi-weekly,147,≥18,60% M/40% F,0-1,2,1,Moderate impairment,Fatigue,Hematological,Gastrointestinal,Moderate,4,24.4,Yes,No,Dose reduction,Dose adjustment,12,29,Yes,Reduction,No,No,No,Regulatory,Yes,None,ECOG,Unknown
RCT49133,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,52,6,Bi-weekly,36,18-65,60% M/40% F,1-2,4,0,Mild impairment,Fatigue,Hepatic,Hepatic,Severe,5,4.25,No,Yes,Treatment hold,Monitoring,24,7,Yes,None,Yes,Yes,No,,Yes,Negative,ECOG,Low
RCT88657,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 1,51,14,Weekly,42,21-85,60% M/40% F,0-1,4,3,Moderate impairment,Rash,Hematological,Skin,Severe,1,14.71,No,No,Supportive care,Premedication,17,5,No,Discontinuation,No,No,No,Efficacy,Yes,Negative,ECOG,High
RCT50693,Rituximab,Anti-CD20,Crossover,None,Phase 1,224,9,Weekly,90,21-85,40% M/60% F,1-2,0,1,Mild impairment,Infusion reaction,Cardiac,Gastrointestinal,Mild,4,16.58,Yes,Yes,Supportive care,Dose adjustment,16,32,Yes,Discontinuation,Yes,No,Yes,Efficacy,Yes,Positive,Age,Medium
RCT89766,Trastuzumab,Anti-HER2,Randomized,None,Phase 1,88,1,Weekly,66,18-75,40% M/60% F,0-2,1,1,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Severe,4,24.03,Yes,No,Supportive care,Premedication,5,10,No,Delay,No,Yes,Yes,Efficacy,No,Positive,Prior treatments,Low
RCT44736,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,62,12,Every 3 weeks,140,18-65,60% M/40% F,0-1,1,2,Mild impairment,Neutropenia,Dermatological,Skin,Severe,4,3.78,No,Yes,Supportive care,Dose adjustment,23,51,Yes,Discontinuation,No,Yes,No,,,Positive,Prior treatments,Unknown
RCT92273,Bevacizumab,Anti-VEGF,Crossover,None,Phase 1,110,9,Monthly,46,18-65,50% M/50% F,0-1,0,0,Moderate impairment,Rash,Hematological,Skin,Mild,2,7.75,No,No,Supportive care,Patient education,25,48,Yes,Discontinuation,Yes,No,Yes,,,None,None,Medium
RCT48490,Cetuximab,Anti-EGFR,Single-arm,None,Phase 1,122,6,Bi-weekly,58,18-65,60% M/40% F,1-2,0,3,Moderate impairment,Rash,Dermatological,Cardiac,Mild,4,1.6,No,Yes,Discontinuation,Monitoring,16,45,No,Discontinuation,Yes,Yes,No,Regulatory,Yes,Unknown,ECOG,Low
RCT59670,Rituximab,Anti-CD20,Randomized,None,Phase 1,188,14,Weekly,39,18-65,50% M/50% F,0-2,1,0,Normal,Fatigue,Cardiac,Hepatic,Mild,3,14.03,Yes,Yes,Supportive care,Monitoring,18,8,Yes,Reduction,Yes,Yes,Yes,Efficacy,No,None,Gender,Unknown
RCT88810,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 1,244,14,Every 3 weeks,58,18-75,40% M/60% F,0-2,3,2,Moderate impairment,Nausea,Gastrointestinal,Skin,Severe,1,15.8,No,Yes,Discontinuation,Dose adjustment,15,3,Yes,None,Yes,Yes,No,Efficacy,No,Positive,Gender,Unknown
RCT95715,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,30,1,Bi-weekly,47,21-85,50% M/50% F,0-1,1,2,Mild impairment,Neutropenia,Dermatological,Skin,Mild,4,5.04,No,No,Treatment hold,Patient education,26,7,No,Reduction,No,Yes,Yes,Safety,No,Negative,None,Medium
RCT72019,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 2,198,12,Every 3 weeks,37,21-85,50% M/50% F,0-1,4,3,Moderate impairment,Neutropenia,Cardiac,Blood,Mild,5,14.8,Yes,No,Treatment hold,Dose adjustment,10,12,Yes,Discontinuation,Yes,Yes,No,Safety,Yes,Positive,Gender,High
RCT41351,Cetuximab,Anti-EGFR,Single-arm,None,Phase 1,189,9,Weekly,113,18-65,40% M/60% F,1-2,1,1,Mild impairment,Nausea,Gastrointestinal,Skin,Moderate,4,19.22,No,Yes,Discontinuation,Patient education,19,38,No,Delay,No,Yes,No,,No,None,Prior treatments,Unknown
RCT92983,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,62,8,Monthly,140,18-65,40% M/60% F,0-1,3,2,Mild impairment,Nausea,Gastrointestinal,Skin,Severe,4,29.59,No,No,Dose reduction,Dose adjustment,3,37,Yes,Discontinuation,Yes,No,No,Competition,,Negative,ECOG,High
RCT27778,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 1,68,1,Every 3 weeks,165,18-75,50% M/50% F,1-2,2,0,Normal,Fatigue,Hepatic,Hepatic,Moderate,5,26.45,Yes,No,Supportive care,Premedication,7,10,No,Reduction,Yes,Yes,Yes,Efficacy,Yes,Unknown,None,Low
RCT18536,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 2,213,8,Every 3 weeks,166,18-65,50% M/50% F,1-2,5,0,Normal,Neutropenia,Hepatic,Cardiac,Mild,3,24.98,No,No,Dose reduction,Monitoring,23,38,No,None,Yes,No,Yes,Efficacy,No,Positive,Prior treatments,Unknown
RCT14327,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 1,116,2,Weekly,97,18-65,60% M/40% F,0-2,4,0,Normal,Rash,Cardiac,Cardiac,Moderate,2,23.06,No,No,Discontinuation,Dose adjustment,21,20,Yes,None,No,Yes,No,,Yes,Positive,Gender,Medium
RCT67329,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,63,1,Monthly,41,≥18,40% M/60% F,0-1,5,2,Normal,Neutropenia,Hepatic,Blood,Severe,3,28.85,No,Yes,Discontinuation,Premedication,13,34,Yes,Discontinuation,Yes,No,No,Regulatory,No,Unknown,Age,Medium
RCT20310,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 2,203,10,Bi-weekly,163,18-75,50% M/50% F,0-2,1,0,Moderate impairment,Rash,Hepatic,Blood,Mild,4,15.94,No,Yes,Supportive care,Monitoring,6,48,No,None,Yes,No,No,,,None,Prior treatments,Low
RCT12582,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 1,188,15,Bi-weekly,73,≥18,60% M/40% F,0-1,0,3,Mild impairment,Nausea,Cardiac,Hepatic,Moderate,4,24.75,No,No,Discontinuation,Dose adjustment,22,40,Yes,Delay,No,No,No,Regulatory,Yes,None,None,Medium
RCT98957,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 2,22,14,Monthly,69,≥18,40% M/60% F,0-2,3,2,Mild impairment,Rash,Cardiac,Gastrointestinal,Moderate,5,2.67,Yes,Yes,Dose reduction,Dose adjustment,24,25,Yes,Delay,No,Yes,Yes,Safety,,Negative,None,Unknown
RCT95231,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,257,7,Monthly,77,18-65,50% M/50% F,1-2,5,2,Normal,Neutropenia,Hepatic,Hepatic,Moderate,4,3.34,Yes,Yes,Supportive care,Premedication,19,25,Yes,Delay,No,No,No,Safety,No,None,Age,Medium
RCT95329,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 2,291,5,Bi-weekly,78,18-75,50% M/50% F,0-2,4,2,Mild impairment,Neutropenia,Dermatological,Gastrointestinal,Moderate,4,17.73,No,No,Treatment hold,Monitoring,23,8,No,Reduction,No,Yes,Yes,Safety,,None,Gender,High
RCT61147,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 2,260,11,Monthly,50,≥18,60% M/40% F,1-2,1,3,Moderate impairment,Rash,Hematological,Gastrointestinal,Mild,2,5.08,Yes,No,Treatment hold,Premedication,15,18,No,None,Yes,No,No,Efficacy,No,Unknown,Gender,Unknown
RCT88442,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,288,9,Weekly,57,18-65,50% M/50% F,0-1,1,0,Normal,Neutropenia,Cardiac,Gastrointestinal,Moderate,1,3.56,No,No,Supportive care,Monitoring,25,9,Yes,None,No,Yes,No,Safety,No,Positive,Age,Medium
RCT88971,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,192,11,Weekly,157,≥18,40% M/60% F,1-2,2,1,Normal,Rash,Gastrointestinal,Hepatic,Moderate,3,13.22,Yes,No,Dose reduction,Patient education,4,11,No,Reduction,Yes,No,No,Efficacy,Yes,None,Age,Unknown
RCT19405,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 3,201,9,Every 3 weeks,36,21-85,60% M/40% F,1-2,1,1,Mild impairment,Neutropenia,Hematological,Cardiac,Severe,4,23.26,No,Yes,Dose reduction,Dose adjustment,19,43,Yes,Delay,No,Yes,No,Efficacy,No,None,Gender,Medium
RCT37462,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,233,10,Monthly,42,21-85,40% M/60% F,0-1,3,0,Normal,Infusion reaction,Cardiac,Gastrointestinal,Severe,4,17.29,No,No,Discontinuation,Dose adjustment,9,30,No,Reduction,Yes,No,Yes,Regulatory,No,Unknown,Gender,Medium
RCT18786,Rituximab,Anti-CD20,Randomized,None,Phase 1,70,15,Weekly,86,18-75,50% M/50% F,1-2,2,2,Moderate impairment,Rash,Hepatic,Hepatic,Severe,4,1.72,Yes,Yes,Supportive care,Premedication,13,49,No,Reduction,No,Yes,Yes,Competition,,Unknown,None,Unknown
RCT85756,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,79,13,Bi-weekly,60,18-65,40% M/60% F,1-2,4,0,Normal,Nausea,Cardiac,Hepatic,Moderate,3,4.9,Yes,Yes,Discontinuation,Dose adjustment,13,48,Yes,Delay,No,No,No,Safety,Yes,Positive,Gender,Low
RCT40519,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,47,2,Weekly,84,21-85,60% M/40% F,1-2,2,1,Mild impairment,Rash,Hematological,Hepatic,Severe,1,16.68,No,No,Discontinuation,Premedication,15,57,No,Reduction,No,Yes,Yes,Competition,,None,Prior treatments,Low
RCT19893,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 3,41,6,Bi-weekly,169,18-75,50% M/50% F,0-2,4,3,Mild impairment,Nausea,Dermatological,Blood,Moderate,3,2.56,Yes,No,Supportive care,Monitoring,27,4,No,Discontinuation,No,No,No,Efficacy,No,Positive,Prior treatments,Medium
RCT48375,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,169,7,Every 3 weeks,69,18-75,40% M/60% F,1-2,3,0,Normal,Infusion reaction,Hematological,Cardiac,Moderate,4,8.85,Yes,No,Dose reduction,Patient education,8,17,No,Delay,Yes,No,No,,No,Unknown,Age,Unknown
RCT40964,Rituximab,Anti-CD20,Single-arm,None,Phase 1,24,2,Monthly,93,18-75,40% M/60% F,1-2,1,3,Moderate impairment,Rash,Dermatological,Cardiac,Moderate,4,27.72,Yes,Yes,Supportive care,Premedication,16,29,Yes,None,No,Yes,Yes,Efficacy,No,Negative,Age,Unknown
RCT77794,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,262,15,Bi-weekly,108,18-75,40% M/60% F,0-1,2,1,Mild impairment,Neutropenia,Cardiac,Hepatic,Severe,5,4.22,No,No,Dose reduction,Monitoring,22,52,Yes,Delay,Yes,Yes,Yes,Safety,No,None,None,High
RCT26619,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 2,57,8,Monthly,116,≥18,60% M/40% F,0-2,5,2,Moderate impairment,Nausea,Hepatic,Gastrointestinal,Mild,3,22.24,Yes,No,Treatment hold,Dose adjustment,10,14,Yes,None,Yes,Yes,No,Competition,No,None,ECOG,High
RCT66537,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 3,189,14,Bi-weekly,51,18-75,50% M/50% F,1-2,2,2,Mild impairment,Infusion reaction,Cardiac,Hepatic,Moderate,1,3.28,Yes,No,Dose reduction,Patient education,21,28,No,Discontinuation,Yes,No,Yes,Safety,No,Positive,Prior treatments,Unknown
RCT28327,Cetuximab,Anti-EGFR,Crossover,None,Phase 3,174,3,Weekly,40,18-65,40% M/60% F,1-2,4,3,Normal,Infusion reaction,Cardiac,Gastrointestinal,Mild,2,22.33,Yes,Yes,Discontinuation,Dose adjustment,15,53,Yes,Discontinuation,No,Yes,Yes,Competition,Yes,None,None,High
RCT12549,Rituximab,Anti-CD20,Crossover,None,Phase 3,273,8,Every 3 weeks,175,18-75,60% M/40% F,1-2,4,1,Normal,Nausea,Dermatological,Skin,Moderate,5,18.04,Yes,Yes,Treatment hold,Dose adjustment,28,36,No,Discontinuation,No,No,No,Regulatory,,Positive,None,Unknown
RCT15153,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,164,6,Weekly,90,21-85,40% M/60% F,0-1,2,2,Moderate impairment,Nausea,Cardiac,Cardiac,Severe,1,17.82,Yes,Yes,Discontinuation,Dose adjustment,21,55,No,None,No,No,Yes,,Yes,Unknown,Prior treatments,Medium
RCT81864,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 2,260,8,Every 3 weeks,112,21-85,60% M/40% F,0-2,5,0,Mild impairment,Fatigue,Dermatological,Gastrointestinal,Severe,5,28.75,Yes,Yes,Supportive care,Monitoring,7,22,Yes,Discontinuation,Yes,Yes,Yes,Safety,No,None,ECOG,Medium
RCT78860,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 1,120,15,Monthly,128,18-65,40% M/60% F,1-2,2,1,Moderate impairment,Infusion reaction,Cardiac,Blood,Mild,1,23.18,Yes,No,Treatment hold,Dose adjustment,5,14,Yes,Reduction,No,No,No,Competition,,Positive,Age,Low
RCT96499,Cetuximab,Anti-EGFR,Crossover,Placebo,Phase 2,208,13,Weekly,117,≥18,60% M/40% F,0-2,1,0,Mild impairment,Neutropenia,Hepatic,Gastrointestinal,Mild,2,26.47,No,Yes,Dose reduction,Monitoring,13,17,No,Reduction,Yes,No,No,,Yes,Positive,Age,Low
RCT47239,Rituximab,Anti-CD20,Randomized,Placebo,Phase 1,129,2,Monthly,101,21-85,50% M/50% F,0-2,5,0,Moderate impairment,Rash,Cardiac,Gastrointestinal,Moderate,1,21.06,Yes,Yes,Treatment hold,Premedication,15,27,Yes,Reduction,Yes,No,Yes,Regulatory,,None,Age,Medium
RCT18729,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,249,2,Weekly,155,18-75,40% M/60% F,0-2,2,3,Normal,Neutropenia,Cardiac,Skin,Moderate,2,23.77,No,No,Discontinuation,Patient education,8,56,Yes,Delay,No,Yes,No,Efficacy,No,None,Age,Unknown
RCT50230,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,184,3,Weekly,46,18-75,60% M/40% F,0-1,2,0,Normal,Neutropenia,Gastrointestinal,Cardiac,Moderate,5,22.37,No,Yes,Dose reduction,Premedication,15,46,No,Discontinuation,Yes,No,Yes,Competition,Yes,Positive,None,Unknown
RCT24931,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,129,11,Every 3 weeks,118,21-85,50% M/50% F,0-2,3,0,Normal,Nausea,Hepatic,Skin,Severe,5,21.2,No,Yes,Supportive care,Dose adjustment,21,40,Yes,Delay,Yes,Yes,No,Competition,,None,Prior treatments,Medium
RCT77784,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,75,5,Bi-weekly,91,21-85,60% M/40% F,1-2,5,3,Mild impairment,Rash,Gastrointestinal,Blood,Moderate,4,10.91,No,No,Supportive care,Dose adjustment,10,28,Yes,None,No,Yes,Yes,Efficacy,No,Unknown,Prior treatments,Low
RCT72421,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,43,6,Every 3 weeks,33,18-65,50% M/50% F,0-1,5,2,Mild impairment,Infusion reaction,Dermatological,Hepatic,Moderate,2,13.9,Yes,Yes,Dose reduction,Monitoring,17,36,No,Discontinuation,Yes,Yes,No,Safety,,Unknown,ECOG,Low
RCT35730,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 3,157,12,Weekly,85,≥18,60% M/40% F,0-2,3,2,Normal,Fatigue,Gastrointestinal,Gastrointestinal,Mild,3,6.03,Yes,No,Discontinuation,Patient education,11,48,Yes,Delay,No,No,Yes,Efficacy,Yes,Negative,ECOG,Unknown
RCT21257,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 2,160,12,Monthly,56,≥18,40% M/60% F,1-2,2,0,Mild impairment,Nausea,Dermatological,Gastrointestinal,Severe,1,3.65,No,No,Supportive care,Patient education,27,48,No,None,No,Yes,No,Competition,Yes,Unknown,Prior treatments,Medium
RCT40321,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 2,76,5,Weekly,149,≥18,60% M/40% F,1-2,0,2,Moderate impairment,Fatigue,Dermatological,Skin,Mild,5,8.68,No,No,Supportive care,Premedication,13,2,No,Delay,Yes,Yes,Yes,Safety,Yes,Negative,None,Unknown
RCT42346,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,171,15,Every 3 weeks,158,≥18,50% M/50% F,1-2,1,0,Moderate impairment,Fatigue,Cardiac,Blood,Severe,3,13.5,No,No,Supportive care,Dose adjustment,2,52,Yes,Discontinuation,No,Yes,No,Competition,Yes,Unknown,ECOG,Low
RCT88087,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,261,3,Bi-weekly,157,≥18,60% M/40% F,1-2,3,2,Mild impairment,Rash,Gastrointestinal,Skin,Moderate,1,7.46,Yes,Yes,Treatment hold,Monitoring,14,27,No,Discontinuation,No,Yes,No,Regulatory,Yes,Negative,None,Low
RCT11214,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,144,10,Weekly,174,18-65,40% M/60% F,0-2,3,0,Mild impairment,Nausea,Gastrointestinal,Blood,Severe,4,29.95,Yes,Yes,Supportive care,Dose adjustment,28,57,No,Discontinuation,Yes,Yes,No,Safety,No,Unknown,None,Low
RCT26967,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,299,12,Every 3 weeks,146,18-75,40% M/60% F,0-2,1,3,Mild impairment,Fatigue,Hematological,Cardiac,Moderate,5,24.13,Yes,No,Supportive care,Monitoring,3,30,Yes,Discontinuation,Yes,No,No,Safety,No,None,Age,Medium
RCT20974,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,135,9,Weekly,51,21-85,60% M/40% F,1-2,2,3,Mild impairment,Nausea,Cardiac,Blood,Mild,4,22.14,No,No,Dose reduction,Dose adjustment,20,25,No,Delay,Yes,Yes,No,Competition,,Negative,Age,Low
RCT98474,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,210,14,Every 3 weeks,176,21-85,40% M/60% F,0-1,0,3,Normal,Rash,Hepatic,Skin,Moderate,5,14.45,Yes,Yes,Dose reduction,Dose adjustment,12,22,Yes,Reduction,No,No,No,Regulatory,Yes,Positive,None,Medium
RCT66700,Rituximab,Anti-CD20,Randomized,None,Phase 2,82,9,Bi-weekly,105,21-85,50% M/50% F,0-2,1,2,Normal,Nausea,Gastrointestinal,Gastrointestinal,Mild,2,14.46,Yes,Yes,Dose reduction,Dose adjustment,21,20,No,Delay,No,No,No,Competition,No,None,ECOG,Unknown
RCT22374,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 1,300,6,Bi-weekly,111,18-75,40% M/60% F,0-1,3,3,Moderate impairment,Infusion reaction,Hepatic,Hepatic,Mild,2,15.48,No,Yes,Dose reduction,Dose adjustment,13,49,No,Reduction,Yes,No,No,Regulatory,Yes,Negative,Prior treatments,Low
RCT10996,Pembrolizumab,Anti-PD-1,Crossover,Placebo,Phase 1,251,2,Weekly,105,≥18,50% M/50% F,1-2,0,3,Normal,Infusion reaction,Dermatological,Blood,Mild,5,13.47,No,No,Supportive care,Premedication,28,50,No,None,No,Yes,No,Regulatory,Yes,Positive,ECOG,Low
RCT26541,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,241,11,Weekly,60,≥18,60% M/40% F,0-2,4,3,Mild impairment,Fatigue,Gastrointestinal,Gastrointestinal,Mild,5,15.83,Yes,Yes,Discontinuation,Premedication,24,2,No,Reduction,No,Yes,Yes,Competition,Yes,None,None,High
RCT66270,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 3,225,13,Every 3 weeks,50,≥18,60% M/40% F,1-2,5,0,Moderate impairment,Nausea,Hematological,Cardiac,Severe,3,18.22,No,Yes,Supportive care,Monitoring,6,40,No,Delay,No,Yes,Yes,Regulatory,No,Negative,ECOG,High
RCT86235,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,172,11,Every 3 weeks,39,18-75,40% M/60% F,1-2,2,1,Moderate impairment,Infusion reaction,Hematological,Gastrointestinal,Severe,5,16.12,Yes,No,Discontinuation,Dose adjustment,24,9,Yes,Reduction,Yes,Yes,Yes,Efficacy,,None,None,High
RCT17311,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,209,10,Monthly,65,18-65,50% M/50% F,1-2,4,0,Normal,Fatigue,Dermatological,Hepatic,Moderate,2,21.73,No,Yes,Dose reduction,Monitoring,5,53,No,None,Yes,Yes,Yes,Regulatory,,Negative,Age,Medium
RCT54841,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,65,5,Bi-weekly,168,21-85,50% M/50% F,1-2,1,3,Normal,Infusion reaction,Gastrointestinal,Gastrointestinal,Severe,1,1.93,Yes,No,Supportive care,Premedication,26,46,Yes,Delay,Yes,Yes,No,Efficacy,No,Negative,Age,Low
RCT36501,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,154,7,Weekly,50,18-65,40% M/60% F,1-2,1,0,Moderate impairment,Rash,Hematological,Gastrointestinal,Moderate,4,17.61,Yes,No,Treatment hold,Patient education,12,32,Yes,Discontinuation,Yes,No,Yes,Efficacy,Yes,Unknown,Gender,Unknown
RCT32149,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 2,208,6,Every 3 weeks,32,21-85,60% M/40% F,0-2,2,2,Moderate impairment,Fatigue,Hematological,Hepatic,Mild,1,3.87,No,No,Treatment hold,Premedication,14,27,Yes,Discontinuation,No,No,No,Competition,No,None,ECOG,Unknown
RCT39125,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 2,253,8,Bi-weekly,146,18-75,50% M/50% F,0-2,0,0,Normal,Nausea,Cardiac,Cardiac,Mild,1,18.9,No,No,Supportive care,Patient education,15,31,Yes,None,No,Yes,No,Competition,Yes,Negative,None,High
RCT84443,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,235,1,Every 3 weeks,84,21-85,60% M/40% F,1-2,3,1,Normal,Rash,Hepatic,Blood,Severe,1,6.55,Yes,No,Dose reduction,Patient education,25,18,No,Delay,Yes,No,Yes,Competition,No,Unknown,Gender,Low
RCT17568,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 2,81,1,Weekly,120,21-85,40% M/60% F,0-1,3,2,Mild impairment,Neutropenia,Hematological,Gastrointestinal,Moderate,4,13.83,No,Yes,Discontinuation,Monitoring,15,43,Yes,None,No,Yes,Yes,Competition,Yes,Negative,Prior treatments,Medium
RCT50757,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 2,216,2,Weekly,86,≥18,60% M/40% F,1-2,5,3,Normal,Rash,Dermatological,Cardiac,Severe,5,13.12,Yes,No,Dose reduction,Dose adjustment,24,32,Yes,Delay,Yes,Yes,No,Efficacy,No,Positive,Gender,Unknown
RCT12989,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,223,2,Weekly,58,18-75,50% M/50% F,1-2,1,3,Normal,Nausea,Dermatological,Hepatic,Mild,3,26.76,Yes,No,Discontinuation,Premedication,8,51,No,None,Yes,Yes,No,Safety,No,None,Age,Low
RCT62890,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,85,10,Every 3 weeks,108,21-85,50% M/50% F,1-2,5,3,Mild impairment,Neutropenia,Hepatic,Gastrointestinal,Moderate,1,16.21,Yes,Yes,Treatment hold,Dose adjustment,20,23,Yes,Delay,Yes,No,Yes,,No,Negative,None,Medium
RCT55283,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 2,213,11,Bi-weekly,50,18-65,40% M/60% F,0-2,4,0,Mild impairment,Nausea,Hematological,Hepatic,Severe,4,8.06,No,No,Treatment hold,Monitoring,25,5,No,Discontinuation,No,Yes,Yes,Safety,Yes,Unknown,None,Medium
RCT30673,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,86,15,Weekly,105,18-75,60% M/40% F,1-2,2,1,Normal,Fatigue,Cardiac,Hepatic,Mild,2,4.19,No,No,Treatment hold,Dose adjustment,12,30,Yes,Reduction,No,Yes,Yes,Efficacy,,Positive,Gender,High
RCT86004,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 3,272,9,Monthly,50,18-65,40% M/60% F,0-1,5,0,Moderate impairment,Nausea,Hematological,Hepatic,Moderate,4,1.9,Yes,No,Supportive care,Dose adjustment,7,1,Yes,Discontinuation,No,No,No,Regulatory,Yes,Unknown,Age,Medium
RCT77117,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,228,14,Every 3 weeks,45,21-85,50% M/50% F,0-2,5,2,Mild impairment,Infusion reaction,Hematological,Cardiac,Mild,4,29.38,No,No,Supportive care,Premedication,24,3,Yes,Delay,No,No,No,Regulatory,Yes,Positive,Age,Medium
RCT82450,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 2,26,10,Bi-weekly,100,18-75,50% M/50% F,0-1,0,1,Moderate impairment,Neutropenia,Hematological,Hepatic,Moderate,1,17.91,No,No,Supportive care,Dose adjustment,26,40,Yes,Reduction,Yes,Yes,Yes,Safety,No,Unknown,Age,High
RCT56589,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,34,1,Weekly,145,18-75,60% M/40% F,0-1,3,2,Normal,Fatigue,Hepatic,Cardiac,Severe,4,18.88,No,No,Supportive care,Patient education,21,18,Yes,Reduction,Yes,No,No,Efficacy,No,None,Prior treatments,High
RCT81213,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 3,230,7,Monthly,167,18-75,60% M/40% F,1-2,5,0,Mild impairment,Infusion reaction,Hepatic,Hepatic,Severe,5,15.35,No,Yes,Discontinuation,Patient education,19,34,Yes,Delay,No,Yes,No,Regulatory,Yes,Unknown,Prior treatments,Unknown
RCT85571,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 3,113,1,Bi-weekly,132,21-85,60% M/40% F,0-1,5,2,Moderate impairment,Fatigue,Hepatic,Hepatic,Mild,4,12.34,Yes,Yes,Dose reduction,Patient education,18,7,No,Delay,No,No,Yes,Competition,No,Unknown,ECOG,Low
RCT82636,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 2,153,1,Monthly,169,18-75,40% M/60% F,0-2,4,0,Mild impairment,Fatigue,Cardiac,Blood,Mild,2,10.35,Yes,Yes,Discontinuation,Monitoring,11,33,Yes,Delay,No,No,Yes,Competition,Yes,Unknown,Gender,Low
RCT55504,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,243,10,Weekly,35,21-85,40% M/60% F,0-2,2,2,Normal,Rash,Hepatic,Skin,Moderate,4,9.16,Yes,Yes,Treatment hold,Patient education,17,28,No,None,Yes,Yes,Yes,Regulatory,,Negative,None,High
RCT91106,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,202,9,Weekly,100,18-65,40% M/60% F,0-1,5,0,Moderate impairment,Fatigue,Dermatological,Cardiac,Mild,3,17.14,Yes,Yes,Treatment hold,Monitoring,2,16,No,None,No,No,Yes,Efficacy,No,Unknown,ECOG,Unknown
RCT84212,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,180,13,Monthly,97,21-85,40% M/60% F,0-2,4,1,Mild impairment,Infusion reaction,Hematological,Cardiac,Moderate,5,10.04,No,No,Treatment hold,Premedication,7,49,Yes,None,No,No,Yes,,,Negative,Gender,Low
RCT70358,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,86,12,Every 3 weeks,180,18-65,40% M/60% F,0-1,3,2,Normal,Infusion reaction,Hepatic,Cardiac,Moderate,4,4.75,Yes,No,Supportive care,Dose adjustment,22,19,Yes,Delay,No,No,No,Efficacy,No,Positive,None,Medium
RCT92662,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,298,5,Weekly,98,18-75,60% M/40% F,0-1,3,2,Normal,Infusion reaction,Hematological,Hepatic,Moderate,1,28.99,Yes,Yes,Supportive care,Monitoring,13,29,Yes,None,No,No,No,Efficacy,Yes,None,Prior treatments,Unknown
RCT75520,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,169,14,Bi-weekly,55,18-75,50% M/50% F,0-1,2,2,Mild impairment,Nausea,Gastrointestinal,Gastrointestinal,Severe,3,26.25,Yes,Yes,Discontinuation,Premedication,3,60,No,Reduction,No,No,No,Regulatory,,None,Prior treatments,High
RCT34816,Trastuzumab,Anti-HER2,Single-arm,None,Phase 2,272,7,Monthly,58,18-65,50% M/50% F,1-2,3,2,Moderate impairment,Fatigue,Cardiac,Gastrointestinal,Moderate,4,29.97,No,Yes,Treatment hold,Premedication,25,12,Yes,None,No,No,Yes,Safety,,None,Gender,Unknown
RCT29948,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,125,11,Monthly,72,18-65,60% M/40% F,0-2,4,0,Moderate impairment,Rash,Hepatic,Skin,Severe,5,1.74,No,Yes,Treatment hold,Patient education,9,57,No,Discontinuation,No,Yes,No,Efficacy,No,Positive,Prior treatments,Medium
RCT36841,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,129,13,Every 3 weeks,180,≥18,60% M/40% F,0-1,1,0,Normal,Fatigue,Cardiac,Gastrointestinal,Mild,3,3.38,Yes,No,Supportive care,Premedication,16,33,No,Delay,Yes,No,Yes,Regulatory,,Unknown,Gender,Low
RCT98072,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 1,36,4,Bi-weekly,35,18-75,50% M/50% F,1-2,0,1,Mild impairment,Infusion reaction,Hepatic,Hepatic,Mild,3,2.67,No,No,Discontinuation,Dose adjustment,27,20,No,Discontinuation,No,Yes,No,Competition,,Positive,Age,Medium
RCT81137,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 3,81,8,Every 3 weeks,141,18-75,50% M/50% F,0-2,4,3,Mild impairment,Fatigue,Hematological,Blood,Severe,1,26.14,No,Yes,Dose reduction,Patient education,19,12,Yes,Discontinuation,Yes,No,Yes,,No,Negative,ECOG,Unknown
RCT18637,Trastuzumab,Anti-HER2,Single-arm,None,Phase 3,153,11,Bi-weekly,148,21-85,60% M/40% F,0-1,0,3,Normal,Nausea,Gastrointestinal,Blood,Moderate,2,1.3,Yes,No,Supportive care,Dose adjustment,25,30,Yes,Delay,Yes,Yes,Yes,Efficacy,Yes,None,ECOG,Unknown
RCT83668,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,162,12,Bi-weekly,43,18-65,40% M/60% F,0-1,1,1,Moderate impairment,Infusion reaction,Gastrointestinal,Cardiac,Mild,2,19.11,No,Yes,Discontinuation,Dose adjustment,25,60,Yes,Discontinuation,Yes,Yes,Yes,Competition,No,Unknown,Age,High
RCT61928,Bevacizumab,Anti-VEGF,Randomized,None,Phase 3,281,3,Every 3 weeks,44,21-85,60% M/40% F,1-2,0,2,Normal,Nausea,Gastrointestinal,Gastrointestinal,Moderate,3,22.26,No,No,Treatment hold,Dose adjustment,9,60,Yes,None,Yes,No,Yes,,Yes,Unknown,Age,Low
RCT71041,Cetuximab,Anti-EGFR,Randomized,None,Phase 1,250,13,Bi-weekly,136,18-75,50% M/50% F,0-1,3,0,Mild impairment,Nausea,Dermatological,Gastrointestinal,Mild,5,29.19,No,Yes,Discontinuation,Dose adjustment,8,2,Yes,Discontinuation,Yes,Yes,Yes,,Yes,Unknown,Gender,Unknown
RCT45784,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 1,110,3,Weekly,145,18-75,60% M/40% F,0-2,2,1,Moderate impairment,Fatigue,Cardiac,Hepatic,Severe,4,24.56,No,No,Supportive care,Dose adjustment,10,32,Yes,Discontinuation,No,Yes,No,,,None,ECOG,Unknown
RCT45958,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,21,4,Monthly,89,≥18,60% M/40% F,1-2,1,3,Mild impairment,Infusion reaction,Cardiac,Skin,Severe,3,24.66,Yes,No,Supportive care,Monitoring,26,42,Yes,Delay,No,No,No,Efficacy,No,Negative,Gender,Low
RCT14108,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 1,150,7,Bi-weekly,89,≥18,60% M/40% F,0-2,0,1,Normal,Fatigue,Hepatic,Cardiac,Mild,1,3.62,No,Yes,Supportive care,Monitoring,7,4,No,Delay,Yes,Yes,Yes,Regulatory,,Positive,Prior treatments,Low
RCT45029,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 1,116,14,Every 3 weeks,147,18-65,40% M/60% F,0-2,5,0,Normal,Infusion reaction,Gastrointestinal,Hepatic,Mild,1,23.93,No,No,Dose reduction,Patient education,14,52,Yes,Reduction,Yes,Yes,No,Efficacy,No,None,None,Medium
RCT52164,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,30,4,Monthly,154,18-65,40% M/60% F,0-2,5,2,Normal,Rash,Hematological,Blood,Moderate,5,9.52,No,No,Dose reduction,Patient education,26,9,Yes,Discontinuation,No,No,No,Safety,Yes,Unknown,Gender,Unknown
RCT45371,Rituximab,Anti-CD20,Crossover,None,Phase 3,51,12,Bi-weekly,75,21-85,50% M/50% F,1-2,0,3,Normal,Neutropenia,Cardiac,Skin,Moderate,4,23.43,No,No,Discontinuation,Monitoring,3,55,Yes,Delay,Yes,Yes,Yes,,,Negative,Age,Unknown
RCT65321,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 2,284,2,Weekly,154,≥18,40% M/60% F,1-2,1,3,Normal,Fatigue,Cardiac,Hepatic,Severe,4,22.37,Yes,No,Dose reduction,Dose adjustment,25,41,Yes,Delay,Yes,No,Yes,Competition,No,Negative,ECOG,High
RCT81940,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,268,10,Bi-weekly,37,18-65,50% M/50% F,0-1,5,2,Moderate impairment,Fatigue,Hepatic,Cardiac,Mild,1,19.78,Yes,Yes,Supportive care,Patient education,5,22,No,Reduction,No,Yes,Yes,Regulatory,No,Positive,Prior treatments,Unknown
RCT57673,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 1,213,10,Every 3 weeks,129,18-75,60% M/40% F,1-2,4,0,Moderate impairment,Infusion reaction,Dermatological,Cardiac,Severe,3,7.0,Yes,Yes,Discontinuation,Premedication,26,59,Yes,Delay,Yes,Yes,No,Efficacy,,None,None,High
RCT26067,Cetuximab,Anti-EGFR,Randomized,None,Phase 3,179,5,Every 3 weeks,120,18-65,50% M/50% F,0-2,1,0,Moderate impairment,Rash,Hepatic,Cardiac,Severe,1,5.59,No,Yes,Supportive care,Monitoring,13,42,Yes,Reduction,No,Yes,No,Safety,No,Unknown,Age,High
RCT97895,Rituximab,Anti-CD20,Crossover,None,Phase 3,119,10,Weekly,97,18-65,60% M/40% F,0-2,2,3,Normal,Fatigue,Hepatic,Hepatic,Severe,2,10.66,Yes,Yes,Discontinuation,Premedication,16,17,No,Reduction,No,Yes,Yes,Regulatory,Yes,Positive,Prior treatments,Medium
RCT79650,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 1,277,2,Monthly,118,18-75,50% M/50% F,0-2,5,0,Moderate impairment,Fatigue,Hematological,Skin,Severe,2,25.98,Yes,Yes,Treatment hold,Patient education,2,30,No,Discontinuation,Yes,Yes,No,Efficacy,,None,ECOG,Medium
RCT89115,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 3,245,6,Every 3 weeks,32,21-85,60% M/40% F,0-1,3,0,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Moderate,2,24.1,Yes,No,Discontinuation,Dose adjustment,13,45,Yes,Discontinuation,No,Yes,No,Efficacy,,None,ECOG,Medium
RCT14313,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,133,1,Monthly,82,21-85,60% M/40% F,0-2,1,0,Normal,Nausea,Hematological,Gastrointestinal,Severe,4,24.28,No,Yes,Dose reduction,Dose adjustment,8,6,Yes,Discontinuation,Yes,No,Yes,Regulatory,,Unknown,ECOG,Low
RCT99556,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,134,1,Monthly,109,18-65,40% M/60% F,0-2,2,0,Moderate impairment,Infusion reaction,Dermatological,Skin,Moderate,4,29.7,No,Yes,Discontinuation,Dose adjustment,18,27,Yes,Reduction,No,Yes,No,Regulatory,Yes,Unknown,ECOG,Unknown
RCT60197,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,138,13,Weekly,50,18-65,60% M/40% F,0-2,3,3,Mild impairment,Fatigue,Hematological,Cardiac,Severe,1,26.19,Yes,No,Treatment hold,Monitoring,23,46,No,Delay,Yes,Yes,Yes,,Yes,None,Gender,High
RCT37595,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,82,5,Monthly,135,18-75,60% M/40% F,0-1,5,3,Moderate impairment,Fatigue,Hepatic,Skin,Severe,5,14.7,No,Yes,Supportive care,Patient education,4,39,Yes,None,No,Yes,Yes,,,Unknown,None,Unknown
RCT32283,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,106,11,Monthly,62,21-85,60% M/40% F,0-1,5,2,Moderate impairment,Neutropenia,Gastrointestinal,Hepatic,Mild,4,27.03,Yes,No,Treatment hold,Patient education,11,6,No,Discontinuation,No,Yes,No,Efficacy,Yes,None,Prior treatments,Low
RCT11342,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,293,3,Bi-weekly,30,18-75,60% M/40% F,0-1,3,3,Moderate impairment,Nausea,Hematological,Hepatic,Moderate,5,11.94,No,No,Dose reduction,Patient education,12,6,No,Discontinuation,No,No,No,Safety,Yes,None,Gender,Unknown
RCT98451,Cetuximab,Anti-EGFR,Single-arm,None,Phase 2,213,4,Every 3 weeks,58,≥18,40% M/60% F,1-2,3,1,Mild impairment,Nausea,Hepatic,Cardiac,Moderate,1,23.83,No,No,Dose reduction,Dose adjustment,6,39,No,None,No,No,No,Regulatory,,Positive,Age,High
RCT84900,Rituximab,Anti-CD20,Crossover,None,Phase 2,41,11,Every 3 weeks,39,≥18,40% M/60% F,1-2,4,0,Normal,Neutropenia,Hematological,Skin,Mild,5,28.85,No,No,Treatment hold,Dose adjustment,14,37,No,Reduction,No,No,Yes,Safety,No,Positive,Prior treatments,Unknown
RCT78962,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 1,261,14,Weekly,50,18-65,40% M/60% F,1-2,1,0,Normal,Infusion reaction,Hematological,Gastrointestinal,Severe,4,1.12,Yes,Yes,Treatment hold,Patient education,27,34,Yes,None,Yes,Yes,Yes,Regulatory,,Unknown,ECOG,Medium
RCT81766,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,109,2,Bi-weekly,170,18-65,50% M/50% F,0-2,2,3,Normal,Fatigue,Gastrointestinal,Skin,Mild,5,9.16,Yes,No,Dose reduction,Premedication,18,6,Yes,Delay,No,Yes,Yes,,,Negative,Gender,Unknown
RCT50976,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,168,2,Every 3 weeks,60,18-65,60% M/40% F,1-2,1,3,Normal,Rash,Hepatic,Hepatic,Mild,5,29.72,Yes,No,Supportive care,Monitoring,17,15,Yes,None,Yes,Yes,No,,Yes,Unknown,Prior treatments,Unknown
RCT26358,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 2,288,14,Every 3 weeks,90,≥18,60% M/40% F,1-2,2,2,Mild impairment,Infusion reaction,Cardiac,Hepatic,Moderate,5,24.9,No,Yes,Discontinuation,Premedication,23,38,Yes,None,Yes,No,No,,No,Positive,None,Low
RCT37434,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 2,63,14,Monthly,125,21-85,40% M/60% F,0-1,1,3,Normal,Nausea,Gastrointestinal,Hepatic,Moderate,4,25.01,No,No,Treatment hold,Dose adjustment,23,41,No,Reduction,Yes,Yes,Yes,Regulatory,,Negative,Prior treatments,Medium
RCT30273,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 2,228,15,Weekly,123,18-65,50% M/50% F,1-2,3,2,Normal,Fatigue,Gastrointestinal,Skin,Severe,4,19.85,No,Yes,Dose reduction,Patient education,3,18,No,Reduction,No,Yes,No,Safety,,Positive,ECOG,High
RCT16200,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 1,222,11,Every 3 weeks,75,18-75,40% M/60% F,1-2,3,3,Normal,Nausea,Hematological,Hepatic,Severe,5,16.57,No,Yes,Dose reduction,Monitoring,18,40,No,None,Yes,No,No,Competition,,Positive,ECOG,High
RCT59719,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 1,26,12,Bi-weekly,124,18-65,50% M/50% F,0-1,3,3,Normal,Neutropenia,Gastrointestinal,Cardiac,Moderate,1,7.87,No,No,Discontinuation,Monitoring,2,27,No,Reduction,No,Yes,Yes,Competition,,None,Prior treatments,Low
RCT91384,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,55,7,Bi-weekly,124,18-75,60% M/40% F,1-2,3,0,Mild impairment,Fatigue,Cardiac,Blood,Moderate,5,27.57,No,No,Dose reduction,Premedication,22,43,Yes,Discontinuation,Yes,Yes,Yes,Safety,No,Positive,ECOG,Medium
RCT80229,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 3,129,7,Bi-weekly,151,18-65,60% M/40% F,0-1,2,3,Mild impairment,Neutropenia,Gastrointestinal,Blood,Moderate,5,11.98,Yes,No,Supportive care,Premedication,19,58,Yes,Delay,No,No,No,Regulatory,Yes,None,None,Medium
RCT19176,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,226,2,Monthly,136,≥18,60% M/40% F,0-2,1,3,Mild impairment,Infusion reaction,Cardiac,Cardiac,Severe,5,23.22,Yes,Yes,Treatment hold,Dose adjustment,22,53,Yes,Reduction,No,Yes,No,Regulatory,,Positive,None,High
RCT59458,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 2,283,15,Bi-weekly,42,≥18,50% M/50% F,1-2,2,2,Mild impairment,Rash,Cardiac,Blood,Mild,1,18.92,Yes,Yes,Discontinuation,Patient education,19,3,No,None,No,No,Yes,,,None,Gender,High
RCT92781,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,250,12,Weekly,118,21-85,40% M/60% F,1-2,4,1,Moderate impairment,Fatigue,Dermatological,Skin,Moderate,1,20.13,No,Yes,Supportive care,Monitoring,21,34,No,Reduction,Yes,Yes,Yes,Efficacy,No,Unknown,Prior treatments,Low
RCT52458,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,246,2,Weekly,96,18-65,50% M/50% F,1-2,0,0,Moderate impairment,Rash,Gastrointestinal,Blood,Moderate,3,7.82,Yes,Yes,Treatment hold,Patient education,23,15,Yes,Discontinuation,Yes,Yes,Yes,Regulatory,No,Unknown,None,Unknown
RCT58964,Rituximab,Anti-CD20,Single-arm,None,Phase 3,30,5,Weekly,106,≥18,50% M/50% F,1-2,4,1,Moderate impairment,Nausea,Gastrointestinal,Cardiac,Mild,3,10.13,Yes,Yes,Supportive care,Premedication,17,13,Yes,Discontinuation,No,No,No,Efficacy,,Positive,Gender,Low
RCT59995,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 2,217,15,Every 3 weeks,55,18-65,60% M/40% F,1-2,1,3,Normal,Infusion reaction,Hepatic,Cardiac,Severe,4,5.66,No,Yes,Discontinuation,Premedication,28,52,No,Discontinuation,Yes,Yes,Yes,Regulatory,,Negative,Gender,High
RCT54765,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 1,142,3,Bi-weekly,174,18-75,40% M/60% F,0-1,2,0,Normal,Fatigue,Hematological,Gastrointestinal,Severe,3,11.69,Yes,No,Supportive care,Patient education,5,60,No,Discontinuation,No,Yes,No,Efficacy,Yes,Unknown,Age,High
RCT36850,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,72,4,Bi-weekly,64,≥18,50% M/50% F,1-2,2,3,Mild impairment,Neutropenia,Hematological,Skin,Mild,2,25.61,Yes,No,Supportive care,Monitoring,11,57,No,Delay,No,No,No,Competition,Yes,None,None,Medium
RCT39950,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,133,9,Every 3 weeks,65,18-75,60% M/40% F,0-2,5,1,Moderate impairment,Rash,Dermatological,Blood,Severe,4,21.31,Yes,Yes,Dose reduction,Patient education,11,26,Yes,None,Yes,Yes,Yes,Safety,Yes,None,ECOG,Low
RCT57404,Rituximab,Anti-CD20,Single-arm,Placebo,Phase 1,35,14,Monthly,162,≥18,40% M/60% F,0-1,5,3,Normal,Fatigue,Cardiac,Gastrointestinal,Mild,5,18.32,Yes,No,Dose reduction,Dose adjustment,7,34,Yes,Delay,Yes,Yes,Yes,Regulatory,,Negative,Gender,High
RCT42993,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,60,8,Bi-weekly,63,18-65,40% M/60% F,0-1,1,0,Moderate impairment,Nausea,Hematological,Gastrointestinal,Mild,5,19.51,No,Yes,Treatment hold,Dose adjustment,16,4,No,Discontinuation,No,No,No,Regulatory,Yes,Negative,Age,Medium
RCT84923,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,199,12,Weekly,54,21-85,40% M/60% F,0-1,0,3,Normal,Infusion reaction,Hematological,Blood,Severe,4,3.59,No,Yes,Dose reduction,Premedication,15,54,Yes,Reduction,Yes,No,No,Efficacy,No,Positive,Age,Medium
RCT21799,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 2,168,11,Weekly,54,21-85,50% M/50% F,0-2,0,3,Moderate impairment,Fatigue,Hepatic,Gastrointestinal,Mild,5,22.62,Yes,Yes,Treatment hold,Monitoring,21,44,Yes,Delay,No,Yes,Yes,,,None,ECOG,Medium
RCT88662,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,234,7,Bi-weekly,123,21-85,40% M/60% F,0-1,0,1,Normal,Rash,Dermatological,Gastrointestinal,Moderate,2,2.42,Yes,No,Supportive care,Monitoring,5,45,Yes,Reduction,Yes,Yes,Yes,Regulatory,Yes,Unknown,Prior treatments,Medium
RCT11564,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 2,269,13,Bi-weekly,93,21-85,60% M/40% F,0-2,2,1,Normal,Nausea,Hematological,Gastrointestinal,Moderate,4,29.59,No,No,Discontinuation,Monitoring,18,34,Yes,Reduction,No,No,No,,Yes,Positive,ECOG,Unknown
RCT10902,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,49,4,Monthly,71,18-75,60% M/40% F,1-2,5,1,Normal,Infusion reaction,Cardiac,Blood,Mild,1,3.9,No,Yes,Dose reduction,Monitoring,16,12,Yes,Reduction,No,Yes,No,,No,None,ECOG,Unknown
RCT61563,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 2,187,12,Weekly,57,21-85,50% M/50% F,0-1,2,2,Moderate impairment,Rash,Gastrointestinal,Cardiac,Severe,3,2.4,No,Yes,Dose reduction,Premedication,4,35,Yes,None,No,No,Yes,Efficacy,Yes,Negative,Gender,Unknown
RCT10125,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 2,215,6,Weekly,147,≥18,50% M/50% F,1-2,0,1,Normal,Nausea,Cardiac,Cardiac,Mild,4,21.21,Yes,Yes,Dose reduction,Dose adjustment,14,22,Yes,Discontinuation,Yes,No,No,Safety,Yes,None,ECOG,Low
RCT86283,Cetuximab,Anti-EGFR,Crossover,None,Phase 1,118,6,Weekly,46,18-65,50% M/50% F,0-1,0,2,Normal,Infusion reaction,Gastrointestinal,Hepatic,Mild,3,2.69,No,Yes,Treatment hold,Patient education,3,40,No,None,Yes,No,Yes,Regulatory,No,Unknown,Gender,High
RCT43144,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 2,228,3,Weekly,150,≥18,60% M/40% F,1-2,3,3,Mild impairment,Fatigue,Hepatic,Gastrointestinal,Severe,2,14.6,No,No,Supportive care,Premedication,17,17,Yes,Discontinuation,No,Yes,Yes,,No,None,Prior treatments,Unknown
RCT78949,Trastuzumab,Anti-HER2,Randomized,None,Phase 2,129,7,Monthly,31,21-85,50% M/50% F,0-1,0,0,Normal,Nausea,Dermatological,Skin,Moderate,5,13.52,Yes,Yes,Dose reduction,Premedication,20,25,Yes,None,Yes,Yes,Yes,Efficacy,Yes,Negative,None,Low
RCT15420,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,253,9,Weekly,157,18-65,50% M/50% F,1-2,2,0,Mild impairment,Infusion reaction,Cardiac,Cardiac,Moderate,1,6.92,No,Yes,Dose reduction,Patient education,28,31,Yes,Reduction,Yes,No,Yes,Regulatory,No,Negative,Age,High
RCT65362,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,149,14,Bi-weekly,50,18-75,40% M/60% F,0-2,0,2,Mild impairment,Rash,Cardiac,Gastrointestinal,Moderate,3,20.51,No,No,Discontinuation,Patient education,26,27,No,Reduction,No,No,Yes,,No,Positive,None,Low
RCT47140,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,153,10,Weekly,82,18-75,60% M/40% F,0-2,4,1,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,2,13.49,Yes,No,Discontinuation,Patient education,23,30,Yes,Reduction,Yes,Yes,No,Safety,,Unknown,None,High
RCT27511,Rituximab,Anti-CD20,Single-arm,None,Phase 3,209,6,Weekly,105,18-65,60% M/40% F,0-2,0,2,Moderate impairment,Infusion reaction,Dermatological,Gastrointestinal,Severe,5,18.3,Yes,No,Treatment hold,Dose adjustment,24,14,Yes,Reduction,No,Yes,Yes,Efficacy,,Positive,None,High
RCT74163,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 1,233,9,Bi-weekly,172,18-75,60% M/40% F,1-2,1,3,Moderate impairment,Fatigue,Cardiac,Skin,Mild,2,2.75,Yes,Yes,Treatment hold,Patient education,23,52,Yes,Delay,No,Yes,No,Safety,Yes,Negative,Age,Unknown
RCT81561,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 3,36,13,Every 3 weeks,79,18-65,60% M/40% F,0-1,2,0,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Moderate,4,15.12,No,No,Dose reduction,Dose adjustment,4,15,Yes,Reduction,Yes,No,No,Regulatory,Yes,Unknown,Gender,High
RCT33917,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 3,82,10,Bi-weekly,47,21-85,40% M/60% F,0-2,1,2,Normal,Neutropenia,Cardiac,Gastrointestinal,Moderate,5,3.16,No,Yes,Treatment hold,Premedication,19,40,Yes,Discontinuation,Yes,Yes,No,Regulatory,,None,None,Low
RCT42277,Cetuximab,Anti-EGFR,Single-arm,None,Phase 2,277,7,Bi-weekly,54,18-65,60% M/40% F,1-2,3,0,Mild impairment,Rash,Hematological,Hepatic,Moderate,2,1.24,No,No,Treatment hold,Premedication,26,24,No,Reduction,No,Yes,No,,Yes,Negative,Prior treatments,Unknown
RCT12947,Rituximab,Anti-CD20,Crossover,None,Phase 1,70,5,Bi-weekly,34,18-65,40% M/60% F,0-2,1,2,Mild impairment,Neutropenia,Hepatic,Hepatic,Moderate,3,14.04,Yes,Yes,Discontinuation,Patient education,3,51,No,Discontinuation,Yes,No,No,Efficacy,No,Negative,None,High
RCT57477,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,26,6,Every 3 weeks,149,18-75,40% M/60% F,0-1,1,2,Normal,Nausea,Hepatic,Blood,Mild,5,28.63,Yes,No,Dose reduction,Monitoring,27,18,No,None,No,Yes,No,Competition,,Negative,ECOG,High
RCT57192,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 1,29,12,Every 3 weeks,156,21-85,60% M/40% F,1-2,0,2,Normal,Fatigue,Hematological,Hepatic,Severe,5,2.32,No,No,Supportive care,Monitoring,9,48,Yes,None,No,Yes,No,Regulatory,No,Positive,Prior treatments,Unknown
RCT77692,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 2,158,8,Bi-weekly,127,≥18,50% M/50% F,0-1,2,0,Normal,Fatigue,Hepatic,Skin,Mild,3,29.87,Yes,Yes,Supportive care,Premedication,21,38,No,Delay,No,Yes,Yes,Efficacy,,Negative,ECOG,High
RCT41173,Cetuximab,Anti-EGFR,Crossover,None,Phase 3,247,15,Monthly,30,21-85,60% M/40% F,1-2,4,0,Moderate impairment,Infusion reaction,Hematological,Blood,Severe,4,16.46,No,Yes,Discontinuation,Dose adjustment,20,56,No,None,Yes,No,No,Competition,,Negative,ECOG,Low
RCT78369,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,51,10,Weekly,119,18-65,50% M/50% F,1-2,1,3,Moderate impairment,Neutropenia,Gastrointestinal,Blood,Severe,5,11.17,Yes,No,Treatment hold,Monitoring,11,17,Yes,Reduction,Yes,Yes,Yes,Regulatory,Yes,None,ECOG,High
RCT71813,Trastuzumab,Anti-HER2,Randomized,Standard of care,Phase 2,166,14,Bi-weekly,160,18-75,50% M/50% F,0-1,3,3,Moderate impairment,Nausea,Hematological,Cardiac,Severe,1,8.27,Yes,No,Treatment hold,Monitoring,16,36,Yes,Reduction,Yes,Yes,Yes,,,None,None,Unknown
RCT61910,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,143,5,Every 3 weeks,50,≥18,50% M/50% F,0-1,0,3,Moderate impairment,Fatigue,Hematological,Blood,Severe,2,15.58,No,Yes,Treatment hold,Premedication,9,27,No,Reduction,Yes,Yes,Yes,,,Positive,Prior treatments,Unknown
RCT97609,Bevacizumab,Anti-VEGF,Randomized,None,Phase 1,252,15,Every 3 weeks,31,18-75,60% M/40% F,0-2,2,2,Mild impairment,Fatigue,Cardiac,Skin,Mild,5,6.17,No,Yes,Discontinuation,Premedication,10,51,Yes,Discontinuation,Yes,No,Yes,Safety,,None,None,Medium
RCT87213,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,256,3,Weekly,162,21-85,50% M/50% F,0-1,3,0,Moderate impairment,Nausea,Gastrointestinal,Skin,Severe,4,17.86,Yes,Yes,Supportive care,Dose adjustment,24,41,Yes,None,Yes,Yes,No,,Yes,Positive,Prior treatments,High
RCT80680,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 3,63,3,Weekly,176,21-85,60% M/40% F,0-2,3,3,Mild impairment,Fatigue,Cardiac,Hepatic,Mild,1,17.61,Yes,Yes,Treatment hold,Premedication,4,56,No,Discontinuation,No,Yes,Yes,Regulatory,,Unknown,Gender,Low
RCT79384,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 1,99,8,Monthly,91,18-65,40% M/60% F,0-1,4,2,Mild impairment,Nausea,Hematological,Gastrointestinal,Mild,1,13.0,No,Yes,Treatment hold,Patient education,27,40,No,None,Yes,Yes,No,Efficacy,No,None,Age,Unknown
RCT83215,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 2,215,5,Bi-weekly,118,≥18,60% M/40% F,0-2,4,0,Normal,Neutropenia,Hepatic,Gastrointestinal,Severe,1,3.95,Yes,Yes,Discontinuation,Dose adjustment,20,42,No,None,Yes,Yes,No,Efficacy,Yes,Positive,None,High
RCT13400,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 2,245,13,Monthly,55,21-85,60% M/40% F,0-2,0,2,Moderate impairment,Fatigue,Hematological,Blood,Moderate,1,29.81,Yes,Yes,Supportive care,Patient education,17,40,Yes,None,No,No,No,Safety,,Unknown,None,High
RCT56421,Cetuximab,Anti-EGFR,Crossover,None,Phase 2,75,4,Bi-weekly,151,18-75,40% M/60% F,1-2,5,0,Mild impairment,Neutropenia,Cardiac,Hepatic,Severe,5,23.68,Yes,No,Dose reduction,Patient education,27,8,No,None,Yes,Yes,Yes,Competition,Yes,Positive,Gender,Unknown
RCT21990,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,142,10,Every 3 weeks,58,21-85,40% M/60% F,1-2,4,3,Moderate impairment,Infusion reaction,Gastrointestinal,Gastrointestinal,Severe,4,19.14,Yes,Yes,Discontinuation,Dose adjustment,23,32,Yes,Discontinuation,Yes,Yes,No,Efficacy,Yes,Unknown,Gender,Low
RCT75991,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,272,3,Every 3 weeks,34,18-75,50% M/50% F,1-2,4,2,Mild impairment,Rash,Cardiac,Cardiac,Moderate,3,19.97,No,Yes,Discontinuation,Patient education,19,50,Yes,None,Yes,No,No,Regulatory,,Unknown,ECOG,High
RCT67157,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 1,101,10,Bi-weekly,33,18-65,50% M/50% F,0-1,5,2,Mild impairment,Rash,Hematological,Blood,Severe,4,24.53,No,Yes,Supportive care,Premedication,3,37,Yes,Discontinuation,No,Yes,Yes,Competition,,Negative,Gender,High
RCT78684,Bevacizumab,Anti-VEGF,Randomized,None,Phase 2,211,2,Every 3 weeks,125,21-85,50% M/50% F,0-1,0,3,Mild impairment,Neutropenia,Hepatic,Gastrointestinal,Moderate,4,21.6,Yes,No,Dose reduction,Monitoring,26,37,No,Reduction,No,Yes,Yes,,No,None,Prior treatments,High
RCT21533,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 2,187,5,Weekly,143,18-65,50% M/50% F,1-2,2,2,Normal,Fatigue,Dermatological,Blood,Mild,4,16.66,No,Yes,Treatment hold,Dose adjustment,16,18,Yes,Reduction,Yes,Yes,No,Competition,,None,ECOG,Low
RCT15241,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,152,5,Bi-weekly,81,≥18,40% M/60% F,0-1,0,0,Mild impairment,Infusion reaction,Gastrointestinal,Hepatic,Severe,1,9.42,Yes,No,Treatment hold,Dose adjustment,1,15,Yes,None,No,Yes,Yes,Regulatory,No,Positive,Age,Unknown
RCT49284,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,101,8,Monthly,172,≥18,50% M/50% F,1-2,3,0,Moderate impairment,Nausea,Dermatological,Gastrointestinal,Moderate,5,1.68,No,No,Dose reduction,Premedication,5,36,Yes,Reduction,No,Yes,Yes,Regulatory,Yes,Unknown,None,Unknown
RCT70090,Pembrolizumab,Anti-PD-1,Randomized,Standard of care,Phase 3,82,2,Every 3 weeks,62,18-75,40% M/60% F,0-2,2,0,Moderate impairment,Infusion reaction,Cardiac,Blood,Moderate,5,15.91,No,Yes,Dose reduction,Dose adjustment,27,25,No,Delay,Yes,Yes,Yes,Competition,,None,Gender,High
RCT46889,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 2,151,3,Every 3 weeks,71,≥18,60% M/40% F,1-2,5,1,Normal,Infusion reaction,Dermatological,Cardiac,Mild,3,22.12,Yes,Yes,Supportive care,Dose adjustment,1,54,No,Delay,Yes,No,Yes,Regulatory,No,Unknown,None,Unknown
RCT53333,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 2,101,11,Weekly,160,18-75,40% M/60% F,1-2,5,2,Mild impairment,Infusion reaction,Cardiac,Blood,Mild,2,24.69,No,Yes,Treatment hold,Patient education,23,30,Yes,Discontinuation,No,No,No,Regulatory,,None,None,Medium
RCT11394,Rituximab,Anti-CD20,Randomized,Placebo,Phase 3,64,12,Weekly,173,18-75,40% M/60% F,0-2,3,3,Mild impairment,Nausea,Hepatic,Blood,Moderate,5,7.08,No,No,Discontinuation,Patient education,7,41,No,None,No,Yes,No,Safety,,None,ECOG,Medium
RCT36845,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 1,26,4,Every 3 weeks,155,≥18,50% M/50% F,0-1,5,2,Moderate impairment,Fatigue,Hematological,Cardiac,Mild,5,25.98,No,Yes,Dose reduction,Dose adjustment,12,29,No,Discontinuation,Yes,Yes,Yes,,,None,Age,Low
RCT59596,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,276,7,Bi-weekly,163,18-75,60% M/40% F,1-2,3,1,Mild impairment,Rash,Hematological,Hepatic,Moderate,3,6.27,Yes,Yes,Dose reduction,Premedication,11,4,Yes,Discontinuation,No,Yes,No,Regulatory,,Unknown,ECOG,High
RCT43299,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,94,12,Monthly,112,≥18,50% M/50% F,0-1,0,2,Mild impairment,Neutropenia,Cardiac,Skin,Mild,3,22.11,Yes,No,Discontinuation,Dose adjustment,22,38,No,Reduction,No,Yes,No,Safety,No,Negative,None,Unknown
RCT48510,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,90,5,Weekly,64,18-65,40% M/60% F,1-2,2,3,Normal,Fatigue,Dermatological,Hepatic,Severe,5,3.23,No,No,Supportive care,Monitoring,5,60,Yes,None,Yes,No,Yes,Regulatory,No,Positive,Prior treatments,Medium
RCT88617,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 3,232,8,Bi-weekly,54,21-85,40% M/60% F,0-2,4,3,Mild impairment,Fatigue,Cardiac,Hepatic,Mild,5,13.25,Yes,Yes,Discontinuation,Dose adjustment,24,3,No,None,Yes,No,No,Regulatory,No,None,ECOG,High
RCT18971,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,50,4,Monthly,113,21-85,60% M/40% F,1-2,1,0,Normal,Neutropenia,Hepatic,Skin,Mild,3,2.44,Yes,No,Treatment hold,Premedication,11,38,No,Reduction,No,Yes,Yes,Competition,No,Negative,Gender,High
RCT17671,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 3,133,13,Monthly,169,≥18,60% M/40% F,0-2,0,1,Mild impairment,Fatigue,Hepatic,Hepatic,Moderate,1,1.16,Yes,No,Discontinuation,Dose adjustment,13,48,No,Discontinuation,No,No,No,Regulatory,Yes,None,Gender,Medium
RCT57086,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 1,239,10,Monthly,95,18-65,50% M/50% F,1-2,5,0,Normal,Rash,Cardiac,Skin,Severe,1,9.34,Yes,No,Discontinuation,Patient education,23,28,Yes,None,Yes,No,Yes,Safety,,Unknown,Prior treatments,Low
RCT70832,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,25,8,Every 3 weeks,135,21-85,40% M/60% F,1-2,4,1,Mild impairment,Rash,Hepatic,Blood,Mild,4,16.68,No,No,Dose reduction,Monitoring,7,8,No,None,No,No,No,Efficacy,,Positive,None,Low
RCT15550,Rituximab,Anti-CD20,Crossover,None,Phase 3,53,15,Weekly,100,≥18,40% M/60% F,0-2,1,2,Mild impairment,Rash,Hepatic,Cardiac,Severe,3,13.57,No,Yes,Supportive care,Monitoring,11,38,Yes,Discontinuation,No,No,Yes,Regulatory,No,Unknown,ECOG,Medium
RCT20838,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,108,12,Weekly,52,21-85,40% M/60% F,0-1,2,0,Normal,Fatigue,Hematological,Blood,Mild,3,5.99,No,Yes,Discontinuation,Dose adjustment,14,37,No,None,No,No,Yes,Efficacy,,None,Prior treatments,Low
RCT38601,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,131,13,Bi-weekly,104,21-85,40% M/60% F,0-1,5,2,Moderate impairment,Nausea,Hematological,Cardiac,Moderate,1,2.73,Yes,No,Treatment hold,Patient education,26,40,No,Delay,No,Yes,No,Safety,Yes,None,ECOG,High
RCT21188,Bevacizumab,Anti-VEGF,Randomized,Standard of care,Phase 1,159,11,Every 3 weeks,175,21-85,50% M/50% F,1-2,2,3,Mild impairment,Rash,Dermatological,Cardiac,Mild,2,29.84,Yes,No,Treatment hold,Dose adjustment,19,25,Yes,None,Yes,No,No,Regulatory,Yes,Unknown,Prior treatments,Medium
RCT84038,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,275,9,Weekly,80,≥18,50% M/50% F,0-2,2,2,Normal,Rash,Cardiac,Gastrointestinal,Moderate,5,6.76,Yes,Yes,Treatment hold,Patient education,27,15,No,Delay,No,Yes,No,Safety,Yes,Unknown,Age,Medium
RCT33266,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,60,2,Weekly,122,21-85,50% M/50% F,0-2,5,3,Normal,Nausea,Cardiac,Hepatic,Mild,2,14.68,Yes,Yes,Supportive care,Premedication,25,28,No,Delay,No,Yes,Yes,Regulatory,,Negative,None,Unknown
RCT74156,Trastuzumab,Anti-HER2,Crossover,None,Phase 2,101,5,Monthly,54,≥18,40% M/60% F,0-1,1,1,Moderate impairment,Neutropenia,Cardiac,Cardiac,Moderate,3,27.32,No,No,Discontinuation,Patient education,24,44,No,Delay,Yes,No,Yes,Safety,Yes,Unknown,Prior treatments,Unknown
RCT64928,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,53,4,Every 3 weeks,77,≥18,40% M/60% F,0-1,2,2,Normal,Infusion reaction,Cardiac,Hepatic,Severe,4,29.02,No,Yes,Treatment hold,Premedication,21,30,Yes,Delay,No,No,Yes,Regulatory,Yes,None,Age,Low
RCT61710,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,98,9,Every 3 weeks,81,21-85,40% M/60% F,0-2,1,1,Normal,Neutropenia,Hepatic,Skin,Mild,5,26.51,Yes,No,Treatment hold,Monitoring,1,14,Yes,Delay,Yes,Yes,No,Safety,No,None,ECOG,Medium
RCT95770,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,299,1,Weekly,159,21-85,40% M/60% F,0-1,2,0,Moderate impairment,Nausea,Gastrointestinal,Gastrointestinal,Mild,3,14.34,Yes,Yes,Dose reduction,Patient education,10,22,Yes,Reduction,No,Yes,No,Efficacy,Yes,Unknown,Prior treatments,Medium
RCT18942,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 2,213,4,Monthly,47,18-75,50% M/50% F,0-1,1,1,Normal,Neutropenia,Hematological,Hepatic,Mild,2,23.04,No,Yes,Supportive care,Dose adjustment,9,54,No,Discontinuation,No,No,Yes,Regulatory,No,None,ECOG,Low
RCT19087,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 1,122,1,Bi-weekly,35,≥18,40% M/60% F,0-1,5,0,Mild impairment,Nausea,Hepatic,Blood,Severe,2,26.62,Yes,Yes,Treatment hold,Dose adjustment,16,49,Yes,Reduction,No,Yes,Yes,Competition,No,Positive,Prior treatments,High
RCT73136,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,298,10,Weekly,144,18-65,60% M/40% F,0-2,0,0,Normal,Neutropenia,Gastrointestinal,Blood,Moderate,4,9.51,No,No,Treatment hold,Monitoring,26,47,No,Reduction,No,Yes,Yes,Efficacy,Yes,Negative,None,Unknown
RCT84587,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 2,28,13,Weekly,95,21-85,40% M/60% F,0-1,2,3,Moderate impairment,Nausea,Dermatological,Skin,Severe,4,25.39,Yes,Yes,Treatment hold,Monitoring,25,15,No,Reduction,No,Yes,No,Regulatory,Yes,Positive,None,Medium
RCT54395,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 3,283,2,Weekly,91,18-65,60% M/40% F,0-2,0,0,Mild impairment,Infusion reaction,Cardiac,Hepatic,Severe,4,23.43,No,No,Supportive care,Dose adjustment,16,1,Yes,Delay,Yes,No,Yes,Safety,,Positive,None,High
RCT48360,Rituximab,Anti-CD20,Randomized,None,Phase 1,148,1,Every 3 weeks,42,21-85,50% M/50% F,1-2,3,1,Moderate impairment,Nausea,Hematological,Hepatic,Moderate,4,28.23,Yes,No,Discontinuation,Monitoring,3,47,No,Reduction,Yes,No,Yes,Competition,No,Positive,Age,Low
RCT96572,Trastuzumab,Anti-HER2,Crossover,Active comparator,Phase 3,253,6,Every 3 weeks,136,≥18,50% M/50% F,0-2,3,1,Normal,Neutropenia,Gastrointestinal,Hepatic,Mild,4,26.58,Yes,No,Dose reduction,Patient education,4,48,No,Reduction,No,Yes,No,Regulatory,,Unknown,Gender,Medium
RCT24865,Pembrolizumab,Anti-PD-1,Single-arm,Active comparator,Phase 1,139,7,Bi-weekly,132,≥18,60% M/40% F,0-2,2,2,Normal,Nausea,Hematological,Cardiac,Severe,3,29.67,Yes,Yes,Supportive care,Monitoring,3,32,Yes,Delay,Yes,Yes,Yes,Efficacy,Yes,None,Prior treatments,Low
RCT66832,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 2,58,2,Bi-weekly,165,21-85,40% M/60% F,0-1,0,2,Moderate impairment,Nausea,Dermatological,Gastrointestinal,Moderate,5,15.95,No,Yes,Treatment hold,Monitoring,4,42,No,None,Yes,Yes,No,Competition,Yes,Negative,None,High
RCT94907,Cetuximab,Anti-EGFR,Single-arm,Placebo,Phase 1,289,4,Every 3 weeks,45,≥18,40% M/60% F,0-1,1,1,Normal,Nausea,Hepatic,Skin,Mild,3,28.37,Yes,Yes,Discontinuation,Dose adjustment,20,51,No,None,Yes,No,No,Efficacy,No,Positive,Age,Unknown
RCT50123,Rituximab,Anti-CD20,Single-arm,Active comparator,Phase 2,134,3,Every 3 weeks,118,18-75,60% M/40% F,1-2,0,0,Mild impairment,Neutropenia,Gastrointestinal,Hepatic,Mild,4,28.35,Yes,No,Supportive care,Premedication,28,51,No,None,No,Yes,Yes,,Yes,Unknown,Gender,Low
RCT87667,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 3,224,12,Every 3 weeks,63,21-85,40% M/60% F,0-2,1,3,Mild impairment,Fatigue,Dermatological,Blood,Severe,5,7.63,No,No,Supportive care,Premedication,2,37,No,Reduction,No,Yes,Yes,Regulatory,,None,Age,Unknown
RCT19941,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 3,22,1,Monthly,136,≥18,50% M/50% F,0-2,1,1,Moderate impairment,Nausea,Gastrointestinal,Skin,Moderate,5,4.29,Yes,No,Discontinuation,Dose adjustment,5,35,Yes,Delay,No,Yes,Yes,Safety,No,Unknown,Age,High
RCT32320,Bevacizumab,Anti-VEGF,Crossover,Active comparator,Phase 1,134,9,Monthly,67,18-75,60% M/40% F,0-1,5,2,Moderate impairment,Neutropenia,Dermatological,Hepatic,Severe,5,10.38,No,Yes,Discontinuation,Premedication,9,53,Yes,Discontinuation,Yes,Yes,Yes,,No,Negative,ECOG,Unknown
RCT54089,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 2,76,10,Monthly,156,≥18,60% M/40% F,0-2,4,0,Moderate impairment,Neutropenia,Cardiac,Gastrointestinal,Moderate,5,22.24,No,No,Treatment hold,Dose adjustment,28,23,No,None,Yes,No,Yes,Competition,Yes,Positive,ECOG,High
RCT26926,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 1,24,13,Weekly,60,21-85,40% M/60% F,1-2,4,0,Mild impairment,Neutropenia,Cardiac,Cardiac,Severe,4,12.81,No,No,Treatment hold,Premedication,15,13,No,Discontinuation,No,No,Yes,,,Negative,None,Medium
RCT35526,Trastuzumab,Anti-HER2,Crossover,None,Phase 3,111,12,Monthly,157,21-85,60% M/40% F,0-2,4,1,Mild impairment,Infusion reaction,Hepatic,Gastrointestinal,Severe,1,17.98,Yes,No,Dose reduction,Patient education,6,28,Yes,Delay,No,No,No,Regulatory,Yes,Negative,Gender,Low
RCT77102,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 2,298,5,Monthly,157,≥18,40% M/60% F,0-2,0,2,Moderate impairment,Rash,Cardiac,Hepatic,Mild,3,5.55,No,Yes,Supportive care,Dose adjustment,11,29,Yes,Discontinuation,No,No,Yes,,No,Negative,Prior treatments,High
RCT47076,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 1,55,5,Every 3 weeks,104,21-85,50% M/50% F,0-1,3,1,Mild impairment,Neutropenia,Hepatic,Hepatic,Severe,5,11.38,No,Yes,Dose reduction,Monitoring,13,37,Yes,None,Yes,Yes,Yes,Regulatory,No,None,Gender,High
RCT97592,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,199,15,Weekly,102,≥18,50% M/50% F,0-2,4,0,Mild impairment,Fatigue,Dermatological,Gastrointestinal,Moderate,2,9.46,Yes,No,Discontinuation,Monitoring,12,28,No,Reduction,Yes,No,No,,No,None,ECOG,Unknown
RCT69569,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 1,275,12,Monthly,111,≥18,40% M/60% F,0-2,5,1,Moderate impairment,Rash,Cardiac,Blood,Mild,1,15.48,No,Yes,Supportive care,Premedication,21,26,No,None,No,No,Yes,Safety,Yes,None,Age,Low
RCT34627,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 1,223,11,Bi-weekly,169,18-75,40% M/60% F,0-1,0,2,Moderate impairment,Fatigue,Hematological,Skin,Mild,2,13.6,No,Yes,Dose reduction,Dose adjustment,10,9,Yes,Reduction,Yes,No,No,Competition,,Negative,ECOG,Unknown
RCT19738,Pembrolizumab,Anti-PD-1,Randomized,None,Phase 3,294,11,Every 3 weeks,179,21-85,40% M/60% F,1-2,5,3,Normal,Nausea,Hematological,Gastrointestinal,Severe,2,17.53,No,Yes,Dose reduction,Patient education,19,22,No,Discontinuation,No,No,Yes,Competition,,Negative,Age,High
RCT34156,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,206,11,Every 3 weeks,77,18-75,60% M/40% F,0-2,5,2,Mild impairment,Infusion reaction,Cardiac,Blood,Severe,5,26.02,No,No,Dose reduction,Premedication,9,17,No,Delay,No,Yes,Yes,Regulatory,No,Negative,Prior treatments,Medium
RCT41641,Cetuximab,Anti-EGFR,Randomized,Standard of care,Phase 1,177,7,Bi-weekly,38,≥18,40% M/60% F,0-1,5,2,Moderate impairment,Infusion reaction,Hepatic,Hepatic,Severe,1,18.73,Yes,No,Treatment hold,Premedication,22,5,No,Reduction,Yes,Yes,Yes,Efficacy,No,None,Gender,Low
RCT71172,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 3,162,14,Every 3 weeks,65,21-85,40% M/60% F,0-1,2,2,Normal,Rash,Cardiac,Blood,Mild,5,25.53,No,Yes,Discontinuation,Dose adjustment,3,20,No,Discontinuation,Yes,No,Yes,Regulatory,,Negative,ECOG,Low
RCT44650,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,200,12,Monthly,43,≥18,60% M/40% F,0-1,5,0,Mild impairment,Nausea,Cardiac,Gastrointestinal,Severe,3,9.95,Yes,Yes,Discontinuation,Patient education,4,60,Yes,Discontinuation,Yes,Yes,Yes,,,Positive,Gender,Low
RCT26200,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,35,12,Every 3 weeks,57,≥18,50% M/50% F,0-2,0,1,Mild impairment,Infusion reaction,Cardiac,Blood,Moderate,3,4.32,Yes,Yes,Treatment hold,Dose adjustment,14,30,Yes,Delay,Yes,Yes,Yes,Efficacy,Yes,None,Prior treatments,Unknown
RCT20914,Bevacizumab,Anti-VEGF,Crossover,None,Phase 2,96,12,Monthly,41,18-75,60% M/40% F,0-1,1,1,Normal,Rash,Cardiac,Cardiac,Moderate,2,18.96,No,Yes,Supportive care,Dose adjustment,7,2,Yes,Reduction,No,No,No,,No,Positive,Prior treatments,Medium
RCT16114,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,143,2,Every 3 weeks,54,21-85,40% M/60% F,0-1,5,0,Moderate impairment,Infusion reaction,Gastrointestinal,Blood,Mild,3,6.97,No,No,Discontinuation,Monitoring,13,3,Yes,Discontinuation,No,Yes,No,Competition,Yes,Positive,None,Unknown
RCT70841,Rituximab,Anti-CD20,Randomized,None,Phase 1,223,13,Every 3 weeks,47,18-65,50% M/50% F,0-2,2,2,Mild impairment,Neutropenia,Cardiac,Cardiac,Moderate,3,27.41,No,Yes,Dose reduction,Premedication,28,31,No,Delay,No,No,No,Safety,Yes,Positive,Age,High
RCT79696,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 2,290,11,Weekly,122,18-65,40% M/60% F,1-2,0,1,Mild impairment,Rash,Cardiac,Blood,Mild,3,27.18,Yes,Yes,Treatment hold,Patient education,4,33,No,Discontinuation,Yes,No,No,Efficacy,,Positive,ECOG,High
RCT94429,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 3,193,4,Every 3 weeks,139,21-85,40% M/60% F,0-2,0,3,Mild impairment,Rash,Dermatological,Hepatic,Mild,5,16.39,No,Yes,Dose reduction,Patient education,7,50,No,Reduction,No,Yes,No,Regulatory,,None,Prior treatments,Medium
RCT77537,Bevacizumab,Anti-VEGF,Randomized,Active comparator,Phase 2,277,5,Bi-weekly,91,18-75,60% M/40% F,0-2,0,2,Normal,Rash,Hematological,Skin,Mild,1,19.05,Yes,No,Supportive care,Premedication,12,24,No,Reduction,No,Yes,No,Safety,Yes,Negative,None,Unknown
RCT31856,Cetuximab,Anti-EGFR,Single-arm,None,Phase 1,118,14,Monthly,73,≥18,50% M/50% F,0-1,3,2,Moderate impairment,Fatigue,Dermatological,Blood,Moderate,5,7.34,No,Yes,Dose reduction,Premedication,16,35,No,Delay,No,Yes,No,,,Positive,ECOG,High
RCT17484,Rituximab,Anti-CD20,Single-arm,None,Phase 1,26,4,Monthly,31,21-85,50% M/50% F,1-2,3,1,Normal,Infusion reaction,Hepatic,Gastrointestinal,Severe,5,17.74,Yes,No,Treatment hold,Dose adjustment,26,26,Yes,Discontinuation,No,No,No,Regulatory,,Negative,None,Unknown
RCT33429,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,144,11,Every 3 weeks,113,18-75,40% M/60% F,0-1,5,3,Normal,Neutropenia,Gastrointestinal,Skin,Severe,4,14.13,No,No,Dose reduction,Monitoring,22,5,Yes,None,Yes,No,No,,Yes,Unknown,ECOG,Medium
RCT79674,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,136,13,Every 3 weeks,54,18-65,60% M/40% F,0-1,2,2,Moderate impairment,Neutropenia,Cardiac,Gastrointestinal,Severe,3,24.6,Yes,Yes,Discontinuation,Premedication,16,60,No,Discontinuation,No,No,Yes,,Yes,None,ECOG,Medium
RCT89509,Bevacizumab,Anti-VEGF,Single-arm,Placebo,Phase 3,96,8,Monthly,71,≥18,60% M/40% F,1-2,5,3,Mild impairment,Fatigue,Gastrointestinal,Gastrointestinal,Moderate,4,7.32,Yes,No,Treatment hold,Dose adjustment,1,39,No,Discontinuation,Yes,Yes,No,,,Positive,Prior treatments,Unknown
RCT42937,Cetuximab,Anti-EGFR,Single-arm,Standard of care,Phase 1,85,7,Monthly,63,18-75,60% M/40% F,0-1,4,3,Normal,Neutropenia,Cardiac,Cardiac,Moderate,2,28.09,No,Yes,Dose reduction,Patient education,19,54,Yes,Reduction,Yes,Yes,No,Competition,,Negative,ECOG,High
RCT29716,Rituximab,Anti-CD20,Single-arm,None,Phase 1,94,12,Every 3 weeks,61,≥18,50% M/50% F,0-1,2,3,Normal,Rash,Gastrointestinal,Cardiac,Severe,3,9.63,Yes,No,Supportive care,Monitoring,14,57,Yes,Reduction,Yes,No,Yes,Competition,,Negative,Gender,Unknown
RCT36326,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 2,117,10,Bi-weekly,136,18-65,40% M/60% F,0-2,1,1,Mild impairment,Rash,Dermatological,Cardiac,Mild,2,16.41,Yes,Yes,Dose reduction,Patient education,5,28,No,None,Yes,No,No,Competition,No,Positive,Gender,Medium
RCT83135,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,57,13,Monthly,156,≥18,60% M/40% F,0-1,0,2,Moderate impairment,Nausea,Cardiac,Hepatic,Severe,2,22.2,Yes,Yes,Treatment hold,Premedication,8,34,No,Delay,Yes,No,No,Competition,Yes,Unknown,Gender,Unknown
RCT31919,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 3,32,13,Bi-weekly,101,18-65,50% M/50% F,1-2,5,1,Moderate impairment,Rash,Hepatic,Blood,Moderate,2,3.09,No,No,Supportive care,Patient education,20,32,No,Delay,Yes,Yes,No,Competition,Yes,Positive,None,Medium
RCT46811,Cetuximab,Anti-EGFR,Crossover,Active comparator,Phase 1,139,4,Bi-weekly,42,18-65,40% M/60% F,0-1,1,1,Moderate impairment,Nausea,Dermatological,Gastrointestinal,Severe,1,14.7,Yes,No,Supportive care,Monitoring,14,31,Yes,Delay,No,No,No,Competition,,Negative,Gender,Low
RCT85203,Rituximab,Anti-CD20,Crossover,Placebo,Phase 1,69,5,Every 3 weeks,61,18-75,40% M/60% F,0-2,4,3,Moderate impairment,Infusion reaction,Cardiac,Gastrointestinal,Moderate,2,24.93,No,No,Discontinuation,Premedication,13,10,No,None,No,Yes,Yes,Efficacy,,Unknown,ECOG,Medium
RCT50817,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 1,42,4,Bi-weekly,113,≥18,50% M/50% F,0-2,4,1,Moderate impairment,Neutropenia,Hematological,Blood,Mild,4,11.16,No,Yes,Treatment hold,Patient education,22,14,No,Reduction,No,No,No,,No,Unknown,Age,Unknown
RCT20098,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 1,205,2,Weekly,123,18-75,60% M/40% F,1-2,1,1,Normal,Fatigue,Cardiac,Cardiac,Moderate,4,1.45,No,Yes,Discontinuation,Premedication,5,23,Yes,Reduction,Yes,No,No,Regulatory,Yes,None,Prior treatments,Medium
RCT82702,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 2,199,14,Monthly,97,21-85,50% M/50% F,0-1,3,0,Moderate impairment,Neutropenia,Dermatological,Skin,Moderate,3,15.53,No,No,Discontinuation,Monitoring,14,49,No,Delay,No,No,No,Safety,No,Negative,Age,Unknown
RCT51951,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,109,10,Bi-weekly,158,18-75,40% M/60% F,1-2,2,3,Normal,Neutropenia,Hematological,Gastrointestinal,Moderate,1,16.67,Yes,Yes,Dose reduction,Monitoring,17,16,No,None,No,No,No,Safety,No,Negative,Gender,Unknown
RCT53933,Rituximab,Anti-CD20,Crossover,None,Phase 1,258,8,Every 3 weeks,105,≥18,40% M/60% F,0-2,0,2,Normal,Neutropenia,Cardiac,Gastrointestinal,Severe,1,22.78,Yes,No,Dose reduction,Premedication,17,47,Yes,Discontinuation,No,No,Yes,Competition,,Unknown,ECOG,Low
RCT11401,Trastuzumab,Anti-HER2,Single-arm,Active comparator,Phase 3,240,5,Bi-weekly,56,21-85,60% M/40% F,0-1,2,1,Moderate impairment,Rash,Gastrointestinal,Cardiac,Severe,4,20.52,Yes,No,Supportive care,Monitoring,19,18,Yes,Discontinuation,No,No,No,Safety,,Unknown,Gender,Unknown
RCT36639,Pembrolizumab,Anti-PD-1,Crossover,None,Phase 3,239,1,Bi-weekly,132,18-75,60% M/40% F,0-1,4,1,Moderate impairment,Nausea,Hematological,Cardiac,Moderate,5,16.75,No,Yes,Dose reduction,Patient education,1,17,No,Discontinuation,Yes,Yes,Yes,Efficacy,,Unknown,Age,Low
RCT72141,Bevacizumab,Anti-VEGF,Single-arm,None,Phase 3,67,14,Every 3 weeks,72,≥18,50% M/50% F,0-2,4,1,Mild impairment,Fatigue,Dermatological,Cardiac,Severe,4,13.6,No,Yes,Supportive care,Premedication,28,19,No,None,Yes,Yes,No,Safety,No,Positive,ECOG,High
RCT78821,Cetuximab,Anti-EGFR,Randomized,None,Phase 2,93,9,Every 3 weeks,70,≥18,50% M/50% F,0-2,0,1,Mild impairment,Nausea,Cardiac,Hepatic,Severe,5,1.57,No,No,Treatment hold,Monitoring,26,52,No,Delay,Yes,Yes,Yes,Competition,Yes,Positive,None,Low
RCT61229,Rituximab,Anti-CD20,Randomized,Active comparator,Phase 2,294,5,Every 3 weeks,158,21-85,40% M/60% F,0-2,4,3,Mild impairment,Infusion reaction,Cardiac,Gastrointestinal,Severe,5,24.77,No,Yes,Discontinuation,Premedication,16,46,No,Reduction,Yes,No,Yes,Efficacy,,Negative,ECOG,Low
RCT15639,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 2,174,3,Weekly,175,21-85,50% M/50% F,1-2,2,2,Moderate impairment,Rash,Cardiac,Gastrointestinal,Severe,3,18.43,No,No,Dose reduction,Patient education,13,47,No,Reduction,No,Yes,Yes,,No,Positive,None,High
RCT72848,Pembrolizumab,Anti-PD-1,Single-arm,Standard of care,Phase 3,63,13,Every 3 weeks,84,18-65,40% M/60% F,0-2,3,0,Normal,Infusion reaction,Hepatic,Blood,Moderate,1,29.81,No,Yes,Treatment hold,Monitoring,21,36,Yes,Reduction,Yes,Yes,No,Competition,No,Negative,Age,Medium
RCT20723,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 1,173,12,Weekly,127,18-65,40% M/60% F,0-1,5,2,Normal,Neutropenia,Gastrointestinal,Cardiac,Mild,2,16.91,No,Yes,Discontinuation,Monitoring,16,48,Yes,None,Yes,Yes,Yes,Regulatory,,Unknown,Prior treatments,Unknown
RCT86057,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 2,25,3,Monthly,74,≥18,40% M/60% F,1-2,2,3,Moderate impairment,Neutropenia,Cardiac,Hepatic,Mild,2,4.15,No,No,Supportive care,Dose adjustment,28,59,Yes,Reduction,Yes,No,No,Efficacy,Yes,Negative,Prior treatments,High
RCT43396,Rituximab,Anti-CD20,Single-arm,None,Phase 1,261,11,Weekly,75,18-75,50% M/50% F,1-2,0,3,Normal,Neutropenia,Hepatic,Skin,Severe,4,4.8,Yes,Yes,Supportive care,Patient education,18,60,No,None,No,Yes,No,,Yes,None,None,Medium
RCT34108,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,28,4,Weekly,87,18-65,50% M/50% F,1-2,3,2,Mild impairment,Rash,Gastrointestinal,Hepatic,Severe,3,17.46,Yes,No,Treatment hold,Monitoring,26,37,No,Discontinuation,No,Yes,No,,Yes,Positive,Gender,Unknown
RCT93931,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 1,230,14,Every 3 weeks,70,21-85,50% M/50% F,0-2,4,1,Normal,Fatigue,Hepatic,Cardiac,Severe,3,20.22,No,Yes,Discontinuation,Patient education,21,9,No,Reduction,No,Yes,Yes,Safety,Yes,Unknown,Age,Medium
RCT26607,Bevacizumab,Anti-VEGF,Crossover,None,Phase 3,253,6,Every 3 weeks,167,18-65,40% M/60% F,1-2,2,2,Moderate impairment,Fatigue,Dermatological,Blood,Severe,1,29.39,Yes,No,Treatment hold,Premedication,19,30,Yes,Delay,Yes,No,Yes,Safety,Yes,Negative,Gender,Medium
RCT35034,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 3,277,13,Weekly,134,≥18,60% M/40% F,0-2,3,1,Moderate impairment,Fatigue,Cardiac,Skin,Severe,3,13.77,Yes,No,Treatment hold,Patient education,7,52,Yes,Discontinuation,No,Yes,Yes,Regulatory,,Negative,Age,Low
RCT10030,Rituximab,Anti-CD20,Single-arm,Standard of care,Phase 2,211,2,Bi-weekly,86,21-85,60% M/40% F,0-1,1,3,Normal,Neutropenia,Gastrointestinal,Cardiac,Mild,5,26.03,No,Yes,Discontinuation,Monitoring,3,18,No,Delay,Yes,Yes,No,Efficacy,Yes,None,None,Unknown
RCT36951,Trastuzumab,Anti-HER2,Randomized,Active comparator,Phase 3,199,12,Weekly,150,18-75,60% M/40% F,0-2,0,1,Normal,Nausea,Gastrointestinal,Skin,Mild,2,19.74,No,No,Supportive care,Dose adjustment,19,57,No,Reduction,No,Yes,No,Competition,No,Positive,Prior treatments,High
RCT73617,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 3,78,8,Every 3 weeks,157,18-75,60% M/40% F,0-2,3,3,Mild impairment,Infusion reaction,Hepatic,Blood,Moderate,4,8.38,No,No,Dose reduction,Monitoring,4,15,Yes,Reduction,No,Yes,Yes,Regulatory,No,Negative,Prior treatments,Unknown
RCT30423,Bevacizumab,Anti-VEGF,Crossover,Standard of care,Phase 2,204,9,Monthly,157,18-65,60% M/40% F,0-2,0,3,Moderate impairment,Fatigue,Hepatic,Skin,Moderate,1,1.85,No,No,Dose reduction,Premedication,9,47,Yes,Reduction,No,Yes,Yes,,Yes,None,ECOG,High
RCT78260,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,104,10,Weekly,71,≥18,40% M/60% F,1-2,0,0,Normal,Rash,Hematological,Blood,Moderate,3,10.41,Yes,Yes,Supportive care,Monitoring,17,45,No,Reduction,Yes,Yes,No,Efficacy,No,None,Prior treatments,Unknown
RCT11513,Rituximab,Anti-CD20,Crossover,None,Phase 2,170,3,Monthly,46,18-65,40% M/60% F,0-2,4,0,Mild impairment,Neutropenia,Hematological,Cardiac,Severe,5,2.94,Yes,No,Dose reduction,Patient education,1,50,Yes,None,Yes,Yes,No,Safety,,Unknown,Prior treatments,High
RCT55282,Trastuzumab,Anti-HER2,Crossover,Standard of care,Phase 1,209,3,Bi-weekly,107,18-65,60% M/40% F,0-2,1,3,Normal,Infusion reaction,Dermatological,Gastrointestinal,Moderate,3,18.71,Yes,No,Discontinuation,Monitoring,7,22,No,Reduction,Yes,No,Yes,Safety,,Unknown,None,Unknown
RCT87734,Pembrolizumab,Anti-PD-1,Crossover,Standard of care,Phase 2,232,9,Monthly,82,21-85,40% M/60% F,0-1,4,1,Normal,Infusion reaction,Gastrointestinal,Blood,Moderate,1,16.34,No,No,Treatment hold,Premedication,8,10,Yes,Reduction,No,No,No,Efficacy,Yes,Unknown,Prior treatments,Medium
RCT43666,Bevacizumab,Anti-VEGF,Crossover,Placebo,Phase 3,278,9,Bi-weekly,95,18-65,40% M/60% F,0-1,1,0,Moderate impairment,Infusion reaction,Hematological,Gastrointestinal,Severe,1,14.97,Yes,No,Treatment hold,Premedication,24,16,Yes,Reduction,Yes,Yes,Yes,Competition,No,None,Age,Medium
RCT73284,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 1,83,1,Bi-weekly,127,18-65,40% M/60% F,0-1,1,3,Normal,Fatigue,Hepatic,Gastrointestinal,Mild,5,13.3,No,Yes,Supportive care,Premedication,1,42,No,Reduction,Yes,No,No,,Yes,Unknown,Gender,Unknown
RCT26449,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,108,2,Bi-weekly,131,21-85,40% M/60% F,1-2,1,3,Moderate impairment,Rash,Cardiac,Hepatic,Moderate,5,7.84,No,Yes,Dose reduction,Premedication,15,21,No,None,Yes,No,Yes,Competition,No,Unknown,Gender,Medium
RCT74103,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 3,54,9,Bi-weekly,101,18-75,60% M/40% F,0-1,1,3,Moderate impairment,Rash,Hematological,Hepatic,Mild,3,9.61,Yes,No,Dose reduction,Patient education,1,20,Yes,Reduction,Yes,No,Yes,,No,Unknown,Gender,Unknown
RCT35305,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 1,117,4,Every 3 weeks,79,18-75,60% M/40% F,1-2,3,3,Moderate impairment,Nausea,Gastrointestinal,Skin,Moderate,1,29.22,Yes,No,Treatment hold,Patient education,16,22,Yes,Delay,No,No,Yes,,,Unknown,Prior treatments,Low
RCT44026,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 3,230,2,Weekly,43,≥18,50% M/50% F,0-1,1,0,Mild impairment,Nausea,Dermatological,Skin,Severe,2,18.66,No,No,Discontinuation,Dose adjustment,11,52,Yes,Reduction,Yes,Yes,Yes,Safety,Yes,Positive,Prior treatments,High
RCT53442,Cetuximab,Anti-EGFR,Randomized,Placebo,Phase 3,120,4,Every 3 weeks,91,18-65,50% M/50% F,0-2,3,0,Moderate impairment,Fatigue,Cardiac,Blood,Mild,1,25.69,Yes,Yes,Discontinuation,Patient education,12,13,Yes,Delay,No,Yes,No,Regulatory,Yes,None,Prior treatments,Unknown
RCT53315,Rituximab,Anti-CD20,Randomized,Standard of care,Phase 1,264,11,Every 3 weeks,30,18-65,60% M/40% F,1-2,2,3,Normal,Fatigue,Hepatic,Gastrointestinal,Mild,2,14.43,No,Yes,Treatment hold,Premedication,18,51,Yes,None,No,No,No,Safety,Yes,Unknown,ECOG,Low
RCT95505,Trastuzumab,Anti-HER2,Single-arm,Standard of care,Phase 1,238,7,Every 3 weeks,121,21-85,40% M/60% F,0-1,4,2,Mild impairment,Rash,Hematological,Skin,Moderate,2,29.41,Yes,Yes,Supportive care,Patient education,7,59,Yes,None,No,No,No,Efficacy,Yes,Negative,Prior treatments,Medium
RCT92528,Pembrolizumab,Anti-PD-1,Randomized,Placebo,Phase 3,277,9,Bi-weekly,93,18-65,50% M/50% F,1-2,3,3,Mild impairment,Nausea,Gastrointestinal,Gastrointestinal,Mild,3,10.37,Yes,Yes,Dose reduction,Premedication,4,44,No,Discontinuation,No,No,No,Safety,,Negative,Prior treatments,Unknown
RCT13462,Bevacizumab,Anti-VEGF,Randomized,None,Phase 2,124,4,Bi-weekly,116,18-75,50% M/50% F,0-1,2,0,Mild impairment,Nausea,Hepatic,Blood,Severe,1,10.34,No,Yes,Dose reduction,Patient education,3,26,No,Reduction,Yes,No,No,Regulatory,No,None,Age,High
RCT64330,Cetuximab,Anti-EGFR,Single-arm,Active comparator,Phase 2,106,6,Every 3 weeks,95,≥18,40% M/60% F,1-2,0,0,Moderate impairment,Neutropenia,Gastrointestinal,Hepatic,Moderate,1,25.77,No,No,Supportive care,Patient education,9,56,Yes,None,Yes,Yes,Yes,Regulatory,Yes,Unknown,Age,Unknown
RCT39342,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,194,8,Bi-weekly,114,18-75,40% M/60% F,0-2,1,1,Mild impairment,Neutropenia,Gastrointestinal,Skin,Moderate,1,15.77,Yes,No,Treatment hold,Premedication,28,24,Yes,Reduction,Yes,Yes,No,Safety,,None,Age,High
RCT52015,Trastuzumab,Anti-HER2,Crossover,Placebo,Phase 3,38,10,Bi-weekly,176,18-65,50% M/50% F,1-2,1,1,Normal,Fatigue,Dermatological,Skin,Mild,2,24.75,Yes,Yes,Dose reduction,Patient education,10,40,No,Reduction,No,Yes,Yes,Competition,,Positive,None,Medium
RCT86032,Pembrolizumab,Anti-PD-1,Randomized,Active comparator,Phase 1,239,6,Weekly,176,≥18,40% M/60% F,0-1,2,2,Mild impairment,Neutropenia,Hepatic,Skin,Severe,5,11.24,No,Yes,Dose reduction,Monitoring,6,42,No,Reduction,Yes,No,Yes,,Yes,None,Age,Low
RCT48694,Bevacizumab,Anti-VEGF,Randomized,Placebo,Phase 3,45,9,Bi-weekly,80,≥18,40% M/60% F,0-1,2,2,Moderate impairment,Rash,Dermatological,Skin,Moderate,4,5.84,Yes,Yes,Treatment hold,Dose adjustment,15,46,Yes,Reduction,No,Yes,No,Safety,,Unknown,ECOG,High
RCT97106,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 3,159,13,Monthly,41,≥18,40% M/60% F,0-1,5,1,Normal,Fatigue,Hepatic,Hepatic,Moderate,1,14.99,Yes,No,Discontinuation,Patient education,3,15,Yes,Discontinuation,Yes,No,Yes,Efficacy,Yes,None,Gender,High
RCT95074,Rituximab,Anti-CD20,Crossover,Active comparator,Phase 1,124,6,Bi-weekly,154,≥18,60% M/40% F,0-1,4,2,Mild impairment,Fatigue,Cardiac,Skin,Severe,3,17.13,Yes,Yes,Dose reduction,Dose adjustment,16,2,No,Reduction,Yes,Yes,No,Safety,,Positive,Gender,Low
RCT58202,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 1,282,8,Weekly,33,≥18,40% M/60% F,1-2,2,3,Moderate impairment,Rash,Cardiac,Blood,Mild,3,6.38,Yes,Yes,Dose reduction,Premedication,11,17,Yes,Discontinuation,No,Yes,No,Regulatory,No,Negative,Age,Medium
RCT23727,Pembrolizumab,Anti-PD-1,Single-arm,None,Phase 1,224,7,Every 3 weeks,176,21-85,40% M/60% F,1-2,3,3,Moderate impairment,Rash,Hepatic,Cardiac,Moderate,1,5.37,No,No,Discontinuation,Premedication,26,48,No,Discontinuation,No,No,Yes,Regulatory,No,Positive,Age,High
RCT15656,Bevacizumab,Anti-VEGF,Single-arm,Active comparator,Phase 2,142,9,Weekly,155,21-85,40% M/60% F,1-2,1,2,Mild impairment,Rash,Hepatic,Blood,Mild,3,1.31,No,No,Discontinuation,Premedication,7,37,Yes,Discontinuation,No,Yes,No,,Yes,Negative,ECOG,Low
RCT98497,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,132,15,Weekly,69,18-65,50% M/50% F,0-1,1,2,Mild impairment,Fatigue,Cardiac,Gastrointestinal,Mild,4,14.84,No,Yes,Treatment hold,Monitoring,10,13,Yes,Discontinuation,Yes,Yes,No,Efficacy,No,Unknown,None,Low
RCT67829,Rituximab,Anti-CD20,Single-arm,None,Phase 3,110,11,Every 3 weeks,63,21-85,40% M/60% F,0-1,5,3,Mild impairment,Fatigue,Dermatological,Cardiac,Mild,1,23.78,Yes,Yes,Supportive care,Premedication,10,39,Yes,Delay,No,No,No,Efficacy,Yes,Positive,Gender,High
RCT40901,Trastuzumab,Anti-HER2,Single-arm,Placebo,Phase 2,205,8,Weekly,33,≥18,40% M/60% F,0-1,1,3,Normal,Rash,Dermatological,Skin,Moderate,1,9.37,No,Yes,Treatment hold,Dose adjustment,12,34,Yes,Delay,Yes,No,Yes,,No,Positive,Prior treatments,Low
RCT97148,Pembrolizumab,Anti-PD-1,Crossover,Active comparator,Phase 2,189,1,Weekly,61,21-85,50% M/50% F,1-2,0,3,Mild impairment,Infusion reaction,Hepatic,Blood,Moderate,2,13.5,Yes,Yes,Discontinuation,Premedication,18,59,Yes,Delay,Yes,No,Yes,Efficacy,Yes,None,Prior treatments,Low
RCT83944,Bevacizumab,Anti-VEGF,Single-arm,Standard of care,Phase 1,47,1,Every 3 weeks,85,18-65,50% M/50% F,1-2,4,0,Moderate impairment,Fatigue,Gastrointestinal,Hepatic,Severe,5,22.75,Yes,No,Treatment hold,Patient education,6,10,No,Delay,Yes,No,No,Regulatory,No,Unknown,Prior treatments,Medium
RCT88214,Cetuximab,Anti-EGFR,Crossover,Standard of care,Phase 3,110,5,Monthly,76,21-85,40% M/60% F,1-2,0,1,Normal,Nausea,Gastrointestinal,Gastrointestinal,Mild,3,7.78,Yes,Yes,Dose reduction,Monitoring,28,5,Yes,Reduction,No,No,No,Competition,No,Positive,Gender,Unknown
RCT23513,Rituximab,Anti-CD20,Crossover,Standard of care,Phase 1,52,14,Bi-weekly,103,18-75,40% M/60% F,0-1,5,0,Moderate impairment,Nausea,Gastrointestinal,Hepatic,Mild,1,13.81,Yes,No,Discontinuation,Premedication,3,7,Yes,Reduction,No,Yes,No,Safety,No,Negative,Age,Low
RCT44673,Trastuzumab,Anti-HER2,Randomized,Placebo,Phase 3,205,4,Monthly,169,≥18,60% M/40% F,0-2,3,1,Mild impairment,Infusion reaction,Dermatological,Cardiac,Moderate,3,10.73,No,Yes,Dose reduction,Monitoring,27,14,No,None,Yes,Yes,Yes,Competition,No,Unknown,None,Medium
RCT43105,Pembrolizumab,Anti-PD-1,Single-arm,Placebo,Phase 3,132,10,Monthly,173,18-75,60% M/40% F,1-2,1,3,Mild impairment,Neutropenia,Gastrointestinal,Blood,Moderate,5,8.53,No,No,Discontinuation,Patient education,21,26,No,Reduction,Yes,Yes,Yes,Efficacy,Yes,Unknown,None,High
RCT93236,Bevacizumab,Anti-VEGF,Crossover,None,Phase 1,41,9,Bi-weekly,161,18-65,40% M/60% F,0-1,0,2,Mild impairment,Fatigue,Hepatic,Skin,Severe,1,22.49,No,No,Treatment hold,Premedication,16,19,Yes,None,Yes,Yes,Yes,,,Unknown,Prior treatments,Medium
RCT68756,Cetuximab,Anti-EGFR,Randomized,Active comparator,Phase 1,176,2,Every 3 weeks,148,18-65,50% M/50% F,0-1,5,2,Normal,Rash,Hematological,Hepatic,Mild,2,5.18,No,No,Discontinuation,Premedication,27,51,No,Delay,Yes,No,Yes,Regulatory,,None,Gender,Low
